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Abstract 
The transcription factor E2F1, a critical target of the tumour suppressor pRb, is 
deregulated in most human cancers.  Oncogenes have been shown to deregulate 
E2F1 through inhibition of pRB and deregulation of E2F1 is an event that occurs 
in most human cancers.  The essential role of E2F1 in apoptosis is well 
documented and deregulated E2F1 can enhance drug induced death.  E2F1 is 
induced by various chemotherapeutic drugs and this induction, in addition with 
oncogenic stress, contributes to increased chemosensitivity.   
Cells expressing the adenovirus early region 1A (E1A) oncogene have been used 
as a tool to identify cellular regulatory pathways that modulate 
chemosensitivity.  E1A sensitises cells to the induction of apoptosis by diverse 
stimuli, including many chemotherapeutic drugs.  These E1A activities are 
mediated through binding the RB family proteins (pRb, p107 and p130) and via 
the E1A N-terminal domain that interacts with different cellular protein 
complexes including the p300/CBP transcriptional activator and p400/TRRAP 
chromatin-remodeling complex. 
The results presented here illustrate novel mechanisms of E2F1 induction both 
by oncogenes and chemotherapeutic drugs.  Two minimal domains of E2F1 are 
described that are induced following DNA damage via mechanism(s) not 
previously identified.  In addition, data are presented which show that E1A 
expression not only deregulates E2F1, but also elevates E2F1 levels.  E1A is 
dependent on interaction with RB protein to induce E2F1 levels and this 
elevation contributes to cell death.  Using previously described protein binding 
deficient truncations of E1A, we demonstrate that E1A binding to the 
p400/TRRAP protein complex is also critical for the induction of E2F1.  E1A 
binding to p400/TRRAP was also critical in sensitizing these cells to drug induced 
apoptosis. Suppression of p400 using siRNA had similar affect on E2F1 induction 
and caused an increase in drug sensitivity indicating that E1A inhibits p400 
function.   
These results contribute to the understanding of how activation of the E2F1 
pathway may be targeted therapeutically to enhance chemotherapy-induced 
tumour cell death. 
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1 Chapter 1: Introduction  
It is estimated that cancer affects one in three persons in the developed world 
and half of those affected will die from the disease (Evan, 1997).  Treatments 
can include surgery, radiotherapy, chemotherapy or a mixture of these.  
Chemotherapy involves using anti-cancer drugs to destroy cancer cells.  Many 
commonly used cytotoxic drugs cause DNA damage and affect rapidly growing 
cells by interfering with cell division in various possible ways.  However, most 
forms of chemotherapy target all rapidly growing cells and are therefore have 
effects on certain normal cells in addition to cancer cells.  Although some 
degree of specificity may come from the inability of many cancer cells to repair 
DNA damage, cancer cells are often difficult to eliminate because they have 
impaired cell death pathways and are therefore resistant to many drugs.  
Rationally designed therapy utilizing a specific cancer-associated molecular 
target has therefore become a very active research area.   
Drugs that restore the normal cell death pathways have the potential for 
effectively treating cancers that depend on aberrations of the apoptotic 
pathway to survive.  The transcription factor E2F1 is almost always deregulated, 
though rarely mutated, in human cancers (Gorgoulis et al., 2002; Nevins, 2001).  
E2F1 is a potent inducer of apoptosis and can by activated following chemotoxic-
induced DNA damage.  The E2F1 induced apoptotic pathway is therefore an 
attractive target for tailored therapy which can lead to increased chemotherapy 
and better cancer treatment. 
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1.1 Tumourigenesis and cell death 
Humans are multicellular organisms that need proper cellular function of every 
tissue type to survive.  Normal cells proliferate, differentiate and die in order to 
maintain homeostasis within the body.  It is estimated that around 100 thousand 
billion (1014) cells comprise the human body. During the course of a human life 
these cells undergo a total of some 1016 cell divisions that are governed by a 
complex series of extracellular stimuli and intracellular pathways (Evan, 1997).  
These pathways have many internal checkpoints and safety nets.  Normal cells 
can respond to DNA damage by undergoing cell cycle arrest to allow time for the 
repair of damaged DNA.  Successful repair allows the cell to reverse the growth 
arrest and subsequently divide.  For unicellular organism, repair of the damaged 
DNA is the only sensible way to ensure survival.  However, in multicellular 
organisms it may be safer for the organism as a whole to eradicate damaged 
cells.  Programmed cell death (apoptosis) is therefore prudent option when 
severe DNA damage occurs or repair is unsuccessful.   
1.1.1 Cancer formation 
Corruption of the machinery that senses or implements DNA damage can allow 
accumulation of mutations and potentially lead to tumour formation.  A series of 
key aberrations can result in disruption of the intracellular pathways that 
control cell survival and therefore greatly predispose to cancer formation.  The 
complexity of the pathways controlling cell survival and homeostasis reflect the 
diversity of genetic alternations leading to tumours.  Alterations can vary and 
are often specific to tumour type but can also be different between individuals 
with the same tumour.  It is therefore the focus of many researchers to identify 
and dissect the common regulatory pathways that are altered in most human 
cancers to validate targets with therapeutic potential in a wide range of human 
tumours. 
Several lines of evidence indicate that tumourigenesis in humans is a multistep 
process.  These steps reflect genetic alterations in pathways that drive 
transformation of normal cells into highly malignant cancer cells (Foulds, 1954).  
Six essential alterations in cell physiology have been defined to collectively 
contribute to tumour formation.  In addition to being able to evade programmed 
16 
cell death, cells must acquire self-sufficiency in growth signals, insensitivity in 
growth-inhibitory signal, limitless replicative potential, sustained angiogenesis, 
and the ability to invade tissue and metastasise (Hanahan and Weinberg, 2000).  
It is believed that these six capabilities are shared in common by most, if not all 
human cancers, despite their diversity and heterogeneity. 
1.1.1.1 Cell proliferation pathways are deregulated in human cancers 
All tumours share the ability to proliferate beyond the constraints limiting 
growth in normal tissue.  Therefore it is no surprise that each of the pathways 
that are involved in proliferative responses in normal cells is perturbed in most 
cancers.  Activating mutations of the mitogen-responsive receptor tyrosine 
kinases (RTKs) or G-protein signal transducers such as Ras, or mutations 
affecting one of the many intermediary molecules in the pathway, allow cells to 
short circuit the normal requirement of somatic cells for external mitogenic 
signals (Evan and Vousden, 2001).  Mutations that target the cell-cycle 
checkpoint pathway, regulated by the retinoblastoma tumour suppressor pRb are 
also common (Harbour and Dean, 2000).  Defects in this pathway, which may be 
universal in human cancers, include deletion or mutation of the RB gene itself 
and deregulation of the cyclin dependent kinases (CDKs) that phosphorylate and 
functionally inactivate pRb, either through direct over-activation of CDKs or 
through genetic loss of their inhibitors (Fig. 1.1) (Bookstein et al., 1990; Friend 
et al., 1986; Fung et al., 1987; Harbour et al., 1988; Lee et al., 1988; Sherr, 
1996; T'Ang et al., 1988).  Inactivation of pRb in tumours relieves inhibition of 
the activating members of the E2F family of transcription factors (E2F1-3a) 
which express many target genes involved in cell cycle progression (Bell and 
Ryan, 2005; Goodrich et al., 1991; Hiebert et al., 1992; Kowalik et al., 1995).  
Viral oncoproteins such as type 5 adenovirus early region 1A (E1A), simian virus 
40 (SV40) large T, and E7 protein from high-risk human papiloma virus (HPV) all 
target pRb leading to de-regulated E2F activity and cell cycle progression 
(Chellappan et al., 1992; DeCaprio et al., 1988; Dyson et al., 1989; Whyte et al., 
1988).  
E1A, one of the best studied viral oncoproteins, binds to several host proteins 
including the p300/CBP transcriptional activator and p400/TRRAP chromatin-
remodelling complex (Frisch and Mymryk, 2002; Fuchs et al., 2001; O'Connor et 
17 
al., 1999).  E1A has been shown to induce Myc expression in a manner dependant 
on pRb and p300/CBP binding (Baluchamy et al., 2007).  Myc, like E2F, is a 
transcription factor and has the ability to drive cell proliferation.  Myc 
expression is tightly controlled by mitogen availability in normal cells, but it is 
usually expressed in a deregulated or elevated manner in tumour cells (Baudino 
and Cleveland, 2001). 
The presence of mutations in these pathways in most human cancers indicates 
the importance of their role in driving proliferation in tumours.  However, many 
of these growth control mechanisms are linked to apoptosis so that excessive or 
inappropriate proliferation concomitantly signals cell death.  Overexpression of 
growth promoting oncogenes as E2F1, E1A and Myc sensitizes cells to apoptosis 
(Evan et al., 1992; Qin et al., 1994; Shan and Lee, 1994; White et al., 1991).  
Ras, E2F1, E1A (via E2F1) and Myc all induce ARF, an alternate product of the 
INK4a locus which binds and inactivates Mdm2, a key part of the ubiquitin ligase 
Figure 1-1 The pRb pathway is deregulated in most human cancers.  This can occur 
through activating mutations of the mitogen receptor tyrosine kinases (RTKs) or signal 
transducers such as Ras.  pRb itself is often mutated or lost in cancers.  The cyclin 
dependent kinases (such as CDK4/6) that phosphorylate and inactivate pRb are activated 
in many tumours, either through direct over-activation or through loss of their inhibitors 
such as p16.  Inactivation of pRb relives inhibition of the activating E2Fs leading to 
increased cell cycle progression.  Viral oncoproteins can also target and inactivate pRb 
leading to increased E2F activity.  Tumour suppressor proteins are outlined in red, with 
oncoproteins in blue.  Dashed line indicates effect not requiring direct association. 
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that targets the tumour suppressor p53 for degradation (Fig. 1.2) (Lowe, 1999).  
Both E2F1 and E1A induce upregulation of Apoptotic Protease Activating Factor-1 
(Apaf-1) and pro-caspase 9 (Fearnhead et al., 1998; Moroni et al., 2001).  
Elevation of Apaf-1 increases the sensitivity of apoptosome activation to 
cytochrome c release from the mitochondria (Green and Evan, 2002; Zou et al., 
1997). 
Tumour progression therefore, in addition to oncogenes activation, requires the 
expression of anti-apoptotic proteins or inactivation of essential pro-apoptotic 
proteins often encoded by tumour suppressor genes (Bissonnette et al., 1992; 
Harrington et al., 1994; Sabbatini et al., 1995).   
1.1.1.2 Cell death and survival pathways are deregulated in human cancers 
The tumour suppressor p53 is the most frequently mutated gene in human 
cancers.  50% of all tumours carry p53 mutations and the protein may be 
functionally inactive in many more (Hollstein et al., 1994; Hollstein et al., 
1991).  p53 exists at low levels in normal cells but can be stabilized and 
activated by various cellular stresses including DNA damage (Lu and Lane, 1993; 
Ryan et al., 2001).  The N-terminal domain of p53 is phosphorylated by the DNA 
damage sensing kinases Ataxia Telangiectasia Mutated protein (ATM), ATM and 
Rad3-related protein (ATR), Chk2 and Chk1 (Banin et al., 1998; Canman et al., 
1998; Shieh et al., 2000).  Once stabilised, p53 mediates it’s tumour suppressor 
effects by inducing cell cycle arrest and apoptosis (Choisy-Rossi and Yonish-
Rouach, 1998).  p53 is a transcription factor but is able to induce apoptosis 
through a variety of mechanisms including both transcription dependent and 
Figure 1-2 Signals that promote cell proliferation can also promote apoptosis.  
Overexpression of growth promoting oncogenes as E2F1, E1A and Myc sensitize 
cells to apoptosis.  E2F1, E1A (via E2F1), Ras and Myc all induce ARF which binds 
and inactivates Mdm2, a protein that binds p53 and targets it for degradation.  This 
oncogenes activation therefore leads to p53 stabilization and induction of 
apoptosis.  Other pathways are also involved in oncogene-induced cell death 
sensitization (dotted line). 
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transcription independent pathways (Attardi et al., 1996; Chipuk et al., 2004; 
Erster et al., 2004; Erster and Moll, 2005; Marchenko et al., 2000; Mihara et al., 
2003; Moll et al., 2005; Schuler and Green, 2001; Yonish-Rouach et al., 1996).  
The fact that p53 is both stress-responsive and is activated following DNA 
damage to mediate programmed cell death means that there is a strong 
selection for tumour to lose p53 function (Woods and Vousden, 2001). 
In addition to tumours with mutated p53, many tumours containing wild type 
p53 have developed other mechanisms to evade p53 mediated tumour 
suppression.  Overexpression and/or upregulation of Mdm2 has been found in 
approximately 8% of human cancers with upregulation of Mdm2 leading to p53 
degradation (Momand et al., 1998).  Tumours containing amplification of the 
mdm2 gene itself as well as p53 mutations are rare, suggesting Mdm2 is the 
primary regulator of p53 stability (Cordon-Cardo et al., 1994).  The E6 protein 
from oncogenic Human Papilloma Virus (HPV) acts in a similar way to Mdm2 by 
binding and targeting p53 for ubiquitin-mediated proteolysis (Fig. 1.3) (Scheffner 
et al., 1990). Nearly all cervical cancers infected with HPV contain wild type p53 
indicating that E6 can substitute for p53 mutation in human cancers (Mantovani 
and Banks, 2001). 
Many oncogenes can upregulate ARF which binds Mdm2 and inhibits Mdm2-
mediated degradation of p53.  Inactivation of ARF through methylation of the 
ARF promoter occurs in many colorectal cancers making the tumour cells 
permissive for the presence of activated oncogenes even in the context of wild 
type p53 (Esteller et al., 2000; Robertson and Jones, 1998) 
Multiple mechanisms underline the induction of apoptosis by oncogenes.  
Nevertheless, many of them are p53-dependant and induce apoptosis 
predominantly through the intrinsic pathway involving mitochondria (see section 
1.1.2.2).  Following mitochondrial outer membrane permeabilizaton  (MOMP), 
cytochrome c is released from the mitochondrial intermembrane space (Green 
and Reed, 1998).  The pro-apoptotic proteins Bax and Bak are required for 
MOMP, while the antiapoptotic Bcl-2 proteins, including Bcl-2 and Bcl-xL, prevent 
MOMP (Green, 2006).  Different BH3-only proteins also promote apoptosis and 
are presumed to be important mediators of the apoptotic response to genotoxic 
damage.  Bax is a transcriptional target of p53 and two of the BH3-only family, 
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Noxa and Puma, have also shown to be a target of p53 (Miyashita et al., 1994; 
Nakano and Vousden, 2001; Oda et al., 2000; Yu et al., 2001).  A decreased 
expression or m utation of Bax and Bak has been reported in several tumours.  In 
addition, both anti-apoptotic proteins, Bcl-2 and Bcl-xL are overexpressed in 
several tumour types (Crisan, 1996; Kelekar and Thompson, 1998; Krajewska et 
al., 1996; Krajewski et al., 1995; Packham, 1998).   
1.1.2 Apoptosis 
Regulated or programmed cell death is essential to control cell numbers and 
tissue maintenance.  It serves to remove dangerous cells that threaten 
homeostasis.  Discovered and rediscovered several times by various scientists, 
programmed cell death acquired a number of names over the past two centuries 
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Figure 1-3 Cell death and survival pathways are deregulated in human cancers.  The 
tumour suppressor p53 is mutated in around 50% of tumours.  Mdm2 is upregulated 
in many tumours leading to p53 degradation and nearly all cervical cancers have the 
human papilloma virus oncoprotein E6 which also inhibits p53 activity.  ARF, which 
inhibits Mdm2 mediated p53 degradation, is inactivated through methylation in many 
colorectal cancers.  The pro-apoptotic Bax and Bak have decreased expression in 
many tumours, whereas the anti-apoptotic proteins Bcl-2 and Bcl-xL are 
overexpressed in several tumours.  Proteins outlined in red are mutated or 
downregulated in tumours, and overexpressed proteins are outlined in blue. 
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(Hengartner, 2000).  In fact, naturally occurring cell death did not receive 
widespread recognition until 1972 when Kerr et al. described the morphological 
features of an ordered form of death they called ‘apoptosis’ (Kerr et al., 1972).  
Apoptosis (a term derived from the Greek word describing the falling off of 
petals from a flower or leaves from a tree), or natural cell death, were 
recognised after that as wide-spread phenomenon not restricted to 
embryogenesis (Fadeel et al., 1999). 
The anatomy of apoptosis occurs in a sequence of cellular morphological events.  
First, the cell undergoes nuclear and cytoplasmic condensation with blebbing of 
the plasma membrane.  Eventually, the cell breaks up into membrane-bound 
fragments termed apoptotic bodies containing structurally intact organelles, as 
well as portions of the nucleus.  Subsequently, the apoptotic bodies are rapidly 
recognised, ingested and degraded by phagocytic cells (Kerr et al., 1972).  This 
is in contrast to necrosis, a pathological or accidental mode of cell death, 
characterised by irreversible swelling of the cytoplasm and organelles, including 
the mitochondria.  Eventually there is a loss of membrane integrity resulting in 
cell lysis.  Necrosis occurs when cells are subjected to toxic stimuli such as 
hyperthermia, hypoxia and direct cell trauma (Kerr et al., 1972).  However, 
recently necrosis has been shown to have a genetic component.  In respond to 
alkylating DNA damage, cells undergo necrosis as a self-determined cell fate, 
which does not require the central apoptotic mediators p53, Bax/Bak or 
caspases (Zong et al., 2004).   
Apoptosis is found throughout the animal kingdom.  In vertebrates, programmed 
cell death has been observed in almost all tissues and has been studied most 
extensively in the developing nervous system and in the immune system.  In the 
nematode Caenorhabditis elegans, where divisions and deaths of individual cells 
can be observed easily in living animals, apoptosis has been shown to occur in 
normal development in many different cell types (Ellis et al., 1991).  Many 
human homologues of proteins involved in cell death in nematodes have been 
found and the remarkable degree of conservation of the cell death pathway from 
nematodes to humans suggests that core death machinery exists in every cell 
(Horvitz, 1999; Zou et al., 1997). 
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Apoptosis in mammalian cells is mediated by a family of cysteine proteases, 
which are homologous to each other and are a part of a large protein family 
known as the caspases.  Caspases bring about most of the visible changes that 
characterize apoptotic cell death and are therefore thought of as the central 
executioners of the apoptotic pathway.  Caspases are initially expressed in cells 
as inactive pro-caspase precursors and are processed into their active form 
through cleavage at two or more critical aspartate residues.  Caspases have been 
sub-classed into “initiator” and “effector” caspases.  The initiator caspases 
include caspase 8 and -9 (Thornberry and Lazebnik, 1998).  They are activated 
through protein-protein interactions and involved in two alternative death 
pathways.  Caspase-8 is the key initiator caspase in the death-receptor pathway 
(extrinsic pathway, see section 1.1.2.1) while caspase-9 is triggered by the 
mitochondrial pathway (intrinsic pathway, see section 1.1.2.2).  The effector 
caspases are usually activated proteolytically by the initiator caspases.  Once an 
initiator caspase is cleaved and activated, downstream effector caspases such as 
caspase-3, -6 or -7 can cleave a variety of cellular substrates, resulting in 
chromatin condensation, nuclear fragmentation and DNA cleavage in the 
nucleus, blebbing of the cell membrane and the fragmentation of the cytoplasm, 
all characteristics of an apoptotic cell (Cryns and Yuan, 1998; Salvesen and Dixit, 
1997; Thornberry and Lazebnik, 1998).   
1.1.2.1 The extrinsic apoptotic pathway 
The two pathways by which caspase activation can be triggered are the extrinsic 
(death receptor) pathway and the intrinsic (mitochondrial) pathway (Fig.1.4).  
The extrinsic pathway is a receptor-linked pathway that requires the 
engagement of death receptors by their ligands on the surface of a cell.  It is 
triggered by the death-receptor superfamily (such as Fas/CD95, tumour necrosis 
factor (TNF) receptor 1, TRAIL-R1/DR4 and TRAIL-R2/DR5) which have universal 
death domains (DDs) located within their cytoplasmic tails.  The binding of a 
ligand to its receptor, such as FasL to Fas/FasCD95 or TRIAL to TRIAL-R induces 
receptor clustering and formation of a death-inducing signalling complex (DISC) 
(Ashkenazi and Dixit, 1998; Budihardjo et al., 1999).  This complex recruits, via 
the adaptor molecule FADD (Fas-associated death domain protein), multiple pro-
caspase-8 molecules, resulting in caspase-8 activation through induced 
proximity.  Upon caspase-8 cleavage and subsequent activation, caspase-8  
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Figure 1-4 Pathways to cell death.  Apoptosis can be triggered by two alternative 
pathways, the extrinsic (death receptor) and the intrinsic (mitochondrial) pathway.  In 
both circumstances induction of apoptosis leads to activation of initiator caspases 
(caspase-8 in the extrinsic, caspase-9 in the intrinsic pathway) that are cleaved and 
activate the effector caspases.  Active effector caspases finally cleave death 
substrates which eventually leads to apoptosis.  The extrinsic pathway is activated 
following ligand binding to the death receptor family, which recruit FADD and 
caspase-8.  The intrinsic pathway occurs via the mitochondria where cytochrome C 
release is regulated by the Bcl-2 family of proteins.  There is a cross-talk between the 
two pathways, for example the Bcl-2 family protein, Bid, is cleaved by caspase-8 
following activation of the extrinsic pathway, leading to activation of the intrinsic 
pathway, cytochrome C release and apoptosis. 
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initiates the proteolytic cascade through the effector caspases that cleave 
cellular targets and results in apoptosis.  Caspase-8 can also cleave downstream 
caspases indirectly by cleaving Bid, a member of the Bcl-2 family, which then 
translocates to the mitochondria and induces outer membrane permeabilizaton 
and cytochrome c release form the mitochondrial intermembrane space 
(Crighton and Ryan, 2004; Hengartner, 2000; Li et al., 1998; Luo et al., 1998; 
Wang et al., 1996).  
1.1.2.2 The intrinsic apoptotic pathway 
The intrinsic pathway occurs via the mitochondria and is used extensively in 
response to extra and intra cellular stresses such as growth factor withdrawal, 
DNA damage and oncogene activation.  These diverse response pathways induce 
apoptosis, often through activation of a pro-apoptotic member of the Bcl-2 
family, by inducing mitochondrial outer membrane permeabilizaton and release 
of cytochrome c.  Cytochrome c normally resides in the space between the inner 
and outer mitochondrial membranes where it plays a role in electron transport.  
Once released, cytochrome c associates with Apaf-1 and then pro-caspase-9 to 
form a multiprotein caspase-activating complex, the “apoptosome” (Cain et al., 
2002; Chinnaiyan, 1999).   Fully assembled apoptosome recruits pro-caspase-3 
which is then cleaved and activated by active caspase-9.  Active caspase-3 can 
then initiate the apoptotic cascade involving other effector caspases resulting in 
DNA fragmentation and cell death (Green and Reed, 1998). 
Cytochrome c release from the mitochondria is controlled by members of the 
Bcl-2 family proteins (defined by their sharing of, from one to four Bcl-2 
homology (BH) domains).  Pro- and anti-apoptotic Bcl-2 family members meet at 
the surface of the mitochondria, where they regulate cytochrome c release.  
Bcl-2 and Bcl-xL suppress apoptosis by preventing MOMP and cytochrome c 
release and therefore caspase-9 activation.  In contrast, pro-apoptotic Bcl-2 
family members, such as Bax and Bak, appear to be essential for MOMP, and 
probably directly form a pore in the outer membrane (Goping et al., 1998; 
Mikhailov et al., 2003; Nechushtan et al., 2001).  Different pro-apoptotic BH3-
only proteins act to interfere with the function of the anti-apoptotic Bcl-2 
members and/or activate Bax and Bak, but the precise manner in which they do 
so is not clear (Green, 2006; Green and Evan, 2002). 
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Although cytochrome c is necessary for activation of the apoptosome, 
downstream activation of the effector caspases can be inhibited by the IAPs 
(inhibitor of apoptosis proteins).  IAPs act as endogenous caspase inhibitors, 
possibly through their function as E3-ligases, and target active caspases for rapid 
degradation (Suzuki et al., 2001b).  X-linked IAP (XIAP), and probably other IAPs, 
can bind active caspase-9 and inhibit mitochondrial cell death.  XIAP has also 
been shown to inhibit and bind to caspase-3 downstream of caspase-8 in the 
extrinsic pathway.  IAPs are in turn regulated by at least two proteins released 
from the mitochondria upon MOMP.  Smac/DIABLO and Htra2/Omi, which both 
contain IAP binding motifs, can bind IAPs and prevent IAP-mediated inhibition of 
caspases and therefore induce caspase-dependent death (Du et al., 2000; Hegde 
et al., 2002; Suzuki et al., 2001a; Verhagen et al., 2000; Verhagen et al., 2002).   
There are other proteins within the mitochondrial intermembrane space that 
control cell death in caspase-independent ways.  Apoptosis inducing factor (AIF) 
translocates to the nucleus after its release, where it appears to induce 
chromatin condensation and DNA fragmentation (Susin et al., 1999).  In addition, 
Endonuclease G is thought to directly mediate nuclear DNA fragmentation upon 
its release from the mitochondrial intermembrane space (Li et al., 2001). 
1.1.3 DNA damage induces apoptosis 
The genome is constantly exposed to exogenous DNA damaging events such as 
solar radiation, viral infection and chemicals.  Eukaryotic organisms have 
evolved a highly conserved signalling pathway, called the DNA damage response, 
to protect against genomic damage.  Within cells, sensor proteins detect various 
forms of damage and signal via a complex pathway regulated by protein 
phosphorylation, stabilization and transcriptional regulation.  The DNA damage 
response can cause cell cycle arrest and induction of DNA repair function. 
However, the response of many cells with more severe damage is to induce 
apoptosis (Gasser and Raulet, 2006). 
Following DNA damage, the PI3-kinase-related serine/threonine protein kinases 
ATM (Ataxia Telangiectasia, mutated) and ATR (ATM- and Rad3-related) 
cooperate with other proteins to initiate the DNA damage response.  ATM is 
mutated in the genetic disorder ataxia-telangiectasia (AT), causing defective 
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cell cycle checkpoint activation, a reduced repair of DNA double strand breaks 
and abnormal apoptosis (Lavin and Kozlov, 2007).   
Double strand breaks preferentially activate ATM (although other stimuli are also 
capable of ATM activation), whereas stalled DNA replication induces ATR 
activity.  The exact mechanism of activation remains unknown, but the MRN 
complex (Mre11/Rad50/Nbs1) plays an important role both in the recruitment of 
ATM to the sites of DNA damage and in the efficient activation of ATM (Mirzoeva 
and Petrini, 2001; Petrini and Stracker, 2003).  In responses to many genomic 
insults, however, both kinases are eventually activated, ultimately triggering the 
activation of their downstream substrates.   
DNA damage, caused by various DNA damaging agents such as ionizing radiation 
(IR), UV and chemotherapeutic drugs, leads to p53 activation and stabilization.  
ATM directly phosphorylates p53 on serine 15 and a number of other sites which 
contributes to p53 stabilization following DNA damage (Lavin and Kozlov, 2007).  
ATR has also been shown to play a role in the activation of p53 and 
phosphorylates p53 on serine 15 and 37 in cells exposed to UV light (Appella and 
Anderson, 2001).  Phosphorylation at serine 15 and 37 has been shown to 
decrease the interaction of p53 and Mdm2, the ubiquitin ligase that normally 
targets p53 for rapid turnover (Shieh et al., 1997).  Mdm2 has also been shown to 
be phosphorylated by ATM/ATR in response to DNA damage (Kastan and Bartek, 
2004; Maya et al., 2001).  These modifications of p53 and Mdm2 contribute to 
the stabilization and activation of the p53 protein.  Other targets involved in 
apoptosis have also been shown to respond to ATM/ATR activity.  The 
transcription factor E2F1 is phosphorylated at serine 31 following DNA damage 
by ATM kinase, which leads to induced E2F1 accumulation (Lin et al., 2001).  
Downstream of ATM/ATR are the serine/threonine effector kinases Chk2 and 
Chk1.  ATM-mediated phosphorylation preferentially triggers the activation of 
Chk2 where Chk1 is mainly phosphorylated by ATR.  ATM phosphorylates and 
activates Chk2 following double-strand breaks caused by IR, whereas ATR is 
activated by a broader spectrum of genotoxic stimuli such as lesions caused by 
UV and inhibitors of DNA replication.  Both kinases have been shown to be 
phosphorylated following tratment with the topoisomerase II inhibitor 
adriamycin (doxorubicin), a clinically important chemotherapeutic drug (Ho et 
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al., 2005).   Phosphorylation of both proteins leads to their activation and 
subsequent regulation of proteins that are involved in the DNA damage response.   
In response to IR, Chk2 phosphorylates p53 on serine 20.  This site is known to 
interfere with Mdm2 binding and therefore leads to p53 stabilization (Hirao et 
al., 2000).  Chk2 has also been shown to phosphorylate E2F1 following treatment 
with the chemotherapeutic drug etoposide.  This results in stabilization  of the 
E2F1 protein and its subsequent increased transcriptional activity (Stevens et 
al., 2003). 
Another way of activating the transcription factors p53 and E2F1 in response to 
DNA damage is through acetylation.  p53 is acetylated at lysines 320, 373 and 
382 in the C-terminus of the protein.  Following IR or UV induced DNA damage,   
CREB binding protein (CBP)/p300 acetylates p53 at lysine-373 and lysine-382, 
whilst p300/CBP-associated factor (P/CAF) can acetylate p53 at lysine-320, 
resulting in increased affinity of p53 for DNA (Gu and Roeder, 1997; Liu et al., 
1999; Sakaguchi et al., 1998).  It has been implicated that p53 phosphorylation 
at serine 37 and 15 recruit CBP/p300 to p53 and control p53 acetylation, 
therefore suggesting that p53 activation is controlled by a combination of 
phosphorylation and acetylation (Lakin and Jackson, 1999).  E2F1 has also been 
shown to be a target of P/CAF, and to a lesser extent p300/CBP, in vitro.  
Acetylation by P/CAF on lysines 117, 120 and 125, which lie adjacent to the E2F1 
DNA-binding domain, stabilize E2F1 and increase it’s DNA binding ability and 
transactivation potential (Martinez-Balbas et al., 2000).   
A number of genes involved in apoptosis have been demonstrated to be targets 
of p53 and E2F1 following activation or in response to DNA damage.  p53 
stimulates increased expression of the pro-apoptotic protein Bax, which can 
induce apoptosis via the intrinsic pathway (Miyashita et al., 1994).  In addition, 
Noxa and Puma have been shown to be targets of activated p53.  Both proteins 
can interact with anti-apoptotic Bcl-2 resulting in the release of cytochrome c 
from the mitochondria and caspase-9 activation (Nakano and Vousden, 2001; Oda 
et al., 2000; Yu et al., 2001).  Several other genes involved in the intrinsic 
apoptotic pathway have also been shown to be targets of E2F1 when 
overexpressed, for example caspase 7 and Apaf-1 (Furukawa et al., 2002).  
However, it was only recently shown that DNA damage induced E2F1 activates 
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specific subset of target genes, for example, in response to adriamycin-induced 
DNA damage, E2F1 is acetylated and subsequently activates genes involved in 
apoptosis, such as p73 (Pediconi et al., 2003).   
1.1.4 Activated oncogenes sensitize cells to apoptosis 
Many mitogenic oncogenes, such as Ras, E2F1, Myc and E1A force uncontrolled 
proliferation of cells.  However, although the processes of cell proliferation and 
cell death appear to be opposing, much evidence now exists to indicate that the 
two processes are linked.  Many oncogenes have now been shown to enhance 
apoptosis in addition to induced cell division.  c-Myc (one member of the Myc 
family of proteins) was one of the first oncoproteins to show pro-apoptotic 
activity.  c-Myc is a transcription factor and requires the N-terminal 
transactivation domain and the DNA binding domain for its apoptotic potential 
(Evan et al., 1992).  c-Myc is dependent on Max, its dimerization partner, to 
induce both proliferation and apoptosis and is able to induce both p53-
dependent and p53-independent apoptosis (Amati et al., 1993; Sakamuro et al., 
1995).  c-Myc is able to activate p53 directly through induced ARF expression, 
resulting in induced cell death (Zindy et al., 1998). 
E1A is another growth promoting oncoprotein that sensitizes cells to cell death.  
E1A is expressed by adenoviruses which also express the antiapoptotic E1B 
genes, which oppose the cytotoxic effects of E1A, for successful viral replication 
(White et al., 1991).  Both the growth-promoting and apoptotic functions of E1A 
map mainly to the N-terminal half of the protein.  E1A stimulates cell cycle 
progression by binding to proteins that are critical in normal cell cycle control.  
E1A can mediate these effects by binding to the RB family (pRb, p107 and p130) 
through a motif located in a conserved region 2, (CR2) and to a lesser extent CR1 
(Dyson et al., 1992).  The RB family proteins control normal cell cycle by binding 
and inhibiting the E2F proteins.  E1A inhibits the normal activity of RB and 
thereby de-regulate the E2Fs to constitutively activate genes involved in cell 
proliferation and to activate the viral E2 promoter (Chellappan et al., 1992; 
Fattaey et al., 1993).   
However, RB inhibition is not the only way E1A promotes uncontrolled cell cycle 
progression.  The N-terminus of E1A binds and interferes with the function of 
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p300 and CBP, two highly related transcriptional activators that enhance 
expression of genes involved in growth inhibition (Arany et al., 1995; O'Connor et 
al., 1999).  E1A is also able to target p400 and TRRAP, using overlapping 
sequences in the N-terminus.  p400 and TRRAP are unrelated proteins that 
interact with each other and additional proteins involved in chromatin 
remodelling (Fuchs et al., 2001).  TRRAP has also been shown to interact with c-
Myc N-terminus and the transactivation domain of E2F1, suggesting that TRRAP is 
an essential cofactor for other oncogenic transcription factors (Deleu et al., 
2001; McMahon et al., 1998).  The C-terminus of E1A has also been shown to be 
able to bind the cellular proteins CtBP, which has been proposed to recruit 
histone de-acetylases to promoters and promote negative chromatin remodelling 
(Sundqvist et al., 1998).   
The way that these co-factors work and their gene specificity is not well 
understood, however, their interactions appear to be important for the 
apoptotic activity of both E1A and Myc.  E1A can cause an increase in the levels 
of p53 and induction of p53-dependent apoptosis.  By using deletion mutants of 
E1A it has been shown that deletion of a portion of CR1 prevents apoptosis, 
suggesting that binding of p300 and/or pRb is necessary for E1A-induced 
apoptosis.  The ability of E1A to induce p53 levels is also dependent on p300 and 
pRb binding (Mymryk et al., 1994; Querido et al., 1997).  However the 
mechanism through which E1A binding to p300 affects p53 stability is not clear.  
As discussed previously, CBP/p300 can lead to increased p53 activity by 
acetylating p53 following DNA damage.   However, it has been suggested that 
E1A binding to p300-Mdm2-complexes disrupts p53 degradation, possibly by 
blocking poly-ubiquitination of p53 and inhibiting its normal turnover (Grossman 
et al., 2003; Grossman et al., 1998).  In another study it was shown that E1A’s 
ability to induce p53 was dependent on the pRb signaling pathway and ARF 
induction (de Stanchina et al., 1998).  E1A has also been shown to induce p53-
independent apoptosis.  E1A is dependent on binding to pRb and p300 to 
increase expression of p73 mRNA and protein through E2F1 activation.  E1A can 
also induce the p53 target Noxa in p53-deficient cancer cell lines, suggesting 
that E1A can promote apoptosis without p53 activation (Flinterman et al., 2005).  
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1.1.4.1 E1A expression sensitizes cells to drug induced apoptosis 
Many anticancer drugs cause DNA damage leading to induced apoptosis, 
suggesting that chemosensitivity of tumour cells is influenced by the efficiency 
of the drug to activate cellular apoptotic programs.  This suggests that tumours 
with oncogenes that can signal to apoptosis, such as Myc, are more susceptible 
to apoptosis that normal tissue and should be responsive to drug treatment.  In 
contrast, tumours unable to efficiently engage apoptosis due to inactivation of 
tumour suppressor gene such as p53 become more resistant to drug treatment. 
E1A expression has been shown to sensitize cells to apoptosis induced by IR, 5-
fluorouracil, etoposide and adriamycin, in a p53-dependant manner (Lowe et al., 
1993).  The p53 target Bax contributes to apoptosis in E1A expressing cells and 
can therefore function as an effector of p53 in chemotherapy-induced apoptosis 
(McCurrach et al., 1997).  As cells can tolerate ectopic E1A expression but 
become extremely prone to apoptosis, E1A expressing cells have been used as a 
simple model to further investigate cellular processes that modulate 
chemosensitivity.  This allows analysis of induced chemosensitivity following 
oncogene activation in genetically normal cells outside the context of adenoviral 
infection.  Using retrovirally delivered E1A into cells, selective induction of p53 
and increased apoptosis following adriamycin treatment was shown to be 
dependent on E1A binding to pRb (but not p107 and p130) and p300/CBP 
(Samuelson and Lowe, 1997).  However, in this study an N-terminal deletion 
mutant was used that was not refined enough to exclude other targets such as 
the p400/TRRAP complex.  Later, it was showed by the same group, that E1A-
p300/CBP interaction is largely dispensable for E1A to induce ARF, p53 and 
apoptosis following adriamycin treatment.  Instead it was shown that E1A 
interacting with pRb and the p400/TRRAP complex is essential for these effects 
(Samuelson et al., 2005). 
The interaction between E1A and pRb deregulates E2F1 which could contribute 
to the increase in chemosensitivity.  However, E2F1’s contribution to apoptosis 
in this context in not clear.  E2F1’s involvement in apoptosis will be discussed 
later in this chapter. 
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1.2 Cancer therapy 
The diversity of different cancer types and the signaling complexity underlying 
tumourigenesis means that the design of successful therapies becomes very 
complex (Bell and Ryan, 2005).  However, some of the most promising potential 
therapies may lie with targeting the apoptotic pathways.  Defects in apoptosis 
can lead to tumourigenesis and contributes to drug resistance since many of the 
current chemotherapeutic drugs depend on the cellular apoptotic pathway for 
death.  Reactivation of the apoptotic pathway in cancer cells or stimulation 
downstream of defects might therefore prove to be a successful way to kill 
tumours and could be used in combination with existing therapies. 
1.2.1 The apoptotic pathway as a therapeutic target 
Most drugs currently used in anti-cancer therapy kill cancer cells by apoptosis, 
both through the extrinsic and intrinsic apoptotic pathway.  Possible drug targets 
that activate both of these pathways have now been discovered (Fesik, 2005; 
Nicholson, 2000). 
In an attempt to target the extrinsic apoptotic pathway in cancers, agonistic 
antibodies against the TNF-related apoptosis inducing ligand (TRAIL) receptors 
have been made.  These antibodies induce apoptosis in TRAIL-sensitive tumour 
cells whereas normal cells are not affected (Chuntharapai et al., 2001; Ichikawa 
et al., 2001; Takeda et al., 2004).  Another approach for activating TRAIL 
receptors involves the use of soluble truncated version of TRAIL.  It has been 
shown to induce apoptosis independently of p53 expression in a number of cell 
lines without affecting normal cells.  Chemotherapeutic drugs such as etoposide 
and adriamycin significantly increased TRAIL-induced apoptosis in cancer cells 
through upregulation in the TRAIL receptors DR4, DR5, Bax and Bak, and 
induction of caspase activity.  This suggests that both ex- and intrinsic pathways 
can synergize to enhance cell death following drug treatment and TRAIL 
activation (Shankar et al., 2005).  However, varying degrees of TRAIL sensitivity 
or resistance have also been observed.  Targeting the anti-apoptotic proteins 
Bcl-2 and IAPs (X-IAP or survivin) with RNA interference (RNAi) resulted in 
increase in apoptosis when used in combination with TRAIL (Chawla-Sarkar et 
al., 2004).  Additional evidence supports the importance of mitochondrial 
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regulation in TRAIL-induced death.  The pro-apoptotic protein Bax is crucial for 
mitochondrial changes and caspase activation and is essential in TRAIL-mediated 
death in cancer cells (LeBlanc et al., 2002). 
The Bcl-2 family members play a crucial role in the intrinsic apoptotic pathway 
and serve as a potential targets for cancer therapy.  The anti-apoptotic protein 
Bcl-2 is overexpressed in many cancers, confers resistance to treatment with 
radiotherapy and traditional cytotoxic chemotherapy and correlates with poor 
survival and progression of the disease (Fesik, 2005). Therefore, targeting Bcl-2 
in tumours could be a good therapeutic option.   Two main approaches have 
been taken to target the Bcl-2 proteins.  One is to reduce their expression levels 
using antisense oligonucleotides and some data show that reducing the 
expression levels synergizes with many therapeutic agents against various 
tumours (Klasa et al., 2002).  Another approach is to use synthetic peptides to 
mimic the activity of the pro-apoptotic BH3-only proteins.   Small molecular 
inhibitors that bind and inhibit Bcl-2 and Bcl-xL have therefore been made and 
have been shown to enter cells and induce apoptosis (Holinger et al., 1999; 
Wang et al., 2000; Zangemeister-Wittke et al., 2000). 
The IAPs are inhibitors of caspases and are therefore important regulators of 
apoptosis.  The interaction between IAPs and caspases can be inhibited by 
Smac/DIABLO which is released from the mitochondria.  XIAP is the most potent 
member of the IAP family in terms of caspase and apoptosis inhibition.  The XIAP 
protein is overexpressed in various cancers and its expression correlates with 
cell death resistance (Fesik, 2005).  Reduced expression of XIAP by antisense 
oligonucleotides induces apoptosis in lung cancer cells and sensitizes cells to 
death following treatment with chemotherapeutic drugs such as adriamycin and 
etoposide (Hu et al., 2003).  Both peptides and small molecular inhibitors of 
XIAP have also been made in order to mimic Smac/DIABLO binding, activate 
caspases and induce apoptosis (Arnt et al., 2002).  The XIAP inhibitors can 
induce caspase activation and sensitize cells to drug induced apoptosis 
suggesting that XIAP is a viable target for cancer therapy (Arnt et al., 2002; Oost 
et al., 2004). 
Numerous studies have focused on activating p53 as a strategy for cancer 
therapy.  Many different approaches have been established, such as using gene 
33 
therapy to introduce wild type p53 into tumours or use small molecular drugs to 
re-activate p53 in tumours with mutated p53 (Romer et al., 2006).  A chemical 
compound called PRIMA, (p53 reactivation and induction of massive apoptosis) is 
able to restore native confirmation and wild type function to mutant p53, 
activate p53 target genes and induce apoptosis in cell lines with mutant p53 
while having little effect on cells with wild type p53 (Bykov et al., 2002; Li et 
al., 2005; Yu, 2006). 
An alternative approach is to use small inhibitors that inhibit the interaction of 
p53 with its negative regulator Mdm2.  Inhibitors like nutlin and RITA mimic the 
binding of p53 to the p53-binding pocket of Mdm2 and inhibit p53 degradation 
leading to p53 accumulation and apoptosis (Issaeva et al., 2004; Vassilev et al., 
2004).  Nutlins have been shown to activate apoptosis in wild type p53 cancer 
types but not in mutant p53 cancer cells, indicating that they have therapeutic 
potential in tumours with Mdm2 overexpression (Fesik, 2005; Levesque and 
Eastman, 2007; Romer et al., 2006). 
There are many other peptides and compounds that induce apoptosis and have 
therapeutic potential.  Demethylating agents and/or histone deacetylase (HDAC) 
inhibitors have been used to target the silencing mechanism and reactivate pro-
apoptotic proteins (Marks et al., 2001).  In addition, antisense approaches to 
decrease expression of a variety of anti-apoptotic proteins, including Ras and 
Mdm2, are in clinical development (Cunningham et al., 2001; Johnstone et al., 
2002; Tamm et al., 2001). Disruption of pRb, leading to activation of E2F1 in 
tumors, has also been investigated and will be discussed further later in this 
chapter. 
1.3 E2F family proteins 
1.3.1 Identification of E2F  
In 1986 Kovesidi et al. identified a cellular factor that interacts with the 
adenovirus E2 promoter.  The DNA binding activity of this factor increased 
following E1A infection and was involved in transactivation of the E1A viral 
protein itself (Kovesdi et al., 1986a; Kovesdi et al., 1986b).  They later termed 
this factor E2F (E2 promoter binding factor) and showed it was a transcription 
34 
factor responsible for E1A-mediated stimulation of the E2 gene as well as the 
E1A gene, but not involved in the activation of the other E1A-inducible 
promoters (Kovesdi et al., 1987).  That same year, La Thangue and co-workers 
identified a cellular activity called differentiation regulated transcription factor 
1 (DRTF1).  It was involved it the control of gene expression during cell 
differentiation (La Thangue and Rigby, 1987).  This factor was found in several 
protein complexes which have the same DNA specificity.  DRTF1 was able to 
interact with the retinoblastoma (pRb) tumour suppressor gene product that is a 
target of the transforming proteins of several DNA tumour viruses such as E1A 
and simian virus large T antigen (Whyte et al., 1988).  E1A causes dissociation of 
the pRb protein from this complex which requires conserved regions 1 and 2 
(CR1, CR2) of E1A that are known to be essential for efficient cell 
transformation by E1A (Dyson et al., 1992; Fattaey et al., 1993; Whyte et al., 
1989).  This suggested that the pRb protein forms a complex and regulates 
transcription of a DNA bound transcription factor, or the E2F (Bandara and La 
Thangue, 1991; Chellappan et al., 1992; Chellappan et al., 1991). 
The mechanism of how cell proliferation is regulated by pRb was established in 
1991 when pRb was found in a complex with E2F.  The interaction of pRb with 
E2F was suggested to be an important mechanism involved in the control of 
cellular proliferation. The dissociation of the complex by E1A was shown to 
inactivate pRb function (Chellappan et al., 1991).  Other viruses were also shown 
to be able to interact and inhibit pRb by using shared amino acid sequences that 
were the same as those required for the transforming activity to the viral 
proteins.  It was suggested that the ability of E1A, SV40 large T and E7 (from 
high risk human papilloma virus) proteins to dissociate the E2F-Rb complex had 
evolved to stimulate cell proliferation in infected quiescent cells to allow 
efficient viral replication.  These findings, in addition to the discovery that 
either the E2F-Rb complex was absent or pRb was mutated in various human 
cervical carcinoma cell lines, were the first indications that E2F might be 
associated with cancer (Chellappan et al., 1992).   
Since the detection of the E2F factor many discoveries about the importance of 
this factor in cell cycle regulation have emerged.  The regulation is complex and 
E2F activity has been shown to involve many proteins.  Tight cell cycle 
regulation occurs due to the combined action of the E2F family members. 
35 
1.3.2 E2F family members 
The family of E2F transcriptional factors consists now of eight human 
components.  The protein products from these eight genes heterodimerize with 
members of the DP family (DP1, DP2 and DP4) to give a rise to functional E2F 
complexes.  All possible combinations of E2F-DP complexes exist in vivo (Helin et 
al., 1993b; Krek et al., 1993; Wu et al., 1995).  All of the E2Fs have core 
domains that mediate DNA binding and in some cases dimerization with DP.  The 
DNA binding specificity is determined by the E2F through an evolutionary 
conserved DNA binding domain.  The E2F family is believed to be central 
regulators of the cell cycle and regulate overlapping sets of many target genes.  
The family can be further divided into distinct subgroups on the basis of their 
sequence homology and transcriptional properties.   
1.3.2.1 The activating E2F’s 
E2F1 was the first family member to be cloned and characterised as a protein 
that interacts with pRb (Helin et al., 1992).  The transcriptional activity of E2F1 
is inhibited by direct binding of pRb whereas a naturally occurring pRb mutant is 
unable to inhibit this activity (Helin et al., 1993a).  Subsequently, two additional 
E2F-like proteins were characterised.  Both are able to bind to wild-type, but 
not mutant E2F recognition sites and specifically interact with the pRb protein 
(Helin et al., 1993b).  This suggested that many of previously described 
observations resulted from combined action of a family of E2F proteins rather 
than a single E2F protein. 
E2F1, E2F2 and E2F3a are now termed the “activating” sub-group members of 
the E2F family (Fig. 1.5).  They are all able to activate transcription and bind to 
pRb.  E2F1-3a are highly homologous proteins, especially in the domains that are 
responsible for DNA binding, DP dimerization and pRb binding.  Over-expression 
of E2F1-3a induces S phase entry in quiescent cells and overcomes G1 arrest 
mediated by the p16INK4 tumour suppressor protein (Lukas et al., 1996; Mann 
and Jones, 1996).  Over-expression of E2F1 can overcome inhibition of 
proliferation mediated by type β transforming growth factor (TGF- β) (Schwarz 
et al., 1995).  In addition, over-expressed E2F1 can induce p53-mediated 
apoptosis.  This can be suppressed by wild-type pRb but not the naturally 
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occurring loss-of-function pRb mutant (Qin et al., 1994).  The combined effect of 
all three activating E2Fs was tested by conditional gene targeting and revealed 
that the combined loss of E2F1-E2F3a completely abolishes S phase entry and 
cell cycle progression of cells, underlining their essential role in cell cycle 
progression (Wu et al., 2001).   
1.3.2.2 The repressive E2F’s 
The second subclass of the E2F family includes E2F4 and E2F5.  These E2Fs were 
originally identified and cloned by virtue of their association with the RB family 
members p107 and p130 (Beijersbergen et al., 1994; Dyson et al., 1993; Hijmans 
et al., 1995).  The sequences of these proteins diverge from the activating E2Fs 
Figure 1-5  All of the E2F family members have sequence homology in the DNA binding 
and dimerization domain.  E2F1-3a activate transcription and have a cdk2-cyclin A 
binding site, transactivation domain and binding domain for pocket proteins.  E2F3b, 
E2F4 and E2F5 repress activation but also have pocket protein binding domain.  E2F1-3 
have a nuclear localization signal (NLS) but E2F4-5 have a nuclear export signal (NES).  
E2F6 lacks the transactivation domain and can act as a transcriptional repressor.  E2F7 
and E2F8 are also transcriptional repressors.  They have two DNA binding domains but 
lack a transactivation domain.  E2F1-6 all bind DNA as heterodimers with DP family 
proteins, while E2F7 and E2F8 appear to associate with DNA independent of DP 
proteins. 
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and are regulated differently.  E2F4 and E2F5 expression is mainly detected in 
quiescent (G0) cells, where E2F1, E2F2 and E2F3a are primarily restricted to 
actively dividing cells (Ikeda et al., 1996; Moberg et al., 1996).  The repressive 
E2F4 binds to each of the pocket proteins at different points in the cell cycle, 
but E2F5 is mainly regulated by p130.  In contrast to the activating E2Fs, E2F4 
and E2F5 are poor transcriptional activators and are unable to drive quiescent 
cells to re-enter the cell cycle (Muller et al., 1997).  The different activity of the 
two E2F subgroups, when not bound to DP, results from differences in their 
subcellular localisation.  E2F1-3a are constitutively nuclear, whereas E2F4 and 
E2F5, lacking basic nuclear localization signal (NLS), are predominantly 
cytoplasmic (Verona et al., 1997).   
Inactivation of E2F4 and E2F5 in mice suggests that they play individual roles 
during cell differentiation of certain cell lineages.  Mice simultaneously 
nullizygous for both the E2F4 and E2F5 genes result in neonatal lethality, 
suggesting their functions overlap during mouse development.  Fibroblasts from 
these mice proliferate normally but fail to arrest in G1 in response to p16INK4 
(Gaubatz et al., 2000). 
Other E2F family members (E2F3b and E2F6-8) have been discovered more 
recently and also appear to function as transcriptional repressors.  E2F3b, an 
alternative form of the activating E2F3a, is produced from E2F3 mRNA via the 
use of an alternative translational start site and lacks the conserved N-terminal 
region found in E2F3a (He et al., 2000).  E2F3b interacts with pRb and is 
expressed equivalently in quiescent and proliferating cells (Leone et al., 2000). 
E2F6 shares homology with the domains of E2F1-5 that mediate dimerization 
(both the leucine zipper domain and region of homology known as the marked 
box) and DNA binding properties.  However, it lacks the sequences that bind to 
the pRb, p107 and p130.  E2F6 can act as a transcriptional repressor, but 
through a distinct, pocket-protein-independent manner (Trimarchi et al., 1998).  
E2F6 represses transcription through its ability to recruit the polycomb 
transcriptional repressor group (Trimarchi et al., 2001).  E2F6 has also been 
found in a complex that contains Max which can bind to Myc binding sites, 
suggesting that E2F6 can recruit chromatin modifiers and contribute to the 
silencing of E2F- and Myc-responsive genes (Ogawa et al., 2002).  E2F6 deficient 
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mice exhibit no defects in assays of proliferation or quiescence and but display 
similar skeletal transformations observed in polycomb mice, suggesting that the 
main function of E2F6 is to recruit polycomb proteins to specific target 
promoters during development (Storre et al., 2002). 
E2F7 and E2F8 have two distinct DNA-binding domains but lack the dimerization 
domain as well as the transactivation and pRb-binding domain.  They bind to E2F 
DNA consensus sites independently of DP co-factors.  Both have properties of a 
transcriptional repressor capable of negatively influencing cellular proliferation 
(de Bruin et al., 2003; Di Stefano et al., 2003; Logan et al., 2004; Logan et al., 
2005).  The novel structure of E2F7 and E2F8 may suggest a unique role for this 
new sub-set of E2Fs in regulating cellular proliferation. 
1.3.3 The DP family of proteins 
The DP family (DP1, DP2 and DP4) function as binding partners for E2F 
transcription factors.  DP1 (DRFT1-polypeptide-1) was first identified in 1993 as 
a partner for E2F1 (Girling et al., 1993).  DP1 and E2F share similar DNA binding 
domains as well as the ability to recognize the same DNA sequence.  The 
association of phosphorylated DP1 with E2F enhances both the DNA binding 
affinity and the transactivation function of the heterodimer (Bandara et al., 
1993; Helin et al., 1993b). 
In 1995 the second member to the family was isolated (Ormondroyd et al., 1995; 
Zhang and Chellappan, 1995).  Like DP1, DP2 binds to E2F proteins enhancing 
binding and transcriptional function and modulates the function of E2F in cell 
cycle regulation (Wu et al., 1995).  A new member of the family, DP4 was 
recently characterised.  Like the other DP proteins it forms heterodimer with 
E2F, binds to E2F sites and associates with pocket proteins including pRB.  
However, in contrast with DP1 and DP2, DP4 reduces DNA binding activity when 
bound to E2F and can interfere with E2F1-dependent transcription and delay cell 
cycle progression (Milton et al., 2006a). 
39 
1.4 The role of E2Fs in cell cycle control 
E2Fs involvement in cell cycle control is mediated by its interaction with the 
pocket proteins (pRb, p107 and p130).  In normal cells, the activating E2Fs 
(E2F1-E2F3a) are specially regulated by their association with pRb, but not the 
related pocket-proteins (Lees et al., 1993).  The ability of pRb to bind to the 
E2F1-E2F3a  is regulated by its cell cycle dependent phosphorylation (Mittnacht, 
1998).  During the G0 and early G1 stages of the cell cycle pRb is 
unphosphorylated, and in this form it binds to E2F and inhibits activation.  In 
response to growth factor stimulation, cyclin-dependent kinase (cdk) complexes 
are activated (Fig. 1.6).   
D-type cyclins are induced in resting cells following growth factor stimulation 
and are expressed throughout G1 in cycling cells, whereas cyclin E expression is 
induced in mid-late G1.  Subsequently the activated cdks, cdk4/cdk6-cyclin D 
and cdk2-cyclin E, phosphorylate pRb leading to pRb-E2F dissociation and release 
of E2F inhibition.  Cdk2-cyclin E is unable to phosphorylate pRb in the absence of 
prior phosphorylation by cdk4/cdk6-cyclin D and the complete phosphorylation 
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Figure 1-6 pRb binds to E2F1-3 in its unphosphorylated state and inhibits E2Fs 
to become transcriptionally active.  In response to growth factor stimuli, 
activated cyclin-dependent kinase complexes phosphorylate pRb and cause it 
to become dissociated from E2Fs which can then activate transcription of 
genes involved cell proliferation. 
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of pRb requires both D-and E-type cdks (Hinds et al., 1992; Lundberg and 
Weinberg, 1998).  This results in dissociation of pRb-E2F leading to activation of 
free E2F and transcription of E2F-responsive genes.  E2F regulates several 
families of genes whose products are required for DNA synthesis, such as DHFR 
(dihydrofolate reductase) and DNA polymerase α, and for cell cycle progression, 
such as B-myb, cyclin A and cyclin E (DeGregori et al., 1995; Fry et al., 1997; 
Lam and Watson, 1993).  Activation of these genes by E2F in late G1 is sufficient 
to drive cells into S phase (DeGregori et al., 1995).  
The transactivation domain of E2F1 is in the C-terminal region of the protein 
(residues 368-473).  This region also holds an 18 amino-acid motif (409-426) 
essential for pRb binding (Helin et al., 1992).  When pRb is unphosphorylated, it 
can repress E2F activity in two ways (Bell and Ryan, 2004).  Unphosphorylated 
pRb binds E2F via the C-termina pRb binding domain and inhibits E2F’s ability to 
recruit to the basic transcriptional machinery (Dyson et al., 1993; Flemington et 
al., 1993).  In this state E2F can occupy E2F DNA-binding sites, but is unable to 
activate gene expression and is therefore considered a ‘passive’ repressor.  The 
other mechanism is by pRb-mediated recruitment of various chromatin modifiers 
such as histone deacetylases (HDACs), DNA and histone methyl transferases and 
polycomb group proteins to the pRb-E2F complex.  These proteins are able to 
inhibit transcription and contribute to E2Fs ‘active’ repression (Ferreira et al., 
2001; Robertson et al., 2000; Trimarchi et al., 2001; Trouche et al., 1997).  
E2F target genes are bound by different E2F-pocket protein complexes through 
the cell cycle.  Repressor E2F-pocket protein complexes occupy promoters in G0 
and G1.  E2F4 and p130 are the predominant complex found on promoters in 
quiescent cells which correlates with low levels of histone acetylation.  
Expression of many genes in G1 is believed to occur through alleviation of this 
repression (de-repression).  In late G1, E2F4 is replaced largely by E2F1 and E2F3, 
which associates with histones H3 and H4 acetylation and gene activation.  The 
activating E2Fs are most prevalent in early S phase as E2F target genes are 
highly expressed (Takahashi et al., 2000).  However, some promoters are bound 
by E2F complexes both in late G1 and during mid-S phase which contradicts 
current model.  It has also been shown that several different E2F-pocket protein 
complexes can bind to the same DNA site simultaneously suggesting that cell 
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cycle regulation by E2F is a complex process and not yet completely understood 
(Wells et al., 2000).   
In order to use a simpler system, the dE2F/dDP/RBF pathway present in 
Drosophila melanogaster has been utilized.  Drosophila contains two E2F genes, 
one DP gene and two RB family members.  These function in a similar way as 
their homologues in mammals.  dE2F1 is a potent activator of transcription 
whereas dE2F2 is a repressor and both dimerize with dDP.  Like pRb, RBF1 binds 
both E2Fs, whereas RBP2 interacts only with the repressor, dE2F2.  Conversely, 
dE2F2/RBF1 or dE2F2/RBF2 complexes have been found to repress gene 
activation in drosophila melanogaster in actively proliferating cells.  These 
genes, not expressed in a cell cycle dependent manner, proved to be genes 
involved in cell differentiation (Dimova et al., 2003).  Further analysis using this 
system may be able to clarify some of the complexities experienced in 
mammalian E2F mediated cell cycle regulation.  
1.5 E2F1 regulation 
E2F1 is both the founding member of the E2F1 family and is also the best 
studied.  It is comprised of 473 residues and several defined domains that have 
high homology to the other family members.  E2F1 has a cyclin A binding domain 
mapped to residues 67-108 and a nuclear localization signal (NLS) that is located 
directly after the cyclin A domain.  The domain responsible for DNA binding runs 
from residue 120-191.  The DNA binding domain is followed by a homologous 
hydrophobic repeat which is involved in homo- and hetero-dimerization called 
the leucine zipper.  The transactivation domain is contained within residues 380-
437.  The pocket protein binding domain lies within the transactivation domain 
and maps to residues 409-426.  The ARF binding domain is also found within the 
transactivation domain and is located on the far C-terminal end of the E2F1 
poly-peptide (Mundle and Saberwal, 2003). 
Several proteins involved in the cell cycle regulation are actively degraded at 
defined points during the cell cycle.  In some cases, their degradation is 
essential to ensure accurate progression through the cycle.  Cyclins, cyclin 
dependent kinases (cdks) and cdk inhibitors are degraded actively by the 
ubiquitin-proteosome pathway (Ciechanover, 1994; Hochstrasser, 1995).  
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Ubiquitin molecules are bound to lysine residues of the target protein.  
Ubiquitination of proteins are performed by three different enzymes, an 
ubiquitin-activating enzyme (E1), an ubiquitin-conjugating enzyme (E2) and an 
ubiquitin-protein ligase (E3) (Scheffner et al., 1995).  Poly-ubiquitinated 
proteins are then recognized by the 26S protease complex, the proteasome, 
which degrades the targeted protein. 
E2F1 protein levels are also regulated by the ubiquitin-proteasome-dependent 
degradation pathway.  Targeting of E2F1 for ubiquitination can occur through 
the C-terminal activation domain which also holds the pRb binding domain.  The 
physical association of pRb blocks E2F1 ubiquitination and stabilizes E2F1 by 
protecting it from degradation (Campanero and Flemington, 1997; Hateboer et 
al., 1996b; Hofmann et al., 1996). 
Events that affect pRb binding to E2F can therefore regulate E2F1’s stability and 
activity during normal cell cycle.  Phosphorylation of pRb in its C-terminal region 
by cdk4/cdk6-cyclin D releases HDAC activity from pRb and ablates the 
repressive action of pRb.  This does not affect its E2F1 binding but promotes the 
phosphorylation of pRb by Cdk2-cyclin E resulting in complete dissociation from 
E2F1 (Harbour et al., 1999).  Phosphorylation of E2F1 itself may also be 
important in the regulation of its activity during the cell cycle.  E2F1 is 
phosphorylated at serine 332 and 337 residues by cdk4-cyclin D which prevents 
its interaction with pRb (Fagan et al., 1994). 
E2F1 is also phosphorylated by cdk2-cyclin A.  Whereas phosphorylation by cdk2-
cyclin E alleviates pRb repression, phosphorylation by cdk2-cyclin A is able to 
reverse E2F1 transactivation.  During S-phase as cyclin A concentrations 
increases, cdk2-cyclin A complex is able to bind a specific domain (residues 67-
108) that is N-terminal to its DNA binding domain.  After forming a stable 
complex with E2F1, the cdk2-cyclin A complex phosphorylates serine 375 on 
E2F1 and reduces the DNA binding ability of E2F1/DP1 heterodimer (Dynlacht et 
al., 1994; Krek et al., 1995; Xu et al., 1994).  The cdk2-cyclin A complex can 
also phosphorylate DP1 leading to loss of E2F1 DNA binding ability (Guida and 
Zhu, 1999).  This is believed to be a way to suppress activation of free E2F1 at 
the end of the cell cycle.  Disruption of the cyclin A binding domain of E2F1 
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increases its stability and can lead to apoptosis, emphasizing on the importance 
of tight regulation of E2F1 by cdk2-cyclin A (Krek et al., 1995). 
Another protein involved in mediating the activity of the transactivation domain 
of E2F1 is Mdm2.  Mdm2 makes a functional contact with the transactivation 
domain of E2F1 and increases its activation function (Martin et al., 1995).  The 
mechanism of Mdm2-mediated activation is unclear.  It is unlikely that pRb 
displacement from E2F1 is the mechanism since the binding sites for Mdm2 and 
pRb are not overlapping.  
The deacetylase activity bound to pRb appears to maintain E2F1 in deacetylated 
inactive form.  E2F1 binds CBP co-activator via a small region in the activation 
domain without affecting its binding with pRb or Mdm2.  CBP binding to E2F1 
stimulates E2F1 activity (Trouche et al., 1996).  Following dissociation of 
phosphorylated pRb, E2F1 is open to acetylation of lysine residues at 117, 120 
and 125, positioned in or just outside the DNA binding domain toward the N-
terminus.  Acetylation on these residues enhances E2F1’s stability as well as DNA 
binding activity.  The acetyl transferase enzyme complex CBP/pCAF appears to 
be responsible for this acetylation, but whether CBP binding to the C-terminus of 
E2F1 is essential for its acetylation is not clear (Martinez-Balbas et al., 2000). 
A class of E3 ubiquitin-protein ligases, referred to as SCF complexes (SKP1-CDC53 
(cullin)-F-box protein complexes) have been identified which use F-box-proteins 
to recruit specific targets for ubiquitination by a relevant E2 enzyme.  The F-
box-containing protein p45SKP2 is a cell-cycle-regulated component of the 
ubiquitin protein ligase SCFSKP2 and recognizes substrates for this ligase.  The N-
terminal of E2F1 interacts with p45SKP2 leading to ubiquitination of E2F1.  
Disruption of the interaction between E2F-1 and p45SKP2 results in a reduction in 
ubiquitination of E2F1 and the stabilization and accumulation of transcriptionally 
active E2F-1 protein (Marti et al., 1999).  E2F1 accumulates in late G1 phase but 
is rapidly degraded in S/G2 phase and SCFSKP2 mediated degradation of E2F1 may 
be one mechanism through which E2F is downregulated at the end of the cell 
cycle. 
The alternative reading frame (ARF) protein, encoded from the INK4a locus, has 
been shown to promote growth inhibition, which in some cases can be overcome 
by ectopic E2F1 expression.  ARF interacts with E2F and targets it for protein 
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degradation (Martelli et al., 2001).  The mechanism for ARF-mediated E2F1 
degradation is not clear.  Whether Mdm2 is involved in the ARF-E2F1 effect is 
not known.  The possibility that ARF binding to E2F1 leads to SCFSKP2 mediated 
degradation has also not been confirmed.   
Nevertheless, Mdm2 has been shown to promote E2F1 stability by displacing 
SCFSKP2 from E2F1 and therefore inhibit its ubiquitination.  Direct binding of E2F1 
and Mdm2 is necessary for the negative effects of Mdm2 on E2F1 ubiquitination, 
but E2F1 downregulation is not due to either pRb or ARF (Zhang et al., 2005). 
It has been noted that subcellular localization can also provide E2F regulation.  
The activating E2Fs have basic nuclear localization signal (NLS) in their N-
terminal domain that is sufficient to mediate their nuclear localization.  E2F1 
accumulates in the nucleus at times which correlates with its activity.  By 
contrast, the repressive E2Fs lack NLS and have to depend on either DP1 or 
pocket protein for their localization.  The repressive E2Fs have a hydrophobic 
nuclear export signal (NES) and are mostly detected in the cytoplasm (Magae et 
al., 1996; Muller et al., 1997; Verona et al., 1997).   
1.5.1 E2F1 is stabilized following DNA damage 
The regulation of E2F1 activity and stability during the cell cycle has been well 
documented.   In addition, it has recently been shown that E2F1 levels increase 
following DNA damage.  The first indication came in 1997 when Huang et al. 
showed that ionizing radiation increased the expression of E2F1 (Huang et al., 
1997).  Since then many reports have described E2F1 stabilization following 
various DNA damaging agents and chemotherapeutic drugs.  E2F1 is upregulated 
in response to DNA damage caused by irradiation with X-rays or UVC, or 
following treatment with the DNA damaging agents actinomycin D, adriamycin 
and etoposide in a manner analogous to that of p53 (Blattner et al., 1999; 
Hofferer et al., 1999; Meng et al., 1999; O'Connor et al., 1995).  This induction is 
specific to E2F1 rather than other members of the family and exhibits kinetics 
that closely resembles the induction of p53 (Blattner et al., 1999).   
Recent studies have shed some clarity on the modifications that occur and the 
signalling pathways involved in E2F1 stability.  They have also connected E2F1 
induction with apoptosis in response to DNA damage.  E2F1 is a target of DNA 
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damage-responsive protein kinases.  E2F1 is phosphorylated at serine 31 by 
ATM/ATR kinase and by Ckk2 kinase at serine 364 following DNA damage (Lin et 
al., 2001; Stevens et al., 2003).  Both phosphorylation events lead to increased 
E2F1 protein stability and the induction of apoptosis.  The ATM/ATR site at 
serine 31 is within the Skp2 binding domain and it has been suggested that 
phosphorylation at this site might alter the degradation of E2F1 by inhibiting 
Skp2 binding and therefore prevent the normal turnover of E2F1.  Induction of 
both apoptosis and p53 phosphorylation by E2F1 is abolished by caffeine, which 
inhibits ATM/ATR kinases, this supports the notion that E2F1 uses the ATM 
signalling pathway to induce p53 and apoptosis (Powers et al., 2004; Sarkaria et 
al., 1999). 
E2F1 is able to interact with Mdm2 via the E2F1 transactivation domain (residues 
390-406) and this stimulates the activation capacity of E2F1/DP1 (Martin et al., 
1995).  Mdm2 expression can also lead to E2F1 stabilization through the E2F1 
ubiquitination pathway (Zhang et al., 2005).  Mdm2 inhibition can lead to an 
increase in expression of E2F1, similar to the way in which p53 is induced 
following Mdm2 removal (Blattner et al., 1999).  Mdm2 expression has also been 
shown to promote degradation and antagonize the apoptotic properties of E2F1 
(Loughran et al., 2000).  Despite the controversy, given that E2F1 and p53 are 
similarly regulated by ATM/ATR and Chk2 kinases, it has been suggested that 
disruption of the E2F1-Mdm2 interaction might also play a role in the E2F1 
induction following cellular stress.  The Chk2 phosphorylation site at serine 364 
is positioned close to the Mdm2 binding domain, but whether phosphorylation at 
this site affects Mdm2 binding in not clear. 
It has been suggested that E2F1 phosphorylation may lead to stabilization 
through a member of the 14-3-3 family proteins.  14-3-3 proteins are a family of 
dimeric phosphoserine/phosphothreonine-binding proteins and are involved in a 
wide spectrum of biological processes (Fu et al., 2000).  14-3-3τ interacts with 
ATM-phosphorylated (at serine 31) E2F1 during DNA damage and inhibits E2F1 
ubiquitination.  14-3-3τ is also required for the expression and induction of 
several E2F1 apoptotic target genes as well as apoptosis following DNA damage 
(Wang et al., 2004).  Possible mechanism for this function includes 14-3-3τ 
inhibition of E3 ligase binding, similar to the manner in which 14-3-3σ inhibits 
Mdm2-mediated degradation of p53 following adriamycin treatment (Yang et al., 
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2003).  Another member of the family, 14-3-3ε is able to bind DP2 via a region in 
the NLS of DP2.  This interaction alters the cell cycle and apoptotic properties of 
E2F.  In contrast with the effect of 14-3-3τ on E2F1, etoposide treatment causes 
a decrease in the 14-3-3ε-DP2 interaction and a subsequent induction in DP2 
itself (Milton et al., 2006b). 
Phosphorylation of p53 following DNA damage has been shown to promote the 
subsequent acetylation of lysine residues within its C-terminal region, leading to 
enhanced p53 DNA binding and translational activity (Sakaguchi et al., 1998).  
Whether phosphorylation of E2F1 promotes acetylation is not known.  
Nevertheless, E2F1 is acetylated by both p300/CBP and P/CAF at sites adjacent 
to the DNA binding domain (K117, K120, K125)  which leads to increased 
stability, DNA binding and activation of E2F1(Martinez-Balbas et al., 2000; 
Marzio et al., 2000).  E2F1 acetylation occurs following DNA damage which 
requires P/CAF acetyltransferase activity and this leads to activation of E2F1 
target genes involved in apoptosis rather than genes involved in cell cycle 
progression (Ianari et al., 2004; Pediconi et al., 2003).  Proteosomal degradation 
requires that proteins are first targeted for destruction by ubiquitination of 
lysine residues.  Therefore, it is possible that the increase in E2F1 stability 
observed is a result of a phosphorylation-acetylation cascade that prevents E2F1 
turnover.  
E2F1 is regulated by the co-activator and acetyltransferase p300 after DNA 
damage by a mechanism that links acetylation and ubiquitination.  An acetylated 
form of E2F1 accumulates in cells following DNA damage, which can further be 
increased by p300 expression.  Accumulation of ubiquitinated E2F1 is also 
induced by the same DNA damaging agents, which is in contrast to what could be 
expected since ubiquitination usually leads to rapid turnover of proteins.  The 
increase in ubiquitinated E2F1 is again increased by p300 and requires 
acetylation of the three known acetylation sites (K117, K120, K125) (Galbiati et 
al., 2005).  p300-induced E2F1 ubiquitination does not depend on the p45SKP2 E3 
ligase since ubiquitination can occur with an E2F1 mutant devoid of the p45SKP2-
binding domain and is not influenced by pRb.   
Another level of regulation of E2F1 activity following DNA damage is its ability to 
interact with p53 via the cyclin A binding site of E2F1.  Cyclin A binds to E2F1 
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and prevents E2F1 from binding and cooperating with p53 to induce apoptosis.  
However, following DNA damage, cyclin A levels decrease with a parallel 
increase in E2F1-p53 formation, suggesting that E2F1 can directly stimulate 
apoptotic function of p53 following cellular stress (Hsieh et al., 2002).  The 
induction of E2F1 was shown to be independent of transcriptional activity and 
Mdm2 binding. 
1.6 E2F’s role in cancer 
Following the observation that showed E2F to be deregulated by a transforming 
virus it was speculated that E2F might be associated with cancer.  pRb was 
subsequently found to by targeted by other viral oncoproteins, including SV40 
large T antigen and E7 proteins from ‘high-risk’ human papilloma viruses 
(Chellappan et al., 1992).  It is now thought, E2F is deregulated in most human 
cancers.  This can occur by loss or mutation of Rb, viral infection, upregulation 
of the cdk/cyclin complexes that phosphorylate pRb or through loss of the cdk 
inhibitor p16 (Hall and Peters, 1996; Harbour et al., 1988).  
1.6.1 Oncogene or tumour suppressor 
Studies on E2F1 indicate that it may have a unique role compared to other E2Fs, 
showing characteristics of both an oncogene and a tumour suppressor (Pierce et 
al., 1999).  A number of studies suggest that E2F1 functions as a oncogene by 
promoting the proliferation of cells beyond their normal constraints (Cress et 
al., 1993).  Many genes that are involved in regulation of the cell cycle are 
direct targets of E2F1, such as Cdc2, cdc25a and cyclin E and genes which play a 
functional role in DNA synthesis, including thymidine kinase and DNA polymerase 
α (DeGregori et al., 1995; Dyson, 1998; Ohtani et al., 1995; Vigo et al., 1999).  
In addition, it has been shown that overexpression of E2F1 in quiescent cells is 
sufficient to induce entry into DNA synthesis, and E2F1 can function as an 
oncogene in transforming assays (Johnson et al., 1994; Lukas et al., 1996). 
Additional support for E2F1’s oncogenic potential comes from studies in mice 
carrying a germ-line mutation or deletion of the Rb gene.  Embryos homozygous 
for mutation in Rb die between days 14 and 15 of gestation with defects in 
erythropoiesis, cell cycle control and apoptosis while Rb heterozygous mice 
48 
display pituitary tumours (Hu et al., 1994; Jacks et al., 1992).  This phenotype 
can be modified by deletion of E2F1.  Loss of E2F1 reduces the frequency of 
pituitary and thyroid tumours that occur in Rb+/-, and greatly lengthens the 
lifespan if Rb+/-; E2F1-/- animals (Yamasaki et al., 1998).  In addition, Rb/E2F1 
double mutants show significant suppression of apoptosis and S phase entry in 
certain tissues compared to Rb mutants, suggesting E2F1 is a critical mediator of 
these effects (Tsai et al., 1998).  E2F3 has also been shown to make a 
contribution to the effect resulting from pRb loss.  E2F3 mutation completely 
suppresses both the inappropriate proliferation and apoptosis arising in the Rb 
mutant embryos (Ziebold et al., 2001).  
On the other hand, targeted deletion of the E2F1 gene in mice resulted in 
animals that developed and reproduced normally.  However, E2F1-/- mice have 
excess mature T cells due to a defect in thymocyte apoptosis.  As these mice age 
they exhibit a second phenotype marked by abnormal cell proliferation (Field et 
al., 1996).  This suggests that in addition to promoting cell division, E2F1 has a 
role in regulating apoptosis and can suppress cell proliferation in some instances.  
The confirmation of E2F1’s tumour suppressor function came when Yamasaki et 
al showed that mice lacking E2F1 develop broad spectrum of tumours in a 
number of tissues (Yamasaki et at., 1996).  
Mouse models have also been used to explore the affect of increased or 
deregulated E2F1 activity.  Increases in E2F1 activity can promote 
tumourigenesis by co-operating with v-Ha-ras transgene to induce skin tumours 
indicating that deregulated E2F activity can contribute to tumour development 
(Pierce et al., 1998a).  Increased E2F1 activity can also promote tumourigenesis 
by co-operating with p53 deficiency to induce spontaneous skin carcinomas, 
verifying that increased E2F1 expression can contribute to tumour development.  
This suggests that p53 plays an important role in eliminating cells with 
deregulated E2F1 activity (Pierce et al., 1998b).   
However, Pierce et al also showed that E2F1 can have tumour-suppressive 
properties in a transgenic model.  As transgenic mice age they are predisposed 
to develop spontaneous tumours in a variety of tissues, but on the other hand, 
they are found to be resistant to skin tumour development following 
carcinogenic promotion (Pierce et al., 1999).  These results demonstrate that 
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increased E2F1 activity can either promote or inhibit tumourigenesis in mice 
models, depending upon the experimental context.  
The role of E2F1 in UV-induced apoptosis in vivo has also been assessed.  
Contrary to expectations, E2F1-/- mice demonstrate enhanced keratinocyte 
apoptosis after UVB exposure, whereas apoptosis is suppressed by epidermis-
specific overexpression of human E2F1.  Apoptosis induced by γ-radiation was 
also repressed by E2F1, which implies that E2F1 can function as a suppressor of 
an apoptosis pathway that is initiated by DNA damage (Wikonkal et al., 2003).  
The reason for this function of E2F1 might lie in its role in DNA repair since 
inhibition of UV-induced apoptosis by E2F1 correlates with a stimulation of DNA 
repair.  Mice lacking E2F1 are impaired in their ability to remove DNA 
photoproduct, while E2F1 transgenic mice repair UV-induced DNA damage at an 
accelerated rate compared to wild type mice (Berton et al., 2005).   
1.7 E2F1 induced apoptosis 
E2F1 is the only family member that is induced following DNA damage and most 
studies show that induction of apoptosis is a unique property of E2F1 (DeGregori 
et al., 1997; Kowalik et al., 1998; Leone et al., 2001; Lissy et al., 2000).  
However, some research has shown that the other activating members, E2F2 and 
E2F3 also have this capacity (Vigo et al., 1999; Ziebold et al., 2001).  However, 
recent work has shown that apoptosis induced by E2F3 is associated with 
accumulation of E2F1 and that E2F3-induced apoptosis is dependent on E2F1 
(Denchi and Helin, 2005).  This suggests that accumulation of crucial levels of 
E2F1 activity, but not total E2F1 activity, is essential for the induction of 
apoptosis. 
We have gained more understanding of the pathways involved in E2F1-induced 
apoptosis in recent years.  Both overexpression experiments and mutant mouse 
models of E2F1 have shown that apoptosis can occur by mechanisms either 
dependent or independent of the tumour suppressor p53 (Fig. 1.7) (Field et al., 
1996; Kowalik et al., 1995; Macleod et al., 1996; Pan et al., 1998; Qin et al., 
1994; Shan and Lee, 1994; Vigo et al., 1999; Wu and Levine, 1994).   
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1.7.1 p53 dependent E2F1-induced apoptosis 
Some studies show that the ability of E2F1 to promote apoptosis is at least 
partially dependent on p53.  p53 mutant cells infected with an E2F1 adenoviral 
vector display attenuated apoptosis activity whereas augmentation of wild type 
p53 expression enhances cell death (DeGregori et al., 1995; Qin et al., 1994; Wu 
and Levine, 1994).  p53 levels rise during E2F1 mediated apoptosis which 
corresponds with an increase in ARF expression (Bates et al., 1998; Guida and 
Zhu, 1999; Hiebert et al., 1995; Kowalik et al., 1998).  The ARF protein binds to 
MDM2, and by doing so it blocks the ability of MDM2 to inactivate and 
ubiquitinate p53,  which normally leads to p53 degradation (Bates et al., 1998; 
Honda and Yasuda, 1999; Kamijo et al., 1998; Pomerantz et al., 1998; Zhang et 
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Figure 1-7 E2F1 can induce apoptosis in cells with and without functional p53 protein.  
E2F1 transcriptionally activates genes such as ARF, ATM and Chk2 leading to 
activation of p53 and apoptosis.  But E2F1 has also been shown to activate genes 
leading to apoptosis in a p53-independent manner.  Caspases 3, 7, 8 and 9 have all 
been shown to be upregulated by E2F1 activation as well as Apaf1, some pro-apoptotic 
Bcl-2 proteins and the p53 family member p73.  Activation of these proteins all lead to 
increased apoptosis.  E2F1 can also induce apoptosis by downregulating anti-
apoptotic genes such as TRAF2 and Bcl-2. 
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al., 1998).  E2F1 directly transactivates the ARF gene thereby promoting p53 
stability (Bates et al., 1998).  Indeed, the loss of ARF, as well as the 
overexpression of MDM2, impedes the ability of E2F to promote p53-dependent 
apoptosis (de Stanchina et al., 1998; Kowalik et al., 1998).   
E2F1 can also induce apoptosis in a p53 dependent manner in mice and cells 
which lack ARF (Rogoff et al., 2002; Russell et al., 2002; Tolbert et al., 2002; 
Tsai et al., 2002).  Several kinases phosphorylate and thus activate p53 upon 
DNA damage, including ATM/ATR, Chk1 and Chk2 (Banin et al., 1998; Canman et 
al., 1998; Shieh et al., 2000).  E2F1 can directly activate transcription of both 
ATM and Chk2 genes, which phosphorylated p53 and alleviate its Mdm2-mediated 
degradation (Berkovich and Ginsberg, 2003).  Therefore, ATM and Chk2 are most 
likely responsible for mediating the E2F1-driven phosphorylation of p53. 
E2F1 also activates pro-apoptotic co-factors of p53.  E2F1 (and E1A expression) 
upregulates the expression of ASPP1, ASPP2, JMY and TP53INP1 through a direct 
transcriptional mechanism (Chen et al., 2005; Fogal et al., 2005; Hershko et al., 
2005).  In addition, these factors then enhance the ability of p53 to induce cell 
death.  It was also shown that activation of E2F1 leads to phosphorylation of p53 
on serine 46 and this modification is important for E2F1-p53 cooperation in 
apoptosis. 
1.7.2 p53 independent E2F1-induced apoptosis 
In cell types lacking p53, for example, Saos-2 oesteosarcoma cells, E2F1 has still 
been shown to induce death in absence of p53.  E2F1 overexpression caused 
atrophy in testicles and sterility through a process involving increased apoptosis 
in mice which is independent of functional p53, since p53-nullizygous transgenic 
mice overexpressing E2F1 also suffer testicular atrophy (Holmberg et al., 1998). 
In the absence of p53, the p53 family member, p73, may contribute to 
apoptosis.  Expression of E2F1 in p53 nullizygous mice result in the induction of 
p73 expression along with transcription of p73 targets such as p21 and MDM2 
(Irwin et al., 2000).  Furthermore, inhibition of p73 function partially protects 
cells from E2F1-induced apoptosis (Stiewe and Putzer, 2000; Zaika et al., 2001).   
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E2F1 may also cause cellular death by directly targeting genes that regulate the 
apoptotic pathway.  Deregulation of E2F1/DP1 in p53-/- MEF or enforced E2F1 
expression have been shown to give rise to an increase in expression of caspases 
3, 7, 8 and 9 (Budd, 2001; Hitchens and Robbins, 2003; Nahle et al., 2002). 
Additional members of the intrinsic apoptotic pathway are targets of E2F1.  E2F1 
and p53 both upregulate Apaf1 expression, but E2F1 also induces Apaf1 in the 
absence of p53 demonstrating that the E2F1 can directly control Apaf1 
transcription (Furukawa et al., 2002; Moroni et al., 2001).  E2F1 may also 
modulate the expression of the pro-apoptotic Bcl-2 family members Bad, Bak 
and Bid, which are responsible for governing the release of mitochondrial 
proteins such as cytochrome C (Stanelle et al., 2002).  E2F1 can also up-regulate 
the expression of the pro-apoptotic BH3-only proteins PUMA, Noxa and Bim, 
through a direct transcriptional mechanism (Biswas et al., 2005; Cao et al., 
2004). 
In addition to direct activation of pro-apoptotic genes, a second mechanism by 
which E2F1 sensitizes cells to apoptosis is inhibition of anti-apoptotic genes.  
E2F1 overexpression suppresses Bcl-2 protein and RNA levels, and restoration of 
Bcl-2 protein effectively blocks the accelerated apoptosis that occurs when E2F1 
is overexpressed (Eischen et al., 2001). 
E2F1’s ability to inhibit survival factors to induce apoptosis is also supported by 
a study showing inhibition of necrosis factor κB (NF-κB).  NF-κB is stimulated via 
TNF receptor-associated factor 2 (TRAF2) following activation of TNF receptor, 
which contributes to inhibition of cell death (Chen and Goeddel, 2002).  E2F1 
induces apoptosis by a death receptor-dependent mechanism, by downregulating 
TRAF2 protein levels thereby inhibiting anti-apoptotic NF-κB signaling (Phillips et 
al., 1999). 
A number of reposts have indicated that mutants of E2F1 which lack the 
transactivation domain are also able to induce death (Hsieh et al., 1997; Liu and 
Greene, 2001; Phillips et al., 1997).  This suggests that induction of apoptosis by 
E2F1 may be partially mediated through alleviation of E2F-dependent 
transcriptional repression.  Furthermore, only 75 amino acids from within the 
DNA binding domain of E2F1 is sufficient for cell death (Bell et al., 2006).  This 
53 
domain of E2F1 does not bind DNA and is consequently unable to transactivate, 
repress or de-repress E2F target genes. 
Overall, it is now clear that E2F1 can induce apoptosis by various mechanisms.  
E2F1-induced apoptosis can signal through both the extrinsic- and intrinsic-
apoptotic pathways and be both caspase-dependent and caspase-independent.  
E2F1 can also inhibit anti-apoptotic pathways to induce apoptosis.  In addition, 
the ability to both induce p53 expression and activity as well as promote 
expression of pro-apoptotic proteins downstream of p53 establishes the 
importance of E2F1 in apoptosis. 
1.8 E2F1 pathway as a therapeutic target 
Many anticancer studies set out either to boost cell death or to impede anti-
apoptotic and proliferative pathways.  For example, the restoration of the 
apoptotic pathway by reintroduction of p53 or activation of Apaf-1 increases the 
sensitivity of tumour cells to DNA damaging agents (Roemer and Friedmann, 
1994; Soengas et al., 2001).  However, mutant p53 in tumour cells can in some 
conditions weaken the function of wild type p53, and result in ineffective p53-
based gene therapy (Stanelle and Putzer, 2006).  Therefore, targets that 
compensate for or bypass cell death defects, regardless of p53 status, can be 
particularly useful.   
E2F1 can induce apoptosis independently of p53 status, and the stabilization of 
E2F1 in response to DNA damage implies a role for E2F1 as a stress response 
gene that may play a role in enhancing chemosensitivity.  Preclinical 
experiments using E2F1 as an anti-cancer therapy have been initiated.  Induction 
of E2F1 via adenoviral mediated gene transfer results in tumour cell apoptosis in 
vivo with relative sparing of normal tissue (Kaelin, 2003).  Moreover, E2F1 can 
sensitize cells to chemotherapy.  E2F1 increases the effectiveness of 
chemotherapeutic agents that are most active in S-phase cells and/or require 
the presence of a particular cell-cycle dependent target for the induction of cell 
death (for example, topoisomerase).  E2F1 protein levels increase in various 
human cancer cell lines following treatment with the topoisomerase inhibitors 
adriamycin or etoposide.  This occurs independently of Rb or p53 status.  
Induction of E2F1 in tumour cells correlates with their sensitivity to adriamycin 
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or to etoposide, and fibroblasts from E2F1 knockout mice are more resistant to 
DNA damage than cells from normal mice. Overexpression of wild type E2F1 
protein in various tumour cell lines (following transfection or infection with an 
adenovirus encoding wild-type E2F1) leads to enhanced cytotoxicity following 
exposure to DNA damaging agents, which results from enhanced apoptosis 
(Banerjee et al., 1998; Hofland et al., 2000; Meng et al., 1999; Nip et al., 1997). 
Another approach, bearing in mind that the pRb pathway is deregulated in most 
tumours leading to increased E2F1 activity, is to use molecules to further 
increase E2F1 activity throughout the cell cycle.  Cdk2/cyclin A can bind and 
neutralize E2F1 during S phase.  Inhibition of the cdk2/cyclin A binding to E2F1 
causes induction in apoptosis in tumour cells containing inactive pRb but not in 
normal cells (Chen et al., 1999).  
It has been shown that Nutlins, small molecular inhibitors of Mdm2, inhibit 
Mdm2-p53 interaction and activate p53 signalling in cells with wild type p53 but 
not mutant p53.  However, recent studies showed that Nutlin-3a increased 
cytotoxicity of genotoxic agents in human tumour cell lines with mutant p53.  
Nutlin-3a inhibited the binding of E2F1 to Mdm2 and induced stabilization and 
transcriptional activation of E2F1 following drug induced DNA damage, indicating 
that antagonism of Mdm2 by Nutlin-3a in cells with mutant p53 can enhance 
chemosensitivity in a E2F1 dependent manner (Ambrosini et al., 2007).  
E2F1’s downstream target, p73 is a valuable candidate for cancer therapy in 
tumour cells (Bell et al., 2007).  Similar to E2F1, p73 efficiently induces 
apoptosis and enhances chemosensitivity of cells that are primarily resistant to 
apoptosis mediated by wild type p53 (Rodicker and Putzer, 2003).  Moreover, 
therapeutic efficacy of E2F1 in pancreatic cancer correlates with p73 induction 
(Rodicker et al., 2001). 
In addition to activating pro-apoptotic E2F1 target genes, molecules that target 
anti-apoptotic E2F1 regulated genes have been used in clinical studies in an 
attempt to hinder tumour growth.  For example, anti-apoptotic Bcl-2 has been 
targeted by antisense oligonucleotides approaches that interfere with Bcl-2 
activity, resulting in less Bcl-2 expression and in induction of apoptosis (Jansen 
et al., 2000; Klasa et al., 2002). 
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Overall, these results show that DNA damage can cooperate to selectively induce 
p53-independent apoptosis in cells that have deregulated E2F1 activity resulting 
from mutations in the pRb pathway.  This implicates an important role for E2F1 
in p53-independent sensitization to chemotherapy and provides a basis for 
pharmacologically increasing E2F1 protein levels for therapeutic gain. 
1.9 Overview 
Apoptosis is a complex process that regulates the destruction of a damaged cell.  
Therefore, it is thought that targeting the reactivation of apoptosis in malignant 
cells may be an effective method of cancer therapy.  Treatment with existing 
chemotherapeutic drugs leads to changes in networks of proliferation, survival 
and apoptotic genes, some of which are differentially expressed in normal and 
malignant cells, leading to initiation of apoptosis. 
The activation of the cell death pathway is influenced by the activity of many 
cellular genes.  The transcription factor E2F1 has been shown to play an 
important role in apoptosis.  E2F1 has the ability to induce both cell cycle 
progression and programmed cell death, leading potentially to both tumour-
promoting and tumour-suppressive effects (DeGregori et al., 1997).  The 
pathway to cell cycle progression is well known while the pathway to apoptosis 
is less well defined and more complex 
In normal cells apoptosis can occur in response to DNA damage.  Activation of 
oncogenes also sensitizes cells to apoptosis following treatment with 
chemotherapeutic drugs that cause DNA damage.  E2F1 has been shown to 
respond to DNA damage and oncogene activation and may therefore play a vital 
role in tumour suppression and during cellular responses to chemotherapy.  
Therefore, investigating the response of E2F1 to DNA damage and oncogene 
activation should contribute to the understanding of E2F1’s role in 
chemosensitivity. 
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2 Chapter 2: Materials and methods 
Table 2-1 Composition of routinely used solutions and media 
Substance Composition 
Phosphate Buffered 
Saline (PBS) 
170 mM NaCl, 3.3 mM KCl, 1.8 mM Na2HPO4, 10.6 mM 
KH2PO4 
Tris-Buffered Saline 
(TBS) 25 mM Tris-HCl, pH 7.4, 137 mM NaCl, 5 mM KCl 
TBST TBS + 0.1% Tween-20 
L-Broth (LB) 1% Bacto-tryptone, 86 mM NaCl, 0.5% yeast extract 
LB Agar LB + 1.5% agar 
Tris-EDTA (TE) 10 mM Tris-HCl, pH 8.0, 1 mM EDTA 
Tris-acetate-EDTA 
(TAE) 40 mM Tris, 0.1% glaciel acetic acid, 1 mM EDTA 
2 x Western Sample 
Buffer 
100 mM Tris, pH 6.8, 2% SDS, 5% ß- mercaptoethanol, 
15% glycerol, bromophenol blue 
SDS Running Buffer 0.1% SDS, 192 mM glycine, 25 mM Tris pH8.3 
Transfer Buffer 192 mM glycine, 25 mM Tris, 20% methanol, 0.01% SDS 
Tris Borate-EDTA (TBE) 45 mM Tris, 45 mM Boric acid, 0.625 mM EDTA pH 8.0 
5% BSA (in TBST) 5% Albumin, bovine serum (Sigma), 0.01% Sodium Azide, TBST 
5 x Western Sample 
Buffer 
60 mM Tris-HCL, pH 6.8, 2% SDS, 14,4 mM ß- 
mercaptoethanol,25% glycerol, 0.1% bromophenol blue   
 
2.1 Cell culture and treatments 
2.1.1 Cell culture 
Mouse Embryo Fibroblast (MEF) cells and Retinal Pigment Epithelial (RPE) cells 
were grown at 37°C in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal calf serum, (FCS, Autogenbioclear), 2 mM L-
glutamine, 60 μg/ml penicillin and 100 μg/ml streptomycin.  Cells were routinely 
grown in a humidified atmosphere containing 5% CO2 at 37˚C.  Cell culture was 
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performed in a Class II hood, using aseptic technique and sterile equipment and 
reagents.   
Cells were passaged when sub-confluent; approximately every 2-3 days.  After 
media was aspirated from the flask, 5ml of PBS was added to the cells then 
aspirated immediately.  4 ml TE + 0.25% trypsin was added and left for 
approximately 2 minutes at 37˚C.  Following trypsinisation fresh media was 
immediately added to the dissociated cells in order to neutralise the trypsin.  
Cells were centrifuged at 1000g for 5 minutes at room temperature and the 
media removed.  The pelleted cells were then resuspended in fresh media at a 
ratio of 1:3 to 1:4. 
Cryo-freezing was used for storage of all cell lines.  Cells were trypsinised as 
described and following pelleting by centrifugation, cells were resuspended in a 
solution of 90% FCS, 10% dimethylsulphoxide (DMSO).  Cells were aliquotted into 
cryo-tubes and frozen at 80˚C overnight and then transferred to liquid Nitrogen.  
Thawing of cells was performed rapidly by placing cryo-tubes in a water bath at 
37˚C until just thawed.  Cells were then mixed with fresh media, centrifuged at 
1000g for 5 minutes and the supernatant aspirated off to ensure removal of 
DMSO prior to resuspension in 10% FCS DMEM 
2.1.2 Transient transfection of plasmid DNA 
Cells were seeded onto 100 mm tissue culture plates the day prior to 
transfection.  A total of 15 μg plasmid DNA in 440 μl distilled H20 (Invitrogen) 
was mixed with 500 μl 2 x HBS (50 mM HEPES, 250 mM NaCl, 1.5 mM NaHP04 pH 
7.12) and 60 μl 2 M CaCl2 dropwise with vigorous mixing.  DNA calcium phosphate 
precipitate was allowed to form for 30 minutes at 37˚C then added dropwise to 
tissue culture plates.  The precipitate was removed after 16 hours and the cells 
washed twice in DMEM before 10% FCS DMEM added. 
2.1.3 Retroviral infections 
Retroviral infections were carried out using Phoenix-Ampho or Phoenix-Eco 
retroviral packaging cells which were maintained as described above.  2x106 
phoenix cells were plated in a 100 mm dish for each retroviral infection.  The 
following day cells were transfected with 15 μg retroviral vector DNA for 16hours 
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as described above, then three harvests of infectious supernatant were collected 
in DMEM containing 20% FBS at 12 hour intervals.  MEFs and RPEs were seeded at 
0.75 x106 /100mm dish 24 hours before infection.  Retroviral supernatants were 
purified through 0.45 μm filter then added to the MEFs or RPEs cultures together 
with polybrene (hexadimethrine bromide; Sigma) at a final concentration of 5 
μg/ml.  Three rounds of infection were undertaken at 12 hour intervals with 
retroviral pLPC vector alone or pLPC with insert of interest. After a 24 hour 
recovery period in 10% FCS DMEM, MEF cells were selected for four days in 2.5 
μg/ml puromycin (sigma) and RPE cells in 5.0μg/ml puromycin for 6 days. 
2.1.4 Stable cell lines created using retroviral infection 
Cell lines stably expressing scrambled short hairpin or shE2F1 were made using 
Phoenix-Ampho as a packaging cell and RPE and RPE E1A ER cells as a target cell 
line.  Following retroviral infection, as described above, and 24 hour recovery 
period in 10% FCS DMEM, cells were selected in 5.0 μg/ml puromycin for 6 days.   
The following E2F1 knockdown cell lines were created. 
Table 2-2 RPE cell lines with E2F1 knockdown 
Cell line Vector used 
RPE shScr pSuper Retro scramble short hairpin  
RPE shE2F1 pSuper Retro E2F1 short hairpin 
RPE E1A ER shScr pSuper Retro scramble short hairpin 
RPE E1A ER shE2F1 pSuper Retro E2F1 short hairpin 
 
Cell lines stably expressing wild type E1A, wild type E2F1 or deletion mutants of 
E1A were made using Phoenix-Ampho as a packaging cell and PRE cells as a 
target cell line.  Following retroviral infection, as described above, and 24 hour 
recovery period in 10% FCS DMEM, cells were selected in 5.0 μg/ml puromycin 
for 6 days.   
The following RPE cell lines were created. 
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Table 2-3 RPE cell lines expressing E1A truncations 
Cell line Vector used 
RPE pLPC pLPC 
RPE E1A pLPC wt E1A 12S 
RPE E2F1 pLPC E2F1 
RPE E1A ΔCR2 pLPC E1A ΔCR2 
RPE E1A R2G pLPC E1A R2G 
RPE E1A Δ2-11 pLPC E1A Δ2-11 
RPE E1A Δ2-24 pLPC E1A Δ2-24 
RPE E1A Δ2-36 pLPC E1A Δ2-36 
RPE E1A Δ26-35 pLPC E1A Δ26-35 
RPE E1A Δ48-60 pLPC E1A Δ48-60 
RPE E1A 143 pLPC E1A 143 
 
Cell lines stably expressing wild type E2F1, truncated and/or mutated forms of 
E2F1 or E1A-ER fusion protein were made using Phoenix-Eco as a packaging cell 
and wild type MEFs, E2F1-/-, pRb-/- or pRB family triple knockout (pRb-/-, 107-/- 
and 130-/-) MEFs as a target cell line.  Following retroviral infection, as described 
above, and 24 hour recovery period in 10% FCS DMEM, MEF cells were selected 
for four days in 2.5 μg/ml puromycin.   
The following MEF cell lines were created. 
Table 2-4 MEF cell lines expressing E1A-ER, full length or truncations/mutants of E2F1 
Cell line Vector used 
MEF FL E2F1 pLPC FL E2F1 
MEF E2F1 Tr. 1 Δ374 pLPC E2F1 Truncation 1 GFP 
MEF E2F1 Tr. 2 Δ374, 132E pLPC E2F1 Truncation 2 GFP 
MEF E2F1 Tr. 3 Δ284 pLPC E2F1 Truncation 3 GFP 
MEF E2F1 Tr. 4 Δ245 pLPC E2F1 Truncation 4 GFP 
MEF E2F1 Tr. 5 Δ191 pLPC E2F1 Truncation 5 GFP 
MEF E2F1 Tr. 6 Δ120 pLPC E2F1 Truncation 6 GFP 
MEF E2F1 Tr. 7120-374 pLPC E2F1 Truncation 7 GFP 
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MEF E2F1 Tr. 8 245-374 pLPC E2F1 Truncation 8 GFP 
MEF E2F1 Tr. 9 317-374 pLPC E2F1 Truncation 9 GFP 
MEF E2F1 Tr. 10 245-317 pLPC E2F1 Truncation 10 GFP 
MEF E2F1 Tr. 11 120-191 pLPC E2F1 Truncation 11 GFP 
MEF GFP pLPC GFP 
MEF E2F1 S31A pLPC E2F1 S31A 
MEF E2F1 S364A pLPC E2F1 S364A 
MEF E2F1 D390A/F391A 
 
pLPC E2F1 D390A/F390A 
MEF E2F1 S31A/S364A pLPC E2F1 S31A/ S364A 
MEF E2F1 S31A/S364A/ 
D390A/F391A pLPC E2F1 S31A/ S364A/D390A/F391A 
MEF E2F1 K117R/K120R/K125R pLPC E2F1 K117R/K120R/K125R 
MEF E2F1 Tr. 8 S31A pLPC E2F1 Truncation 8 S31A GFP 
MEF E2F1 Tr. 8 245-374 S31A 
K117R/K120R 
pLPC E2F1 Truncation 8 S31A K117R 
GFP 
MEF E2F1 Tr. 8 245-374 S31A 
K117R/K120R  T49A 
pLPC E2F1 Truncation 8 S31A K117R 
T49A GFP 
MEF E2F1 Tr. 8 245-374 S31A 
K117R/K120R T49D 
pLPC E2F1 Truncation 8 S31A K117R 
T49D GFP 
MEF E2F1 Tr. 8 245-374 S31A 
K117R/K120R T75A 
pLPC E2F1 Truncation 8 S31A K117R 
T75A GFP 
MEF E2F1 Tr. 8 245-374 S31A 
K117R/K120R T75D 
pLPC E2F1 Truncation 8 S31A K117R 
T75D GFP 
MEF E2F1 Tr. 8 245-374 S31A 
K117R/K120R Y100F 
pLPC E2F1 Truncation 8 S31A K117R 
Y100F GFP 
MEF E2F1 Tr. 8 245-374 S31A 
K117R/K120R Y100D 
pLPC E2F1 Truncation 8 S31A K117R 
Y100D GFP 
MEF E2F1 Tr. 8 S31A K117R/K120R 
S104A 
pLPC E2F1 Truncation 8 S31A K117R 
S104A GFP 
MEF E2F1 Tr. 8 245-374 S31A 
K117R/K120R S104D 
pLPC E2F1 Truncation 8 S31A K117R 
S104D GFP 
MEF E2F1 Tr. 6 Δ120 S121A pLPC E2F1 DNA Binding Domain S121A GFP 
MEF E2F1 Tr. 6 Δ120 S121D pLPC E2F1 DNA Binding Domain S121D 
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MEF E2F1 Tr. 6 Δ120 S126A pLPC E2F1 DNA Binding Domain S126A GFP 
MEF E2F1 Tr. 6 Δ120 S126D pLPC E2F1 DNA Binding Domain S126D GFP 
MEF E2F1 Tr. 6 Δ120 Y128F 
pLPC E2F1 DNA Binding Domain Y128F 
GFP 
 
MEF E2F1 Tr. 6 Δ120 Y128D pLPC E2F1 DNA Binding Domain Y128D GFP 
MEF E2F1 Tr. 6 Δ120 T130A pLPC E2F1 DNA Binding Domain T130A GFP 
MEF E2F1 Tr. 6 Δ120 T130D pLPC E2F1 DNA Binding Domain T130D GFP 
MEF E2F1 Tr. 6 Δ120 T135A/T136A pLPC E2F1 DNA Binding Domain T135A/T136A GFP 
MEF E2F1 Tr. 6 Δ120 T135D/T135D pLPC E2F1 DNA Binding Domain T135D/T135D GFP 
MEF E2F1 Tr. 6 Δ120 T168A 
pLPC E2F1 DNA Binding Domain T168A 
GFP 
 
MEF E2F1 Tr. 6 Δ120 T168D pLPC E2F1 DNA Binding Domain T168D GFP 
MEF E2F1 GFP pLPC E2F1 E2F1 GFP 
WT MEF E1A-ER pWZL blast E1A-ER 
E2F1 -/- MEF E1A-ER pWZL blast E1A-ER 
pRB -/- MEF E1A-ER pWZL blast E1A-ER 
TKO -/- MEF E1A-ER pWZL blast E1A-ER 
 
2.1.5 siRNA Tranfestions 
The following siRNA duplexes from Ambion were used: 
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Table 2-5 Oligos used in siRNA transfections 
Gene Accession No. Catalogue No. Sense and Antisense sequence 
GCCACCAAUAAGGCACUAU AM167708A 
(131906) AUAGUGCCUUAUUGGUGGC 
GGAUACGCUGACAGAACAA AM167708A 
(131907) UUGUUCUGUCAGCGUAUCC 
GCUUACACCAAUUGAAAAA 
Human 
p400 NM 015409 
AM167708A 
(131908) UUUUUCAAUUGGUGUAAGC 
 
All oligonucleotides were obtained as annealed and desalted duplexes from 
Ambion, having been designed with proprietary algorithms purported to increase 
the likelihood of silencing the desired target.  21-mer constituent 
oligonucleotides were synthesised as shown below, having complementary 
target-specific (N)19 sequences on each strand and 3’ diuridine or 
dideoxythymidine overhangs.  RPE cells were plated in 35 mm wells 24 hours 
before transfection at a density of 1.5 x 105 cells per well.  1.0 μl of 20 μM stock 
siRNA oligo was added to Optimem (Invitrogen) to a final volume of 185 μl.  In 
another tube 4 μl oligofectamine (Invitrogen) was added to 11 μl Optimem and 
incubated for 5-10 minutes before being mixed, vortexed briefly and incubated 
at room temperature for 15-20 minutes.  Meanwhile cells were washed twice 
with Optimem then 800 μl of Optimem was added to each well.  200 μl of the 
lipid complexes were added dropwise to each well, (to a final concentration of 
20 nM), and incubated for 5-6 hours at 37˚C then Optimem replaced with 2 ml 
10% FCS DMEM in each well.  Cells were treated and harvested at the times 
indicated for each assay.   
2.2 Molecular cloning 
2.2.1 Restriction digests 
Restriction Digests were performed with enzymes from New England Biolabs 
(NEB).  Five to ten-fold unit excess of enzyme was incubated with 2-10 μg DNA 
for 1 hour at the appropriate temperature.  For sequential digests DNA was 
purified using Qiagen PCR purification kit and resuspended in the appropriate 
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buffer for the sequential digest.  After digestion, cleaved vector DNA was 
incubated for a further 30 minutes at 37ºC with 5U Calf Intestine Alkaline 
Phosphatase (NEB) then DNA was purified using Qiagen PCR purification kit and 
resuspended in TE. 
2.2.2 Ligation 
Restriction fragments for ligation were purified by gel electrophoresis followed 
by excision using a Qiagen Gel Band Purification Kit.  Ligations were carried out 
usingRapid DNA Ligation Kit (Roche).  An approximate 2 fold molar excess of the 
insert fragment over the vector fragment was combined in a final volume of 10 
μl DNA Dilution Buffer.  10 μl T4 DNA Ligation buffer was then added along with 
5U T4 DNA ligase.  This was incubated at room temperature for 5 minutes. 
2.2.3 Transformation of competent cells 
E.Coli DH5α supercompetent cells (Stratagene) were transformed for plasmid 
storage and preparation.  Cells, which were stored at -80ºC and highly 
temperature sensitive, were thawed on ice to prevent loss of transformation 
ability.  Typically 10-20 ng of plasmid DNA was gently mixed into 50 μl of 
supercompetent cells.  The cells were incubated for 30 minutes on ice before 
being heat shocked at 42ºC for exactly 30 seconds and then transferred to ice for 
a further 2 minutes.  250 μl of 37ºC SOC medium (LB broth, 0.04% glucose, 10 
mM MgSO4, 10 mM MgCl2) was added before incubation for 1 hour on an orbital 
shaker (225-250 rpm).  Typically 150 μl of the transformation mixture was then 
plated on LB agar plates containing 50 μg/ml ampicillin or kanamycin and the 
plates were incubated at 37ºC overnight to allow growth and colony-formation of 
the transformed cells. 
2.2.4 Screening of transformants 
Colonies obtained from transformation were grown in overnight cultures of LB 
with 50 μg ampicillin/kanamycin, and plasmid DNA miniprepped using QIAprep 
Spin Miniprep Kits (Qiagen #27104).  Analytical restriction digests were 
performed and resolved upon agarose gels to validate successful cloning.  Insert-
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vector boundaries were always sequence analysed.  If the insert was PCR 
derived, the entire insert was also sequence analysed. 
2.2.5 Preparation of plasmid DNA 
For large scale plasmid DNA preparation, a single isolated bacterial colony was 
selected from a freshly streaked plate and used to inoculate 4 ml LB medium 
containing 50 μg/ml ampicillin/kanamycin.  This was allowed to incubate with 
vigorous shaking at 37ºC for about 6 hours to form a mini culture and was 
subsequently used to inoculate 100 ml LB containing 50 μg/ml 
ampicillin/kanamycin.  Following an overnight incubation at 37ºC on an orbital 
shaker (300 rpm), cells were harvested by centrifugation at 3000g for 20 minutes 
at 4ºC and plasmid DNA retrieved using the Qiagen Plasmid Maxi Kit. 
The bacterial pellet was resuspended in 10 ml of Buffer P1 (50 mM Tris pH 8.0, 
10 mM EDTA, 100 μg/ml RNase A) and then gently but thoroughly mixed with 10 
ml Buffer P2 (200 mM NaOH, 1% SDS) to initiate an alkaline lysis reaction.  This 
reaction was allowed to proceed for 5 minutes at room temperature before 
neutralising the lysate by the addition of 10 ml chilled buffer P3 (3M potassium  
acetate, pH 5.5) which subsequently resulted in formation of a precipitate of 
dodecyl sulphate.  The SDS-denatured proteins and chromosomal DNA were co-
precipitated with the detergent whilst the plasmid DNA remained in solution due 
to a lack of close protein associations.  Precipitation was enhanced by 20 minute 
incubation on ice and the precipitate was then pelleted by centrifugation at 
4000g for 30 minutes at 4ºC.  The supernatant containing plasmid DNA was 
promptly removed and applied to a QIAGEN-tip 500 pre-equilibriated with 10 ml 
of Buffer QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 15% Isopropanol, 0.15% Triton 
X-100).  Gravity flow allowed the supernatant to pass through the anion-
exchange resin to which plasmid DNA is able to tightly bind.  The resin was the 
washed twice with 30 ml of buffer QC (1 M NaCl, 50 mM MOPS pH 7.0, 15% 
Isopropanol) and the purified plasmid DNA was subsequently eluted with 15 ml 
Buffer QF (1.25 M NaCl, 50 mM Tris pH 8.5, 15% isopropanol) and precipitated 
with 10.5 ml (0.7 volume) of room temperature isopropanol.  This was 
immediately followed with a 4000g centrifugation at 4ºC for 30 minutes.  The 
plasmid DNA pellet was then washed with 70% ethanol, dried at room 
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temperature for 5-10 minutes and resuspended in an appropriate volume of 
sterile TE buffer (pH 8.0 10 mM Tris, 1 mM EDTA). 
2.2.6 Agarose gel electrophoresis 
Agarose (Sigma) was melted by heating in TAE, and then Ethidium Bromide was 
added to 0.5 μg/ml, prior to solidification.  Agarose was allowed to solidify in 
gel trays for at least 1 hour.  Samples for electrophoresis were diluted with 5 x 
gel loading buffer (30% glycerol, bromophenol blue) and electrophoresed at 100V 
in TAE gel running buffer.  Bands were visualised using a UV transilluminator. 
2.3 RNA/cDNA techniques 
2.3.1 Preparation of total cellular RNA 
Total cellular RNA was isolated from cells when approximately 80% confluent 
using TRI reagent (Sigma), in accordance with the manufacturers instructions.  
Media was aspirated off cells grown in 6-well plates or 100 mm plates.  Cells 
from each well were harvested by scraping in 500 μl of TRI reagent per well or 1 
ml per 100 mm plate and transferred to a sterile eppendorf tube.  Cells were 
left to stand for 5 minutes to ensure complete dissociation of nucleoprotein 
complexes.  0.2 ml of chloroform per 1 ml or TRI reagent used was then added 
to each tube and the samples vortexed for 15 seconds.  The samples were then 
allowed to stand for a further 15 minutes at room temperature prior to being 
centrifuged at 13,000g for 15 minutes at 4˚C.  This resulted in separation of the 
samples into three phases: A lower red organic phase containing protein, a 
middle white interphase containing precipitated DNA and an upper colourless 
aqueous phase containing RNA.  The upper phases were carefully removed, 
ensuring no contamination from the remaining phases and transferred to fresh 
eppendorf tubes.  500 μl Isopropanol per 1 ml TRI reagent used was added to 
each of the tubes containing the aqueous RNA and thoroughly mixed by repeated 
inverting.  Following 5-10 minutes incubation at room temperature to allow 
maximal precipitation of RNA, samples were centrifuged at 13,000g for 10 
minutes at 4˚C.  The supernatant was then removed and the remaining RNA 
pellet was washed with 1 ml of 75% ethanol made up with dietypyrocarbonate 
(DEPC)-treated dH2O (Ambion).  The samples were vortexed briefly, 
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microcentrifuged at 7500g for 5 minutes at 4˚C and the supernatant aspirated 
off.  Appropriate volumes of DEPC-H2O, in the range of 5-30 μl were added to 
resuspend the RNA pellet.  RNA concentration was determined by UV 
spectrophotometry.  A ratio of absorbance at 260 nm to 280 nm in the range of 
1.8-2.0 indicated the RNA samples were relatively free from contamination from 
DNA or protein. RNA was stored at 70˚C.  
2.3.2 Preparation of cDNAs 
cDNAs were prepared using the GeneAmp RNA PCR kit (Applied Biosystems) as 
per the manufacturers instructions using 1 μg RNA on Peltier Thermal Cycler (MJ 
Research).  Primer annealing was carried out in a final volume of 20 μl including 
4 μl 25 mM MgCl2, 2 μl 10 x PCR Buffer II (500 mM KCl, 100 mM Tris-HCl, pH 8.3), 
8 μl 10 mM dNTPs, 20U Rnase inhibitor, 50U MuLV Reverse Transcriptase, 1 μl 
Random Hexamers (50 μM) for 10 minutes before reverse transcription was 
allowed to proceed at 42ºC for 30 minutes.  The reaction was stopped by heating 
at 70ºC for 15 minutes and cDNAs were then stored at -20ºC. 
2.3.3 Reverse transcriptase – Polymerase chain reaction (RT-
PCR) 
PCRs were carried out using a Peltier Thermal Cycler (MJ research, Helena 
Bioscience).  2 μl of cDNA was amplified in a final volume of 20 μl containing 1 
nM of each primer, 0.5U AmpliTaq DNA polymerase, 2 μl 10 x PCR Buffer II, 1.2 
μl 25mM MgCl2 and 20 μM dNTP. 
The following forward and reverse primers were used: 
 
Table 2-6 RT-PCR primers 
Primer Sequence 
E2F1 F 5’-GCCACCATAGTGTCACCACC-3’ 
E2F1 R 5’-GGTGAGGTCCCCAAAGTCAC-3’ 
GAPDH F 5’-TCCACCACCCTGTTGCTG-3’ 
GAPDH R 5’-ACCACAGTCCATGCCATCAC-3’ 
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PCR  reaction were carried out under the following cycling parameters: 95˚C for 
3.00 minutes, 20 cycles for GAPDH, 25 cycles for E2F1 of 95˚C for 30 seconds, 
66˚C for 40 seconds 72˚C for 1.00 minute and then cooled down to 4˚C.  
Reaction products were resolved using Agarose Gel Electrophoresis and bands 
visualised using a UV transilluminator as described above. 
2.3.4 Site-directed mutagenesis 
Site-Directed Mutagenesis was carried out using QuickChange Site-Directed 
Mutagenesis Kit (Stratagene) with 5 μl of 10x reaction buffer, 50 ng of dsDNA 
template, 125 ng forward primer, 125 ng reverse primer, 1 μl dNTP mix, 2.5 μl 
DMSO in the final volume of 50 μl.  Then 1 μl of Pfu Turbo DNA polymerase (2.5 
U/μl) was added to the reaction.  The  PCR reactions were carried out under the 
following cycling paramerters: 95˚C for 30 seconds, 18 cycles of 95˚C for 30 
seconds, 55˚C for 5.30 minutes, and then cooled down to 4˚C, using on a Peltier 
Thermal Cycler (MJ Research).  Then 1 μl of the Dpn I restriction enzyme (10 U/ 
μl) was added to each amplification reaction and incubated at 37˚C for 1 hour to 
digest the parental (i.e. the nonmutated) supercoiled dsDNA.  1 μl of the 
digested reaction was used to to transform E.Coli DH5α supercompetent cells 
(Stratagene) as described above.  The day after, 10 colonies were picked for 
each reaction, grown over night, and plasmid DNA miniprepped.  Analytical 
restriction digests were performed and resolved upon agarose gels to validate 
successful amplification and then entire inserts sequence to verify successful 
mutagenesis. 
The following primers were used in Site-Directed Mutagenesis 
Table 2-7 Primers used in Site-Directed Mutagenesis 
Primer Sequence 
E2F1 S31A F CGGCTGCTCGACTCCTCGCAGATCGTCATCATCTCCGC 
E2F1 S31A R CGGCTGCTCGACTCCGCGCAGATCGTCATCATCTCCGC 
E2F1 S364A F GCTGTTGTCCCGGATGGGCAGCCTGCGGGCTCCCGTGGAC 
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E2F1 S364A R GCTGTTGTCCCGGATGGGCGCCCTGCGGGCTCCCGTGGAC 
E2F1 D390A/F391A F CCTGGAGCATGTGCGGGAGGCCGCCTCCGGCCTCCTCCCTGAGG 
E2F1 D390A/F391A R CCTCAGGGAGGAGGCCGGAGGCGGCCTCCCGCACATGCTCCAGG 
E2F 
K117R/K120R/K125R F 
GCCATCCAGGAGAAGGTGTGAGATCCCCGGGGGAGAGGT
CACGCTATGA 
E2F 
K117R/K120R/K125R R 
TCATAGCGTGACCTCTCCCCCGGGGATCTCACACCTTCTCC
TGGATGGC 
E2F1 Tr. 8 K117/120R F CGCCATCCAGGAGAAGGTGTGAGACCGGATCCACC 
E2F1 Tr. 8 
K117R/K120R R GGTGGATCCGGTCTCACACCTTCTCCTGGATGGCG 
E2F1 Tr. 8 T49A F CCGCCGGCTCCCGCCGGCCCCGCGG 
E2F1 Tr. 8 T49A R CCGCGGGGCCGGCGGGAGCCGGCGG 
E2F1 Tr. 8 T49D F CCGCCGGCTCCCGACGGCCCCGCGG 
E2F1 Tr. 8 T49D R CCGCGGGGCCGTCGGGAGCCGGCGG 
E2F1 Tr. 8 T75A_F CGCCCCGGCCCGCACCCAGTGCGCC 
E2F1 Tr. 8 T75A R GGCGCACTGGGTGCGGGCCGGGGCG 
E2F1 Tr. 8 T75D F CGCCCCGGCCCGACCCCAGTGCGCC 
E2F1 Tr. 8 T75D R GGCGCACTGGGGTCGGGCCGGGGCG 
E2F1 Tr. 8 Y100D F GACCATCAGGACCTGGCCGAGAGC 
E2F1 Tr. 8 Y100D R GCTCTCGGCCAGGTCCTGATGGTC 
E2F1 Tr. 8 Y100F F GACCATCAGTTCCTGGCCGAGAGC 
E2F1 Tr. 8 Y100F R GCTCTCGGCCAGGAACTGATGGTC 
E2F1 Tr. 8 S104A F CCTGGCCGAGGCCAGTGGGCCAGC 
E2F1 Tr. 8 S104A R GCTGGCCCACTGGCCTCGGCCAGG 
E2F1 Tr. 8 S104D F CCTGGCCGAGGACAGTGGGCCAGC 
E2F1 Tr. 8 S104D R GCTGGCCCACTGTCCTCGGCCAGG 
E2F1 Tr. 15 S121A F CAGGAAAAGGTGTGAAAGCCCCGGGGGAGAAGTCACG 
E2F1 Tr. 15 S121A R CGTGACTTCTCCCCCGGGGCTTTCACACCTTTTCCTG 
E2F1 Tr. 15 S121D F CAGGAAAAGGTGTGAAAGACCCGGGGGAGAAGTCACG 
E2F1 Tr. 15 S121D R CGTGACTTCTCCCCCGGGTCTTTCACACCTTTTCCTG 
E2F1 Tr. 15 S126A F TGAAATCCCCGGGGGAGAAGGCACGCTATGAGACCTCACT 
E2F1 Tr. 15 S126A R AGTGAGGTCTCATAGCGTGCCTTCTCCCCCGGGGATTTCA 
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E2F1 Tr. 15 S126D F TGAAATCCCCGGGGGAGAAGGACCGCTATGAGACCTCACT 
E2F1 Tr. 15 S126D R AGTGAGGTCTCATAGCGGTCCTTCTCCCCCGGGGATTTCA 
E2F1 Tr. 15 T130A F GGAGAAGTCACGCTATGAGGCCTCACTGAATCTGACCAC 
E2F1 Tr. 15 T130A R GTGGTCAGATTCAGTGAGGCCTCATAGCGTGACTTCTCC 
E2F1 Tr. 15 T130D F GGAGAAGTCACGCTATGAGGACTCACTGAATCTGACCAC 
E2F1 Tr. 15 T130D R GTGGTCAGATTCAGTGAGTCCTCATAGCGTGACTTCTCC 
E2F1 Tr. 15 Y128D F CCCGGGGGAGAAGTCACGCGATGAGACCTCACTGAATCT 
E2F1 Tr. 15 Y128D R AGATTCAGTGAGGTCTCATCGCGTGACTTCTCCCCCGGG 
E2F1 Tr. 15 Y128F F CCCGGGGGAGAAGTCACGCTTTGAGACCTCACTGAATCT 
E2F1 Tr. 15 Y128F R AGATTCAGTGAGGTCTCAAAGCGTGACTTCTCCCCCGGG 
E2F1 Tr. 15 
T135A/T136A F CACTGAATCTGGCCGCCAAGCGCTTCC 
E2F1 Tr. 15 
T135A/T136A R GGAAGCGCTTGGCGGCCAGATTCAGTG 
E2F1 Tr. 15 
T135D/T136D F CACTGAATCTGGACGACAAGCGCTTCC 
E2F1 Tr. 15 
T135D/T136D R GGAAGCGCTTGTCGTCCAGATTCAGTG 
E2F1 S144D/S146D F GAGCTGCTGGACCACGACGCTGACGGTG 
E2F1 S144D/S146D R CACCGTCAGCGTCGTGGTCCAGCAGCTC 
E2F1 Tr. 15 T168A F GCGGCGCATCTTTGACATCACC 
E2F1 Tr. 15 T168A R GGTGATGTCAAAGATGCGCCGC 
E2F1 Tr. 15 T168D F GCGGCGCATCGATGACATCACC 
E2F1 Tr. 15 T168D R GGTGATGTCATCGATGCGCCGC 
 
2.3.5 Quantitative real time polymerase chain reaction (qRT-PCR) 
cDNA synthesis and qRT-PCR was carried out using the DyNAmo SYBR Green 2-
step qRTPCR Kit with 1 μg RNA, 10 μl RT buffer (including dNTP mix and 10 mM 
MgCl2), 1 μl Random Hexamers (300 ng/μl) and 2 μl M-MuLV Rnase H+ reverse 
transcriptase in a final volume of 20 μl per sample. cDNA synthesis was carried 
out under the following parameters: Primer Extension – 25˚C for 10 minutes, 
cDNA Synthesis – 37˚C for 30 minutes, Reaction Termination – 85˚C for 5 
minutes, on a Peltier Thermal Cycler (MJ Research). 
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Prior to analysis, a large preparation of serially diluted RPE total RNA was made 
and frozen in multiple aliquots at -70ºC in order to provide material to construct 
reproducible standard curves.  qRT-PCR was carried out with 2 μl of cDNA, 10 μl 
2x qPCR master mix, (contains modified hot start Tbr DNA polymerase, SYBR 
Green I, optimized PCR Buffer, 5 mM MgCl2 and dNTP mix including dUTP), 5.5 μl 
H2O and 2.5 μl designed primers as indicated (QuantiTect Primer Assays – 
Qiagen) for gene of interest.  18S rRNA control primers were also used for each 
tested cDNA and used to standardise data.  Three repeats were carried out for 
each sample.  For analysis the control sample was normalised to 1 and all other 
samples were compared relative to this value. 
Reactions were pipetted into 96 well optical plate (BioRad) minimizing exposure 
of the qPCR master mix to light and sealed using optically clear flat cap strips 
(BioRad). qPCR was carried out under the following cycling parameters using MJ 
Opticon Moniter Analysis Software version 3.1, on a Peltier Thermal Cycler (MJ 
Research) with a Chromo 4 continuous fluorescence detector.  
Initial Denaturation – 95˚C for 15 minutes, 40 cycles of Denaturation – 94˚C for 
10 seconds, Annealing – 55˚C for 30 seconds, Extension – 72˚C for 30 seconds, 
plate read (data aqusition), followed by Final Extension – 72˚C for 10 minutes, 
Melting Curve 70-90˚C read 0.3C hold 1 second and Reannealing – 72˚C for 10 
minutes.  Data analysed using MJ Opticon Moniter Analysis Software version 3.1 
The following Primers were used 
Table 2-8 Primers used in qRT-PCR 
Gene Catalogue No. 
Hs E2F1 QT00016163 
Hs p400 QT00079807 
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2.4 Protein immunoblotting 
2.4.1 Separation of proteins by polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Proteins were resolved on denaturing polyacrylamide gels according to molecular 
weight by electrophoresis on Amersham Biosciences SE400 standard format 
vertical unit tanks.  Typically, cells were lysed in a 2x western sample buffer.  
Equal numbers of cells were used per plate and equal volumes of sample were 
boiled for 2 minutes prior to loading then electrophoresed on SDS-
polyacrylamide gels in 1 x SDS running buffer at 55V overnight until the dye front 
had reached the bottom of the gel. SDS-PAGE gels consisted of a separating gel 
overlaid by a stacking gel.  Depending on the molecular weight of the product to 
be visualised, the separating gel was between 6% and 15% acrylamide (from 30% 
stock solution (37.5:1 acrylamide:bis acrylamide) Severn Biotech Ltd) and 
otherwise constituted 375mM Tris-HCl, pH8.8, 0.1% SDS, polymerised with 0.05% 
ammonium persulphate, 0.1% TEMED (Sigma).  Stacking gel was 4% acrylamide 
and otherwise constituted 125mM Tris-HCl, pH 6.8 , 0.1% SDS, polymerised with 
0.05% ammonium persulphate, 0.1% TEMED. 
2.4.2 Western blotting 
Electrophoretic transfer of proteins resolved by SDS-PAGE to nitrocellulose 
membrane was achieved using Hoefer TE 42 Protein Transfer tanks.  SDS Gels 
were blotted in a sandwich with sponge and 2 sheets Whatman 3MM paper, all 
equilibrated in Transfer Buffer, either side of the gel and a matching piece of 
nitrocellulose membrane (Amersham Biosciences).  Transfer was carried out in 1 
x Transfer Buffer at 0.5 Amps for 4 hours.  After transfer to nitrocellulose 
membranes, ponceau-S (Sigma) staining was undertaken as a further assessment 
of loading and to check the fidelity of transfer.   
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Table 2-9 Antibodies 
Antibody Type Company Dilution 
Anti-Actin A-4700 Monoclonal Sigma 1:2000 
Anti-Adenovirus (M58 + M73) 
 
Monoclonal Abcam 1:500 
Anti- Adenovirus type 5 E1A Monoclonal BD Pharmingen 1:500 
Anti-Adenovirus 2/5 E1A Polyclonal Santa Cruz 1:500 
Anti-E2F1 C-20 Polyclonal Santa Cruz 1:1000 
Anti-E2F1 KH95 Monoclonal Santa Cruz 1:1000 
Anti-E2F1 KH95/KH20 Monoclonal Upstate Biotechnology 1:1000 
Anti-GFP Monoclonal  Roche 1:1000 
Anti-GFP Monoclonal Covance 1:3000 
Anti-p38 Polyclonal Cell Signalling 1:1000 
Anti-p53 (DO-1) Monoclonal BD Pharmingen 1:5000 
Anti-PARP Monoclonal BD Pharmingen 1:1000 
 
Anti-pRb C-15 Polyclonal Santa Cruz 1:500 
Anti mouse IgG HRP linked  Cell Signalling 1:3000 
Anti rabbit IgG HRP linked  Cell Signalling 1:3000 
 
 
2.4.3 Probing 
Following transfer, the membrane was blocked in TBST milk buffer (TBST + 5% 
skimmed milk powder (Marvel) for 1 hour at room temperature.  Membranes 
were incubated with primary antibodies (typically a 1:1000 dilution in milk 
buffer or 5% BSA in TBST for 2 hour at room temperature or over night at 4˚C.  
Excess primary antibody was removed by washing the blot 3 times in TBST for 10 
minutes before incubating for 1 hour at room temperature with the appropriate 
horseradish peroxidase-conjugated secondary antibody (Cell Signalling) at a 
1:3000 dilution.  To ensure the removal of excess secondary antibody, the blot 
was washed 3 times for 15 minutes in TBST.  The blot was developed using the 
enhanced chemiluminescence method, (ECL Amersham), as directed by the 
manufacturers and X-ray film (Fuji Medical X-ray film). 
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2.4.4 Immunoprecipitation 
Protein-G sepharose beads (SIGMA) were washed twice with 1ml LSAB (20mM 
HEPES, 150mM NaCl, 0.5% Triton and complete mini protease inhibitor tablet 
(Roche). Beads were resuspended at 50:50 ratio of beads to LSAB buffer 
Cells with wild type E1A or E1A ΔCR2 as indicated were washed with PBS then 
scraped in 1ml LSAB and transferred to a sterile eppendorf tube.  Samples were 
spun at 13000g for 10 seconds and the supernatant was transferred to a fresh 
sterile eppendorf tube (60μl kept for SDS page analysis of Input).  Samples were 
pre-incubated with 20μl protein-G sepharose beads at 4˚C for 1 hour on an 
orbital shaker.  The beads were carefully pelleted by pulse microcentrifugation 
and the supernatants carefully removed and transferred to a fresh eppendorf.  
6ul of anti-E1A mouse antibody and 50ul of bead:buffer mix was added to each 
sample and incubated overnight at 4˚C on an orbital shaker.  The beads were 
carefully pelleted by pulse microcentrifugation and the supernatants carefully 
removed.  The beads were then washed three times with cold LSAB before the 
bound material was released by addition of an equal volume of 2 x western 
sample buffer and analysed by SDS PAGE and western blotting. 
2.5 Cell death assays 
After the treatments and times indicated, total populations of cells, including 
floating and adherent cells, were processed for flow cytometric analysis 
(FACScan, Becton Dickinson).  Each sample was harvested by collection of media 
in 15ml falcon tube.  The cells were then washed in 2 ml PBS which was also 
collected into the 15 ml falcon tube and 2 mls of TE + 0.25% trypsin was added 
to remove adherent cells, and subsequently transferred to the falcon tube.  The 
samples were then centrifuged for 5 minutes at 1000g and the supernatants 
removed.  Cells were resuspended in 500 μl PBS followed by 5 ml ice cold 
methanol while vortexing the samples to avoid clumping.  The cells were then 
left to fix at 4˚C for a minimum of 3 hours.    
Directly before FACS analysis the cells were collected by centrifugation and 
resuspended in 400 μl PBS, 20 μl 1 mg/ml Propidium iodide (Sigma) and 0.2 μl 
RNase (100 mg/ml) and incubated for 30 minutes at room temperature then 
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sorted for and analysed for DNA content.  The percentage of cells with a sub-G1 
DNA content was taken as a measure of the apoptotic rate of the cell 
population. 
2.6 Plasmid sources and construction 
pLPC 
Retroviral expression vector deriving transcription from a CMV promoter.  
Obtained from Scott Lowe. 
 
pLPC E2F1 WT 
Retroviral expression vector for WT E2F1.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC E2F1 WT (GFP) 
Retroviral expression vector for WT E2F1 fused to GFP.  Obtained from Kevin 
Ryan, Beatson Institute for Cancer Research 
 
pLPC GFP 
Retroviral expression vector for GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC Tr. 1 GFP 
Retroviral expression vector for Tr. 1 GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC Tr. 2 GFP 
Retroviral expression vector for Tr. 2 GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC Tr. 3 GFP 
Retroviral expression vector for Tr. 3 GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC Tr. 4 GFP 
 Retroviral expression vector for Tr. 4 GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC Tr. 5 GFP 
Retroviral expression vector for Tr. 5 GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC Tr. 6 GFP 
Retroviral expression vector for Tr. 6 GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC Tr. 7 GFP 
Retroviral expression vector for Tr. 7 GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC Tr. 8 GFP 
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Retroviral expression vector for Tr. 8 GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC Tr. 9 GFP 
Retroviral expression vector for Tr. 9 GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC Tr. 10GFP 
Retroviral expression vector for Tr. 10 GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
pLPC Tr. 11 GFP 
Retroviral expression vector for Tr. 11 GFP.  Obtained from Kevin Ryan, Beatson 
Institute for Cancer Research. 
 
 
pLPC E1A WT 
Retroviral expression vector for WT E1A 12S.  Obtained from Scott Lowe. 
 
pLPC E1A ΔCR2 
Retroviral expression vector for E1A ΔCR2.  Obtained from Scott Lowe. 
 
pLPC E1A R2G 
Retroviral expression vector for WT E1A R2G.  Obtained from Scott Lowe. 
 
pLPC E1A Δ2-11 
Retroviral expression vector for WT E1A Δ2-11.  Obtained from Scott Lowe. 
 
pLPC E1A Δ2-24 
Retroviral expression vector for WT E1A Δ2-24.  Obtained from Scott Lowe. 
 
pLPC E1A Δ2-36 
Retroviral expression vector for WT E1A Δ2-36.  Obtained from Scott Lowe. 
 
pLPC E1A Δ26-35 
Retroviral expression vector for WT E1A Δ26-35.  Obtained from Scott Lowe. 
 
pLPC E1A Δ48-60 
Retroviral expression vector for WT E1A Δ48-60.  Obtained from Scott Lowe. 
 
pLPC E1A 143 
Retroviral expression vector for WT E1A 143.  Obtained from Scott Lowe. 
 
pSuperRetro Scr 
Retroviral expression vector for scrambled hairpin.  Obtained from Doron 
Gingsberg 
 
pSuperRetro E2F1 
Retroviral expression vector for E2F1 hairpin.  Obtained from Doron Gingsberg 
 
 
pWZL blast E1A-ER  
Retroviral expression vector for E1A-ER fusion protein.  Obtained from Andy 
Phillips 
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3 Chapter 3: Results 
The essential role of E2F1 in apoptosis is well documented.  The pathways 
leading to programmed cell death that are directed by E2F1 are complex and 
overlapping (Field et al., 1996; Kowalik et al., 1998; Macleod et al., 1996; Qin et 
al., 1994; Shan and Lee, 1994; Wu and Levine, 1994).  E2F1 has the ability to 
induce both cell cycle progression and programmed cell death, leading 
potentially to both tumour-promoting and tumour-suppressive effects.  The 
effect of E2F1 overexpression on tumour growth has been evaluated in several 
types of human cancers and E2F1 has been shown to sensitize tumour cells to 
chemotheraphy (Kaelin, 2003; Stanelle and Putzer, 2006). 
Oncogenes have been shown to deregulate E2F1 through inhibition of pRB and 
oncogenic stress can induce E2F1’s apoptotic activity.  E2F1 has also been shown 
to respond to DNA damage.  However, how cancer cells evade E2F1-induced 
apoptosis in not clear.  Investigating the mechanism(s) leading to the DNA 
damage response and defining the role of E2F1 in DNA-damage induced apoptosis 
should contribute to the understanding of E2F1’s role in chemosensitivity.  That 
may ultimately help to provide novel targets in the E2F1 pathway for 
therapeutic intervention. 
The aims of this project are to investigate E2F1’s response to DNA damage and 
oncogenic stress. 
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Chapter 3-1: E2F1’s involvement in chemotherapeutic response
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3.1 E2F1’s involvement in chemotherapeutic response 
In mammalian cells, DNA damage induces robust changes in gene expression and 
these changes contribute to the execution of cellular responses to mutations and 
DNA damage, including DNA repair, cell cycle arrest and apoptosis.  DNA 
damage, caused by radiation or genotoxic drugs is detected by DNA damage-
sensing proteins.  They then generate the signals leading to the responses, which 
represent defences against genomic instability and tumorigenesis resulting from 
unrepaired damage.  The response depends on the severity of the damage and 
the type of cell affected.  The tumour suppressor p53 is well studied as one of 
the main player in DNA damage checkpoint regulation.  It is stabilized and 
activated as a transcriptional factor in response to genomic DNA damage 
(Latonen and Laiho, 2005; Vousden and Lu, 2002).  In 1997, Huang et al. showed 
that ionizing radiation increased the expression of E2F1 (Huang et al., 1997). 
Later E2F1 was shown to be upregulated in response to DNA damage caused by 
irradiation with X-rays or UVC, or following treatment with the DNA-damaging 
agents actinomycin D, adriamycin and etoposide in a manner analogous to that 
of p53 (Blattner et al., 1999; Hofferer et al., 1999; Meng et al., 1999).  Since 
then several groups have studied E2F1’s response to various DNA damaging 
agents.  Some discoveries have now been published suggesting the post-
translational modifications of E2F1 that follow DNA damage and lead to E2F1 
stabilization.  Some controversy has risen about the physiological importance of 
these modifications and specially their applications in E2F1’s ability to induce 
apoptosis.   
Several genes involved in the activation or execution of apoptosis have been 
shown to be unregulated at the transcriptional level by E2F1 overexpression.  
But how E2F1’s response to DNA damage translates into the activation of this 
specific subset of E2F1 target genes and the importance of E2F1 in drug induced 
apoptosis is not as well studied.  However, some groups have managed to bridge 
the DNA damage response of E2F1 to increased E2F1 activity.  In 2000, Martines-
Balbas et al. showed that E2F1 is acetylated by the p300/CBP-associated factor 
P/CAF, and the consequences of this acetylation is increased DNA-binding 
ability, activation potential and protein half-life (Martinez-Balbas et al., 2000).  
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In 2003, E2F1 was shown to switch from cell cycle progression to apoptotic E2F1 
target genes in response to adriamycin, and p73 was an important E2F1 target 
gene in the DNA damage response (Pediconi et al., 2003). These results indicate 
that E2F1 and downstream targets of E2F1 may prove to be valuable candidates 
for cancer therapy in tumour cells. 
The aim of the studies in this chapter is to further investigate E2F1’s response to 
chemotherapeutic drugs and the importance of E2F1 in drug-induced apoptosis.   
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3.1.1 E2F1 is induced in responce to various chemotherapeutic 
drugs 
In order investigate E2F1’s response to DNA damage, three chemotherapeutic 
drugs used in the clinics; actinomycin D, adriamycin and etoposide were used.  
Actinomycin D binds DNA at the transcription initiation complex and prevents 
elongation by RNA polymerase, and therefore interferes with DNA replication.  It 
is one of the older chemotherapy drugs and has been used in therapy for many 
years.  Adriamycin (doxorubicin) is also a DNA-interacting drug wildly used in 
chemotherapy.  It interacts with DNA by intercalation and inhibits the 
progression of the enzyme topoisomerase II, which unwinds DNA for 
transcription.  Etoposide is also an inhibitor of topoisomerase II and is used as a 
form of chemotherapy for malignancies such as lung, ovarian and testicular 
cancer. 
In order to determine E2F1’s response to these chemotherapeutic drugs, Mouse 
Embryonic Fibroblast (MEF) cells were treated with 100 ng/ml actinomycin D, 
2.0 µg/ml adriamycin and 20 µM etoposide.  The cells were then lysed and 
endogenous E2F1 protein levels measured by Western blotting using an antibody 
specific for E2F1.  This revealed a detectable induction of E2F1 protein levels 
only 6 hours following treatment with all three drugs, compared with untreated 
cells, and the induction continues up to 12 hours of treatment (Fig. 3-1).  The 
MAP kinase p38 showed no induction following treatment and was used to ensure 
equal loading of proteins, suggesting that the increase in E2F1 protein levels in 
response to DNA damage is specific. 
In order to confirm E2F1’s response to DNA damage in primary human cells, 
TERT-immortalized Retinal Pigment Epithelial (RPE) cells were treated for the 
same time period as the MEFs and with the same concentration of adriamycin 
and endogenous E2F1 levels measured by Western blotting.  Similar results were 
obtained as in the MEFs, with detectable E2F1 induction after 6 hours following 
treatment and the induction continuing up to 12 hours (Fig. 3-2a).  In order to 
investigate if the increase in E2F1 protein levels observed were post-
transcriptional or a result of enhanced transcription of the E2F1 gene itself, a 
real-time quantitative PCR (qPCR) was carried out.  RNA was isolated from RPE 
cells following same treatment as in figure 3-2a, cDNA prepared and the inferred  
83 
 
p38
E2F1
Actinomycin D Adriamycin Etoposide
Hrs Un     6      12       Un      6      12      Un     6     12
Figure 3-1 E2F1 is induced following treatment with actinomycin D, 
adriamycin and etoposide. 
WT MEFs were treated with 100 ng/ml actinomycin D, 2.0 µg/ml adriamycin, or 20 
µM etoposide.  Cells were lysed in SDS lysis buffer 6 and 12 hours following 
treatment. Extracts were then resolved by SDS-PAGE and endogenous E2F1 
levels measured by Western blotting using E2F1 specific antibody (C-20). Blots 
were re-probed with a p38 antibody to ensure equal loading. 
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Figure 3-2 E2F1 is post-transcriptionally induced following 
treatment with adriamycin in RPE cells.  
A + B) RPE cells were treated with 2.0 µg/ml adriamycin for 6 and 
12 hours.  A) Following treatment cells were lysed in SDS lysis 
buffer. Extracts were then resolved by SDS-PAGE and endogenous 
E2F1 levels measured by Western blotting using E2F1 specific 
antibody (C-20). Blots were re-probed with a p38 antibody to 
ensure equal loading. B)  RNA was extracted and cDNA made.  
Relative expression of E2F1 was determined by real-time qPCR. 
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E2F1 mRNA levels measured using E2F1 specific primers.  No changes in the 
mRNA levels following adriamycin treatment were observed (Fig. 3-2b), 
indicating that the changes in E2F1 protein levels are not due to increased 
transcription, but are post transcriptional.  Whether the post transcriptional 
induction of E2F1 is a result of increased translation of E2F1 mRNA or increased 
protein stability, or both, remains to be determined. 
3.1.2 E2F1 is involved in drug induced apoptosis 
Given the pro-apoptotic activity of E2F1 and E2F1’s induction following DNA 
damage which can also lead to apoptosis, E2F1’s involvement in drug induced 
apoptosis was tested.  Full length E2F1 was infected into E2F1-/- MEFs (E2F1-/- + 
FL E2F1) and drug induced apoptosis compared with wild type MEFs and E2F1-/- 
MEFs.  Following treatment with 10 µM Etoposide for 48 hours, both wild type 
and E2F1-/- + FL E2F1 MEFs showed over 40 % apoptosis measured by flow 
cytometry whereas E2F1 knockout MEFs showed only 12 % apoptosis (PI staining 
and sub-G1 content used as an indicator of apoptotic cells) (Fig. 3-3).  This 
indicates that E2F1 is involved in drug induced apoptosis. 
To verify E2F1’s involvement in drug induced apoptosis, RPE cells stably 
expressing a shRNA targeting E2F1 and a scrambled hairpin as a control were 
generated.  Significant knockdown of E2F1 protein levels was obtained compared 
with a cell line stably expressing a scrambled hairpin with no effect seen on p38 
in either line (Fig. 3-4a).   
Following treatment with adriamycin both cell lines showed induction of E2F1 
(Fig. 3-4b).  However, after 12 hours of treatment, the levels of E2F1 protein in 
the cells expressing the E2F1 shRNA only reached levels that were comparable to 
the basal level of E2F1 in the control shRNA expressing cells (compare lines 1 
and 6).  p53 was also induced following the treatment.  In untreated cells p53 
levels were very low and hardly detectable by immunoblotting, but following 6 
hours of treatment, p53 levels were easily seen with similar protein 
accumulation following 12 hours of treatment.  E2F1 knockdown did not have an 
effect on basal levels of p53 or the accumulation of p53 following treatment 
(Fig. 3-4b).   
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Figure 3-3 E2F1 knockout cells show reduced drug-induced 
apoptosis 
Wild type MEFs (WT), E2F1 knockout MEFs (E2F1-/-) and E2F1 
knockout MEFs expressing full length human E2F1 (E2F1-/- + FL) 
were treated with 10 µM etoposide (Eto) for 48 hours.  Following 
treatment the DNA content of cells was assessed by flow cytometry. 
The percentage of cells with a s ub-G1 DNA content was taken as 
the apoptotic population. 
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Figure 3-4 Knockdown of E2F1 reduces drug induced apoptosis 
RPE cells were retrovirally infected with scrambled or E2F1 specific shRNA (pRS 
Scr and pRS E2F1.  A) Cells were lysed in SDS lysis buffer, extracts resolved by 
SDS-PAGE and endogenous E2F1 levels measured by Western blotting using 
E2F1 specific antib  ody (C-20). Blots were re-probed with a p38 antibody to 
ensure equal loading. B) pRS Scr and pRS E2F1 cells were treated with 2.0 µg/ml 
adriamycin and lysed in SDS lysis buffer 6 and 12 hours following treatment. 
Extracts were then resolved by SDS-PAGE.  Endogenous E2F1 and p53 levels 
were measured by Western blotting. Blots were re-probed with a p38 antibody to 
ensure equal loading.  C) pRS Scr and pRS E2F1 cells were treated with 0.5 
µg/ml adriamycin (Adr) for 48 hours.  Following treatment DNA content of cells 
was assessed by flow cytometry. The percentage of cells with a sub-G1 DNA 
content was taken as the apoptotic population. 
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To test the affect of E2F1 knockdown on drug induced apoptosis, these cell lines 
were treated with adriamycin for 72 hours and apoptosis measured by flow 
cytometry.  Whereas adriamycin induced extensive apoptosis in the cell line 
expressing scrambled hairpin, apoptosis was robustly inhibited by E2F1 
knockdown (Fig. 3-4c).  
These results clearly demonstrate a critical role for E2F1 in drug induced 
apoptosis and establish the importance of further investigation of E2F1’s 
induction following DNA damage and its role in chemosensitivity of tumour cells 
following drug treatment.   
3.1.3 Summary 
DNA damaging agents that are regularly used to treat cancer were used to 
investigate the affect of E2F1 protein levels.  These drugs cause DNA damage 
and therefore activate DNA damage responsive pathways within cells.  E2F1 was 
shown to be upregulated by a post-transcriptional mechanism in response to 
adriamycin, actinomycin D and etoposide in a time dependent manner.  These 
results are in line with previous studies which also have examined E2F1’s 
response to various DNA damaging agents (Blattner et al., 1999; Meng et al., 
1999).  Our data also support the notion that E2F1 plays a role in drug induced 
apoptosis in a p53-independent manner.  This connection between DNA damage 
and E2F1-depentent apoptosis following drug treatment is of particular 
significance.  The frequent deregulation of E2F1 in human tumours, in addition 
with its apoptotic potential and its stabilization following DNA damage suggests 
that E2F1 plays a role in the enhanced sensitivity of tumour cells to DNA damage 
induced cell death.  Further studies investigating the mechanism leading to E2F1 
accumulation following DNA damage may therefore provide a way to increase 
chemosensitivity in tumours.   
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3.2 Mechanisms of E2F1 induction following DNA 
damage 
Recent studies have shown that the induction of E2F1 following DNA damage are 
mediated by both phosphorylation and acetylation.  E2F1 was shown to be 
phosphorylated by the damage-responsive protein kinase ATM following DNA 
damage and the phosphorylation site was mapped at Serine 31 (Lin et al., 2001).  
This site was shown to be required for ATM-mediated stabilization as E2F1 with 
this site mutated to alanine showed no accumulation following treatment with 
the DNA damaging agent neocarzinostatin (NCS). In a different study E2F1 was 
showed to be phosphorylated by the checkpoint kinase 2 (Chk2) in response to 
etoposide (Stevens et al., 2003).  The phosphorylation occurred within a Chk2 
consensus phosphorylation site at serine 364 and resulted in protein stabilization 
and increased half-life.  Mutation of this site to alanine resulted in 
approximately four times less protein accumulation compared with wild type.   
E2F1 is acetylated by P/CAF leading to increased stability of E2F1 (Martinez-
Balbas et al., 2000).  Later it was shown that this occurs following treatment 
with adriamycin (Pediconi et al., 2003).  These acetylation sites were mapped to 
the N-terminus, adjacent to the DNA binding domain (K117, K120 and K125) of 
E2F1 (Fig. 3-5).   
During a normal cell cycle E2F1 protein levels are regulated by ubiquitin-
proteasome-dependent degradation (Campanero and Flemington, 1997).  The 
physical association of pRb can stabilize E2F1 by protecting it from degradation 
(Hateboer et al., 1996a; Hofmann et al., 1996).  Furthermore, it has been 
suggested that E2F1 modifications following DNA damage also inhibit E2F1’s 
ubiquitination and degradation.  However, the way DNA damage affects E2F1 
ubiquitination or degradation still remains unknown.   
There is also some evidence that E2F1 stabilization is affected by direct binding 
to other cellular proteins.  E2F1 was shown to physically interact with MDM2, 
which targets p53 for rapid degradation by the ubiquitin proteasome pathway 
(Haupt et al., 1997; Martin et al., 1995).  Conversely MDM2 was shown to 
stimulate the activation capacity of E2F1, but the effect on E2F1 stability or 
accumulation following DNA damage was not tested.   
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Figure 3-5 Known mechanisms of E2F1 induction following DNA damage 
E2F1 has been shown to be phosphorylated at serine 31 by ATM kinase and at 
serine 364 by Chk2 kinase in response to DNA damage.  It has also been shown to 
be acetylated by P/CAF following DNA damage.  Physical interaction between C-
terminal end of E2F1 and MDM2 activates E2F1 but whether it leads to increased 
expression following DNA damage is not known.    
 
 
92 
The contribution of each of the known mechanisms on E2F1 stability following 
DNA damage, and in which context they play a role in, is not known in detail.  
Further investigation is therefore needed to fully understand the post-
transcriptional modifications that occur on E2F1 following cellular stress and 
DNA damage and the consequences of these changes. 
The aim of this chapter is to investigate the importance of previously 
characterized mechanisms of E2F1 induction following treatment with 
chemotherapeutic drugs that cause DNA damage.  In addition, it was considered 
if unidentified mechanism(s) could also account for E2F1 stabilization. 
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3.2.1 Contribution of known mechanisms to E2F1 induction 
following DNA damage 
In order to further understand E2F1’s induction following DNA damage and 
analyse the importance of previously known mechanism, E2F1 knockout MEFs 
were used and stably infected by full length or mutated forms of E2F1.  The 
advantage of using E2F1-/- MEFs is that the there is no endogenous E2F1 that can 
have an affect on the response of the exogenous protein.  In addition, as most of 
previous studies have been carried out in cancer cells, which might already have 
lost some of the mechanism leading to E2F1 accumulation following cellular 
stress and DNA damage, it was envisaged that MEFs might prove to be a better 
cell line to investigate the mechanisms leading to E2F1 induction.  
Firstly, in order to test exogenous E2F1’s response to DNA damage a retrovirus 
expressing full length E2F1 was infected into E2F1-/- MEFs and examined.  In the 
untreated cells this exogenously expressed E2F1 was undetectable by Western 
blotting (Fig. 3-6a lane 1).  However, after 6 hours of treatment with 2.0 µg/ml 
adriamycin, E2F1 could be detected with a more robust level of E2F1 being 
detected after 12 hours.  This pattern of response was very similar to what was 
observed in wild type MEFs (Fig. 3-1).  The MAP kinase p38 showed no induction 
following treatment and was used to ensure equal loading of proteins, suggesting 
that the increase in E2F1 protein levels in response to DNA damage is specific.  
In order to investigate if the increase in E2F1 protein levels observed here is a 
result of enhanced transcription from the inserted E2F1 gene itself or if the 
changes are post-transcriptional, RNA from the same samples was prepared and 
mRNA levels measured by RT PCR using E2F1 specific primers and GAPDH primers 
as control.  This revealed no changes in the mRNA levels following adriamycin 
treatment (Fig. 3-6b) indicating that the changes in exogenous E2F1 protein 
levels are post-transcriptional and not due to increased transcription. 
In order to test if E2F1 in this system is degraded by the proteasome, cells were 
treated with the proteasome inhibitor MG132.  E2F1 protein levels were rapidly 
induced following MG132 treatment for 4 hours (Fig 3-7a).  The induction 
following MG132 treatment was similar to E2F1 induction following 10 hours  
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Figure 3-6 Exogenous E2F1 is post-transcriptionally induced 
following treatment with adriamycin in E2F1-/- cells 
A + B) E2F1-/- MEFs were retrovirally infected with full length E2F1 in 
order to make cell line stably expressing E2F1 (MEF E2F1-/- + FL).  Cells 
were then treated with 2.0 µg/ml adriamycin for 6 and 12 hours.  A) Cells 
were lysed in SDS lysis buffer following treatment. Extracts were resolved 
by SDS-PAGE and E2F1 levels measured by Western blotting using 
E2F1 specific antibody (C-20). Blots were re-probed with a p38 antibody 
to ensure equal loading. B) RNA was extracted and cDNA prepared.  
Relative expression of E2F1 following adriamycin treatment was 
determined by RT-PCR.   
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adriamycin treatment.  However, small differences were observed, with E2F1 
levels higher following adriamycin treatment, which is possibly due difference in 
timing of treatment (10 hours adriamycin treatment compared with 4 hours 
MG132 treatment).  When cells were treated with both MG132 and adriamycin, a 
similar level of induction was observed.  That indicates that E2F1 induction 
following DNA damage is likely due to inhibition of degradation by the 
proteasome. 
The effect of acetylation on E2F1 stability was also tested.  Cells were treated 
with the histone de-acetylase (HDAC) inhibitor trichostatin A (TSA) for 24 hours 
(100 µM final concentration).  Following TSA treatment, E2F1 levels increased 
rapidly, indicating that E2F1 can by acetylated leading to protein induction (Fig 
3-7b). 
Next it was tested whether previously described mechanisms for E2F1 
accumulation were being utilised in this system.  First it was investigated 
whether phosphorylation on serines 31 and 364 were playing a role.  To do this, 
constructs were made with these sites mutated leading to alanine substitutions 
(alanine cannot be phosphorylated) and stably expressed in E2F1-/- MEFs.  These 
cell lines were then treated with adriamycin for 6 hours and E2F1 protein levels 
measured by Western blotting.  The protein levels in these cell lined were 
marginally higher than in the cell line expressing the FL E2F1 and interestingly 
both of these cell lines showed robust E2F1 induction following adriamycin 
treatment (Fig. 3-8). The MAP kinase p38 showed no induction following 
treatment and was used to ensure equal loading of proteins.   
This indicates that either phosphorylation on these sites is not required for the 
response or combination of mutations would be required to inhibit the induction 
following DNA damage.  In order to test if both of these phosphorylation events 
contribute to the induction of E2F1, but one would be enough to stabilize the 
protein to the same level as full length, a double mutant carrying serine alanine 
substitutions on both amino acid sites 31 and 364 (S31A/S364A), was created and 
stably expressed in E2F1-/- MEFs.  This cell line still showed E2F1 accumulation 
following adriamycin treatment for 6 hours, with  
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Figure 3-7 DNA damage inhibits proteosomal 
degradation of E2F1 
A) MEF E2F1-/- + FL were treated with 2.0 µg/ml 
adriamycin for 10 hours and/or the proteosomal 
inhibitor MG132 (10 µM final concentration) for 4 hours.  
Cells were then and lysed in SDS lysis buffer and 
extracts resolved by SDS-PAGE.  E2F1 levels were 
measured by Western blotting using E2F1 specific 
antibody (C-20). Blots were re-probed with a p38 
antibody to ensure equal loading.  B) MEF E2F1-/- + FL 
were treated with the HDAC inhibitor trichostatin A 
(TSA) (100 µM final concentration).  Cells were then 
and lysed in SDS lysis buffer and extracts resolved by 
SDS-PAGE.  E2F1 levels were measured by Western 
blotting using E2F1 specific antibody (C-20). Blots were 
re-probed with an actin antibody to ensure equal 
loading.  
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Figure 3-8 E2F1 with S31A or S364A substitution is induced following 
treatment with adriamycin  
E2F1-/- MEFs expressing FL or mutated E2F1 (S31A or S364A) were 
treated with 2.0 µg/ml adriamycin and lysed in SDS lysis buffer 6 hours 
following treatment. Extracts were then resolved by SDS-PAGE and E2F1 
levels measured by Western blotting using E2F1 specific antibody (C-20). 
Blots were re-probed with a p38 antibody to ensure equal loading.  
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Figure 3-9 A ‘double mutant’ of E2F1 with S31A and S364A substitutions 
is induced following treatment with adriamycin  
E2F1-/- MEFs expressing FL or mutated E2F1 (S31A, S364A or S31A/S364A) 
were treated with 2.0 µg/ml adriamycin and lysed in SDS lysis buffer 6 and 12 
hours following treatment. Extracts were then resolved by SDS-PAGE and 
E2F1 levels measured by Western blotting using E2F1 specific antibody (C-20). 
Blots were re-probed with a p38 antibody to ensure equal loading.  
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more induction after 12 hours treatment (Fig. 3-9).  This indicates that neither 
of the two known DNA damage responsive phosphorylation events are required 
for the induction seen on full length E2F1 following DNA damage.   
This raised the question if, in combination or independently, other mechanisms 
played a role it the induction.  In order to investigate if MDM2 binding to the C-
terminal activation domain of E2F1 was responsible for the E2F1 induction seen 
on the S31A/S364A double mutant, a MDM2 binding deficient mutant with the 
aspartic acid at site 390 and phenylalanine at 391 substituted with alanine 
(D390A/F391A) was created in addition to the double S31A/S364A mutant.  This 
mutant, with both known DNA damage phosphorylation sites and deficient in 
binding to MDM2, was expressed in E2F1-/- MEFs.  Basal E2F1 levels of triple 
mutant (S32A, S364A and D390A/F391A) were detectable compared to 
undetectable levels of the previously made full length E2F1 cell line (Fig 3-10 
compare lane 1 and 4).  Following adriamycin treatment the levels of triple 
mutant E2F1 increased, almost to the same levels as seen on the full length 
protein, with detectable induction after 6 hours following treatment and robust 
induction after 12 hours.   
As previously discussed E2F1 has also been shown to be a target for acetylation 
on lysine 117, 120 and 125 by P/CAF which leads to stabilization following 
adriamycin treatment (Martinez-Balbas et al., 2000; Pediconi et al., 2003).  One 
possibility is that acetylation on these lysines plays a major part in the E2F1 
induction seen on the triple mutant in our system.  In order to test that, a 
mutant with all three lysine residues substituted to arginine 
(K117R/K120R/K125R) was created, either on full length E2F1 or on the triple 
mutant (S32A, S364A and D390A/F391A).  These mutants were then stably 
expressed in E2F1-/- MEFs and tested for E2F1 induction following adriamycin 
treatment.  As seen in Fig. 3-11, arginine substitutions for these lysine residues 
on the triple mutant did not impair E2F1 induction following treatment with 
adriamycin indicating that these residues are not critical for E2F1 to accumulate 
following DNA damage (Fig 3-11a).   
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Figure 3-10 A ‘triple mutant’ of E2F1, with S31A and S364A substitutions 
and mutations impairing MDM2 binding is induced following treatment 
with adriamycin  
E2F1-/- MEFs expressing FL or mutated E2F1 (S31A/S364A/D390A/F391A) 
were treated with 2.0 µg/ml adriamycin and lysed in SDS lysis buffer 6 and 12 
hours following treatment. Extracts were then resolved by SDS-PAGE and 
E2F1 levels measured by Western blotting using E2F1 specific antibody (C-
20). Blots were re-probed with a p38 antibody to ensure equal loading.  
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Figure 3-11 Acetylation mutations in addition on the ‘triple 
mutant’ of E2F1, is induced following treatment with 
adriamycin  
A) E2F1-/- MEFs expressing  the E2F1 ‘triple mutant’ with in 
addition, acetylation sites at residue 117, 120 and 125 mutated 
to arginine (S31A/S364A/D390A/F391AK117R/K120R/K125R) 
were treated with 2.0 µg/ml adriamycin and lysed in SDS lysis 
buffer 6 and 12 hours following treatment. Extracts were then 
resolved by SDS-PAGE and E2F1 levels measured by 
Western blotting using E2F1 specific antibody (C-20). Blots 
were re-probed with a p38 antibody to ensure equal loading. B) 
E2F1-/- MEFs expressing E2F1 with acetylatin sites at residue 
117, 120 and 125 mutated to arginine (K117R/K120R/K125R) 
were treated with the HDAC inhibitor trichostatin A (TSA) (100 
µM final concentration) .  Cells were then and lysed in SDS 
lysis buffer and extracts resolved by SDS-PAGE.  E2F1 levels 
were measured by Western blotting using E2F1 specific 
antibody (C-20). Blots were re-probed with an actin antibody to 
ensure equal loading.  
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In addition, the acetylation mutant retains its inducability following TSA 
treatment.  That indicates that additional acetylation sites might play a role in 
the stabilization of E2F1 following DNA damage (Fig. 3-11b). 
These results indicate that there are still mechanism(s) to be found that lead to 
post-transcriptional E2F1 accumulation in response to the chemotherapeutic 
drug adriamycin.  Further studies are therefore required to understand E2F1 
induction under these circumstances. 
3.2.2 Response of regions of E2F1 to DNA damage 
3.2.2.1  Description of E2F1 truncations 
In order to further understand E2F1’s induction following DNA damage and in 
attempt to analyse what regions of E2F1 are responsible for the induction, 
previously made and described truncated forms of E2F1 were used (Bell et al., 
2006).  These series of N- and C-terminal truncations of E2F1 were fused at the 
C-terminus to Green Fluorescent Protein (GFP).  That allowed easy detection by 
Western blotting of all of the E2F1 truncated forms when expressed in cells.  The 
truncations had a series of E2F1 domains removed and could therefore be used 
to determine which components of E2F1 may be important for induction in an 
attempt to find a minimal region of E2F1 that responds to DNA damage (Fig. 3-
12).   
3.2.2.2  C-terminal truncations 
The first truncation (tr. 1 Δ374) used lacks the entire transactivation domain of 
E2F1 (amino acids 375-437) including the pRb binding domain and the region 
necessary for MDM2 binding.  It has been shown previously that E2F1 is actively 
degraded by the ubiquitin-proteasome pathway and efficient degradation 
depends on the availability of selected sequences within the C-terminus of E2F1 
and pRb binding (Hofmann et al., 1996).  The importance of this region in DNA 
damage response has not been determined.  Truncation 1 has previously been 
shown to be able to induce cell death in transactivation independent manner by  
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Figure 3-12 Description of E2F1 truncations  
A series of C-terminal and N-, C-terminal truncations of E2F1 were used in order to 
find a minimal region of E2F1 that responds to DNA damage.  Truncation 1 lacks 
the whole transactivation domain of E2F1.  Truncation 2 has a mutation in the DNA 
binding domain.  All other C-terminal truncations lack part of the C-terminus.  All N-, 
C-terminal truncations lack part of the N-terminus in addition of lacking the 
transactivation domain.  All truncations were fused to GFP at the C-terminus for 
detection by Western blotting. 
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a mechanism considered to be via de-repression of E2F1 target genes (Hsieh et 
al., 1997; Liu and Greene, 2001; Phillips et al., 1997).  Truncation 2 (tr.2 Δ374, 
132E) has a glutamic acid substitution at amino acid 132 within the DNA-binding 
domain that abrogates DNA binding and also lacks the transactivation domain, 
like all the other remaining truncations made (Cress et al., 1993; Helin and 
Harlow, 1994).  This truncation is impaired in activating E2F1 target genes and 
does not induce apoptosis when overexpressed (Bell et al., 2006; Hsieh et al., 
1997; Phillips et al., 1997).  Truncation 3 (tr. 3 Δ284) lacks amino acids 285 to 437 
and therefore lacks both the entire transactivation domain, including the pRb 
binding domain, and the Chk2 phosphorylation site at S364.  It also lacks a part 
of the marked box within the dimerization domain.  Truncation 4 (tr. 4 Δ245) lacks 
amino acids 246 to 437 and therefore the whole marked box.  Truncation 5 (tr. 5 
Δ191) lacks the entire dimerization domain and is therefore unable to bind to DP 
family of proteins.  Truncation 6 (tr. 6 Δ120), the smallest C-terminal truncation 
made, lacks amino acids 121-473 and therefore the entire DNA binding domain in 
addition to the transactivation domain.   
3.2.2.3  N- and C-terminal truncations 
Truncation 7 (tr. 7 120-374) is an N- and C-terminal domain truncation which lacks 
the first 120 amino acids plus the transactivation domain. This truncation 
therefore lacks the nuclear localisation signal (NLS) of E2F1 and is expressed 
throughout the entire cell when overexpressed compared with truncations that 
remains the NLS which are primarily, though not exclusively, localised in the 
nucleus, a pattern generally observed for WT E2F1 (L.A. Bell, Ph.D. thesis, 
University of Glasgow, 2006).  Truncation 8 (tr. 8 245-374) only consists of amino 
acids 245 to 374 so it includes the marked box and the Chk2 phosphorylation site 
at 364.  Truncation 9 (tr. 9 317-374) consists of amino acids 317 to 374.  Truncation 
10 (tr. 10 245-317) consists of the marked box only (amino acids 245 to 317). 
Truncation 11 (tr. 11 120-191), the smallest truncation, consists only of the DNA 
binding domain of E2F1 (amino acids 120 to 191).  This domain has been shown 
to induce apoptosis in a transactivation independent manner and does not bind 
DNA (Bell et al., 2006).   
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3.2.2.4  DNA damage response of GFP linked full length E2F1 
Before infection with the truncations it was decided to infect full length E2F1 
protein linked to GFP in to E2F1-/- MEFs to certify that C-terminal GFP linked 
E2F1 remains it’s induction following DNA damage as seen with full length 
unlinked E2F1 (Fig. 3-6a).  Following infection of FL E2F1-GFP and GFP alone as 
control into E2F1-/- MEFs, cells were treated with adriamycin for 6 and 12 hours.  
The E2F1 protein levels were measured by Western blotting following treatment 
using GFP specific antibody.  This revealed a clear induction after 6 hours 
following treatment and with similar levels after 12 hours (Fig. 3-13).  No 
induction was seen following adriamycin treatment in cells expressing GFP alone 
indicating that the induction seen on E2F1 is not due to GFP stabilization 
following drug treatment.  It was noticed that the basal level of GFP alone was 
higher than GFP fused with E2F1 and could indicate that it lacks domains found 
in E2F1 that is responsible for active degradation and is therefore more stable in 
untreated cells.  These results indicated that E2F1-GFP behaves in similar 
manner in terms of induction following DNA damage as wild type E2F1 (Fig 3-1 
and 3-6a).  Therefore, using the truncations of E2F1 may be a good model in an 
attempt to find minimal regions of E2F1 that are responsive to DNA damage. 
3.2.2.5  DNA damage response of C-terminal truncations 
In order to analyse the response of C-terminal truncations to DNA damage, tr. 1 
Δ374 was first stably expressed in E2F1-/- MEFs and analysed.  This revealed low 
basal expression and barely detectable with the GFP specific antibody (Fig. 3-
14a).  When these cells were treated with adriamycin a detectable induction 
was seen after 6 hours with the accumulation increasing at 12 hours.  This 
indicates that the transactivation domain, with the pRb binding domain and 
sequences necessary for MDM2 binding is not necessary for E2F1 induction 
following DNA damage.  However, it can not be concluded that pRb or MDM2 do 
not contribute to the induction of the full length E2F1 under these conditions, 
since quantitative comparison is not possible between these different cell-lines, 
especially when the basal expression levels differ.   
Next the question if DNA binding of E2F1 was necessary for its induction 
following DNA damage was asked.  Following infection of tr. 2 Δ374, 132E and 
treatment with adriamycin for 6 and 12 hours, E2F1 levels were measured by  
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Figure 3-13 E2F1 fused to GFP is induced following treatment with adriamycin 
in E2F1-/- MEFs  
E2F1-/- MEFs expressing E2F1 fused with GFP (E2F1 GFP) or GFP alone were 
treated with 2.0 µg/ml adriamycin and lysed in SDS lysis buffer 6 and 12 hours 
following treatment. Extracts were resolved by SDS-PAGE and E2F1 and GFP 
levels measured by Western blotting using GFP specific antibody. Blots were re-
probed with a p38 antibody to ensure equal loading.  
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Western blotting.  This revealed a modest induction after 6 hours following 
treatment and similar levels of accumulation after 12 hours (Fig. 3-14b).  This 
indicates that DNA binding is not necessary for E2F1 to respond to DNA damage.   
In order to further map the domain that could be responsible for induction seen 
on1 Δ374 and tr.2 Δ374, 132E, tr. 3 Δ284 was infected into in E2F1-/- MEFs and analysed 
for protein accumulation following drug treatment.  Tr. 3 Δ284 responded to 
adriamycin treatment in a similar fashion as tr. 1 Δ374 and tr.2 Δ374, 132E indicating 
that the region responsible for induction seen on tr. 1 Δ374  does not contain 
amino acids 284 to 374 and therefore does not require phosphorylation of serine 
364 (Fig 3-14c).  Similar results were obtained with tr. 4 Δ245 and tr. 5 Δ191.  Both 
truncations showed induction after 6 and 12 hours following adriamycin 
treatment when stably expressed in E2F1-/- MEFs (Fig. 3-14 d and e).  This ruled 
out the dimerization domain as a region responsible for the induction 
experienced on tr. 1 Δ374  and indicated that the induction is not dependent on 
E2F1 binding to it’s DP binding partners.   
The next question asked was whether induction seen by tr. 5 Δ191 in response to 
DNA damage was dependent on the DNA binding domain.  Tr. 6 Δ120 was therefore 
expressed in E2F1-/- MEFs and analysed for induction following DNA damage.  
This truncation showed higher basal expression compared with truncations 1-5, 
but whether that was due to higher viral infection efficiency or increased 
protein stability was not determined.  When cells expressing tr. 6 Δ120 were 
treated with adriamycin for 12 hours period, clear induction was seen after 6 
hours and even more induction after 12 hours following treatment (Fig. 3-14f).   
This indicates that the first 120 amino acids of E2F1 are able to respond to DNA 
damage with the possibility that some modifications may occur that lead to 
protein accumulation of this N-terminal truncation.  The only previously 
described DNA damage responsive mechanisms within this region are the ATM 
phosphorylation site at serine 31 and the acetyl responsive lysines at 117 and 
120.  In order to investigate if tr. 6 Δ120 is induced by modifications at these 
sites, mutagenesis on S31, K117 and K120 on this truncation was performed, 
leading to serine/alanine and lysine/arginine substitutions when expressed in 
cells.  Firstly, cells were infected with virus expressing tr. 6 Δ120 S31A to 
determine the importance of ATM phosphorylation on tr. 6 Δ120.  As figure 3-15  
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Figure 3-14 Response of C-terminal truncations of E2F1 to adriamycin treatment  
E2F1-/- MEFs expressing C-terminal truncations of E2F1 were treated with 2.0 µg/ml 
adriamycin and lysed in SDS lysis buffer 6 and 12 hours following treatment. Extracts were 
then resolved by SDS-PAGE and E2F1 levels measured by Western blotting using GFP 
specific antibody.  Blots were re-probed with a p38 antibody to ensure equal loading.  The 
truncations are as follows A) Truncation 1 lacks the entire transactivation domain. B) 
Truncation 2 has glutamic acid substitution at amino acid 132 in addition with lacking the 
transactivation domain. C) Truncation 3 lacks amino acids 285-437. D) Truncation 4 lacks 
amino acids 246-437. E) Truncation 5 lacks amino acids 293-437. F) Truncation 6 lacks amino 
acids 121-473. 
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indicates, ATM phosphorylation at S31 is not responsible for this induction, since 
tr. 6 Δ120 S31A showed similar induction after 6 and 12 hours following adriamycin 
treatment compared with unmutated tr. 6 Δ120  (Fig. 3-15).  To assess if 
acetylation on lysine 117 and/or 120 was responsible for the accumulation of tr. 
6 Δ120 in this assay, tr. 6 Δ120 and tr. 6 Δ120 S31A were expressed with the lysine 
arginine substitutions.  This revealed that tr. 6 Δ120 is induced by some previously 
unknown mechanism, since induction of tr. 6 Δ120 S31A/K117A/K120A was similar 
to induction seen on tr. 6 Δ120 (Fig. 3-16).   
These data indicate that at least one mechanism of E2F1 induction following 
DNA damage is yet to be discovered and that mechanism is in the first 120 amino 
acids of E2F1.  However, the significance of previously characterized 
mechanisms to E2F1 induction in this assay is difficult to ascertain.  The basal 
expression levels of exogenous proteins can not be perfectly controlled and 
therefore vary between different cell lines.  In addition, care should be taken 
when direct comparison of protein accumulation between different Western blot 
membranes is made because of differences in antibody detection and 
differences in exposure time.  Nevertheless, these data prompted us to further 
examine E2F1 induction following adriamycin treatment in order to find other 
regions within full length E2F1 that are responsive to DNA damage and examine 
the importance of previously known mechanisms for induction of these regions.     
3.2.2.6  DNA damage response of N-, C-terminal truncations 
In order to analyse the response of N- and C-terminal truncations to DNA 
damage, tr. 7 120-374 was first stably expressed in E2F1-/- MEFs and analysed.  This 
revealed that the basal expression was low and barely detectable with the GFP 
specific antibody (Fig 3-17a).  Following adriamycin treatment for 6 and 12 hours 
a clear induction was observed, with a detectable induction after 6 hours and 
further accumulation after 12 hours (Fig 3-17a).   This pattern was very similar 
observed with the C-terminal truncations and reveal that even though some 
unknown mechanism exists in the first 120 amino acids of E2F1, they are not 
necessary for the DNA damage response.   
In an attempt to find the minimal responsive region within the C-terminal end of 
E2F1, truncations 8-10 were stably expressed in E2F1-/- MEFs.  The largest 
truncations of these three, tr. 8 245-374 consists of amino acids 245 to 374 and  
110 
 
p38
E2F1
Un 6 Un 12 6 12
Tr. 6
Adr (h)
Tr. 6 S31A
Figure 3-15 Truncation 6 with a serine to alanine substitution at amino 
acid 31 is induced following adriamycin treatment  
E2F1-/- MEFs expressing truncation 6 (Tr. 6) or truncations 6 with serine 31 
substituted to alanine (Tr. 6 S31A) were treated with 2.0 µg/ml adriamycin 
and lysed in SDS lysis buffer 6 and 12 hours following treatment. Extracts 
were then resolved by SDS-PAGE and E2F1 levels measured by Western 
blotting using GFP specific antibody.  Blots were re-probed with a p38 
antibody to ensure equal loading. 
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Figure 3-16 Truncation 6 with a serine to alanine 
substitution at amino acid 31 and with acetylation 
sites K117 and K120 mutated to arginine  is 
induced following adriamycin treatment  
E2F1-/- MEFs expressing truncation 6 with lysine 117 
and 120 substituted with arginine in addition to serine 
31 substituted to alanine (Tr. 6 S31A/K117R/K120R) 
were treated with 2.0 µg/ml adriamycin and lysed in 
SDS lysis buffer 6 and 12 hours following treatment. 
Extracts were then resolved by SDS-PAGE and E2F1 
levels measured by Western blotting using GFP 
specific antibody.  Blots were re-probed with a p38 
antibody to ensure equal loading. 
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includes the marked box and the Chk2 phosphorylation site at 364.  Following 
adriamycin treatment protein levels were measured by Western blotting.  This 
revealed no induction after 6 or 12 hours of treatment indicating that this 
truncation is unable to respond to DNA damage (Fig. 3-17b).  Similar results were 
obtained with tr. 9 317-374 and tr. 10 245-317 with no visible induction under these 
conditions (Fig. 3-17 c and d).  These results indicated that the mechanism 
responsible for induction seen on tr. 7 120-374 is either in the DNA binding domain 
of E2F1 or within amino acids 192 to 245, which consists primarily of the leucine 
zipper region of the dimerization domain.   
In order to ensure that the induction seen on tr. 7 120-374 was not dependent on 
Chk2 phosphorylation on S364, a mutant version of 7 120-374 carrying serine to 
alanine substitution at site 364, was made and expressed in cells.  Following 
adriamycin treatment tr. 7 120-374 S364A showed similar induction as seen on 7 120-
374 (Fig. 3-17e).  In order to further narrow down the region responsible, tr. 11 
120-191 which only consists of the DNA binding domain, was expressed in  E2F1-/- 
MEFs and protein levels measured by Western blotting following treatment with 
adriamycin for 6 and 12 hours.  This revealed a detectable induction after 6 
hours of treatment with similar induction after 12 hours (Fig. 3-17f).   
The DNA binding domain does not include the known ATM and Chk2 
phosphorylation sites and must therefore use different mechanism for induction.  
This domain comprises two of the known DNA damage responsive acetylation 
sites (K120 and K125) that could be responsible for the induction seen.  
However, that was not considered to be a likely explanation since substitution of 
all three lysines on full length E2F1 did not alter its inducability (Fig. 3-11) and 
neither did substitution of two of them on tr. 6 Δ120 (Fig. 3-16).  This data 
therefore indicates that the DNA binding domain of E2F1 can respond to DNA 
damage and be induced following adriamycin treatment by a mechanism(s) not 
previously described.   
In summary, using the C-terminal and N-, C-terminal truncations of E2F1, two 
minimal regions of E2F1 were found to be responsive to DNA damage (Fig. 3-18).  
The data suggest that the mechanism for the induction seen on tr. 6 Δ120 and tr. 
11 120-191 are not by previously identified mechanisms.  That prompted us to  
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Figure 3-17 Response of N-, C-terminal truncations of E2F1 to adriamycin treatment  
E2F1-/- MEFs expressing N- and C-terminal truncations of E2F1 were treated with 2.0 µg/ml 
adriamycin and lysed in SDS lysis buffer 6 and 12 hours following treatment. Extracts were 
then resolved by SDS-PAGE and E2F1 levels measured by Western blotting using GFP 
specific antibody.  Blots were re-probed with a p38 antibody to ensure equal loading.  The 
truncations are as follows A) Truncation 7 lacks the first 120 amino acids in addition with the 
transactivation domain. B) Truncation 8 consists of amino acids 245-374. C) Truncation 9 
consists of amino acids 317-374. D) Truncation 10 consists of amino acids 245-317. E) 
Truncation 7 with serine 31 to alanine substitution. F) Truncation 11 consists only of the DNA 
binding domain (amino acids 120-191). 
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Figure 3-18 Summary of induction of E2F1 truncation following DNA damage  
A series of C-terminal and N-, C-terminal truncations of E2F1 were expressed in 
E2F1-/- MEFs in order to find a minimal region of E2F1 that responds to DNA damage. 
This revealed that two small regions of E2F1,truncation 6 (Tr. 6 Δ120) and truncation 
11 (Tr. 11 120-191) are both induced following DNA damage.  That indicates that 
E2F1 can be induced by mechanism(s) other that those that have been previously 
described.  Truncations that showed induction following DNA damage are in bold.  
Two minimal regions, truncation 6 and truncation 11 are highlighted.  C-terminal 
truncation 8, 9 and 10 showed no induction following DNA damage. 
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further examine the induction of both truncations to try to search for the 
potential mechanism(s) involved.  
3.2.2.7  Identification of potential phosphorylation sites in tr. 6 Δ120   
In order to further investigate the induction of tr. 6 Δ120 and in an attempt to 
find the mechanism responsible for the response it was decided to search for 
potential phosphorylation sites within this region.  Protein phosphorylation 
affects a multitude of cellular signalling processes and two phosphorylation sites 
within E2F1 that affect stabilization have been identified (Lin et al., 2001; 
Stevens et al., 2003).  Human p53 has also been reported to responsive to DNA 
damage.  Increased phosphorylation in the N-terminal domain of p53 has been 
demonstrated for at least nine phosphorylation sites in response to ionizing 
radiation or UV light (reviewed in (Appella and Anderson, 2001; Brooks and Gu, 
2003; Latonen and Laiho, 2005).  Therefore, in light of the data obtained with 
the E2F1 truncations, it was believed to be a strong possibility that unknown 
phosphorylation sites play a role in the induction observed on tr. 6 Δ120.  Using 
NetPhos 2.0 (http://www.cbs.dtu.dk/services/NetPhos/), a neural network-
based method for predicting potential phosphorylation sites at serine, threonine 
or tyrosine residues in protein sequences, several potential phosphorylation sites 
in tr. 6 Δ120 were identified (Fig. 3-19) (Blom et al., 1999).  These potential 
phosphorylation sites were threonine 49 and 75, tyrosine 100 and serine 104.  
This indicated that phosphorylation of any of these sites might, singularly or in 
combination, play a role in the induction of E2F1 following DNA damage.  This 
prompted us to further analyse the importance of these potential 
phosphorylation sites. 
3.2.2.8  Tr. 6 Δ120 with potential phosphorylation sites mutated is induced 
following DNA damage 
In order to investigate the role of potential phosphorylation sites in induction of 
tr. 6 Δ120 mutant constructs of all potential phosphorylation sites that showed 
score similar or higher than serine 31, the only known site within the region, 
were made.  These mutations were made on the tr. 6 Δ120 S31A/K117A/K120A (tr. 
6 Δ120+3mut) to make certain these residues did not play a role in the response.   
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Figure 3-19 Predicted phosphorylation sited in truncation 6  
Potential phosphorylation sites were found in truncation 6 using NetPhos 2.0.  
NetPhos score is the output score (from 0 or low potential to 1 or high potential) 
from the ensembles of neural networks trained on that acceptor residue type.    
Figure adapted from NetPhos 2.0 Server – prediction results.  
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To block potential phosphorylation, threonine 49 was mutated to alanine and, in 
order to mimic phosphorylation at this site, threonine 49 was substituted with 
aspartic acid.  These constructs, tr. 6 Δ120+3mut T49A and T49D, were then 
expressed in E2F1-/- MEFs and protein levels following adriamycin treatment 
analysed by Western blotting.  This revealed that neither alanine nor aspartic 
acid substitution inhibited the inducability of tr. 6 Δ120+3mut after 6 and 12 hours 
of treatment (Fig. 3-20a) and the induction was comparable with the induction 
seen on unmutated tr. 6 Δ120+3mut (Fig. 3-16).   
Next the involvement of threonine 75 phosphorylation was assessed.  Tr. 6 
Δ120+3mut T75A and T75D constructs were made and expressed in E2F1-/- MEFs.  
Following infections and adriamycin treatment, cells were analysed for protein 
expression.  As seen on figure 3-20b, these substitutions did not completely 
inhibit the induction as clear protein accumulation was observed after 12 hours 
following treatment (Fig. 3-20b).   
Constructs with tyrosine 100 substituted with phenylalanine or aspartic acid 
were next analysed.  Detectable inductions were obtained after 12 hours 
following adriamycin treatment (Fig 3-20c), indicating that phosphorylation on 
this tyrosine residue was not completely responsible for the induction 
experienced on tr. 6 Δ120+3mut.  Lastly, tr. 6 Δ120+3mut S104A and S104D constructs 
were generated and analysed.  Detectable accumulation was obtained after 6 
and 12 hours following treatment (Fig. 3-20d).   
These data clearly indicate, since none of these mutations completely inhibited 
the response to DNA damage that either they are not involved in the induction of 
tr. 6 Δ120 or combination of mutations would be required to inhibit the induction.  
However, other post transcriptional mechanism, such as acetylation might play a 
role and be responsible for the induction.  Further studies are therefore required 
to fully understand the mechanism involved in the induction of tr. 6 Δ120, the 
smallest N-terminal truncations that responded to DNA damage in this study. 
3.2.2.9  Identification of potential phosphorylation sites in tr. 11120-191 
In attempt to find the mechanism responsible for the induction seen on tr. 11 120-
191 which consists of the DNA binding domain of E2F1, following DNA damage, it  
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Figure 3-20 Response of truncation 6 with potential phosphorylation sites mutated 
to adriamycin treatment  
E2F1-/- MEFs expressing truncation 6 (tr. 6 Δ120+3mut) with potential phosphorylation sites 
mutated were treated with 2.0 µg/ml adriamycin and lysed in SDS lysis buffer 6 and 12 
hours following treatment. Extracts were then resolved by SDS-PAGE and E2F1 levels 
measured by Western blotting using GFP specific antibody.  Blots were re-probed with an 
actin antibody to ensure equal loading.  The truncations are as follows A) tr. 6 Δ120+3mut 
T49A and T49D. B) tr. 6 Δ120+3mut T75A and T75D. C) tr. 6 Δ120+3mut Y100F and 
Y100D. D) tr. 6 Δ120+3mut S104A and S104D. 
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was also decided to search for potential phosphorylation sites within this region.  
This was done by using the same network based method as used for tr. 6 Δ120, 
NetPhos 2.0 (http://www.cbs.dtu.dk/services/NetPhos/), which predicts 
potential phosphorylation sites at serine, threonine or tyrosine residues in 
protein sequences (Blom et al., 1999).   Using this software it was possible to 
find several potential phosphorylation sites in tr. 11 120-191 (Fig. 3-21).  These 
potential phosphorylation sites were serine 121 and 126, threonine 130, 135 and 
136, and tyrosine 128 and 168.  This indicated that phosphorylation of any of 
these sites might play a role in the induction of E2F1 following DNA damage, 
which prompted us to further analyse the importance of these potential 
phosphorylation sites. 
3.2.2.10 Tr. 11 120-191 with potential phosphorylation sites mutated is induced 
following DNA damage 
In order to investigate the importance of the potential phosphorylation sites 
within tr. 11 120-191 mutagenesis was used to substitute potential phosphorylation 
sites for amino acids that can not be phosphorylated (alanine or phenylalanine) 
or to a phospho-mimicking amino acid (glutamic acid).  Firstly, E2F1-/- MEFs 
expressing tr. 11 120-191 S121A or S121D were analysed for protein induction 6 and 
12 hours following adriamycin treatment.  This revealed a modest induction 
after 6 hours of treatment and more detectable induction after 12 hours (Fig. 3-
22a).  This indicated that phosphorylation on serine 121 was not completely 
responsible for the induction of tr. 11 120-191.  Mutations were next made on 
serine 126.  Following infection into E2F1-/- MEFs, cells were analysed for protein 
accumulation following DNA damage.  Similar to what seen for serine 121 
substitution, tr. 11 120-191 S126A and S126D were insignificantly induced after 6 
hours of treatment with more accumulation after 12 hours (Fig. 3-22b).   
This indicated that phosphorylation on serine 126 did not play an essential role 
in truncation tr. 11 120-191 induction.  To further analyse the role of the potential 
phosphorylation sites to DNA damage response of tr. 11 120-191, mutation were 
made on tyrosine 128 leading to phenylalanine and aspartic acid substitutions.  
Neither tr. 11 120-191 Y128F nor Y128D substitution showed complete inhibition of 
induction of tr. 11 120-191 following adriamycin treatment (Fig. 3-22c).   
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Figure 3-21 Predicted phosphorylation sited in truncation 11  
Potential phosphorylation sites were found in truncation 11 using NetPhos 2.0. 
NetPhos score is the output score (from 0 or low potential to 1 or high potential) from 
the ensembles of neural networks trained on that acceptor residue type. Figure 
adapted from NetPhos 2.0 Server – prediction results.    
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Threonine 130 was next substituted with alanine and aspartic acid.  Cells were 
made and subsequently treated with adriamycin for 6 and 12 hours.  Both cell 
lines showed detectable induction after 12 hours of treatment (Fig. 3-22d).   
The close proximity of threonines at position 135 and 136, which both showed to 
be potential phosphorylation sites by the NetPhos 2.0 program, allowed us to 
mutate them both using single oligo pair by PCR.  Constructs, leading to both 
threonines to alanines and aspartic acids substitutions were made.  Following 
infection into E2F1-/- MEFs, cells were analysed for protein induction following 
DNA damage.  This revealed detectable induction after 12 hours following 
treatment which indicated that neither of these threonines were essential in tr. 
11 120-191 response to DNA damage (Fig. 21e).   
The last potential phosphorylation site to be investigated was threonine at 
position 168.  Constructs leading to T168A and T168D substitution were made on 
tr. 11 120-191.  Cell lines expressing these constructs were treated with adriamycin 
for 6 and 12 hours and protein accumulation analysed.  This revealed a 
detectable induction after 12 hours of treatment indicating that phosphorylation 
at threonine 168 could not be the sole explanation for the DNA damage response 
of tr. 11 120-191 (Fig. 3-22f).   
These data clearly indicate that none of the phosphorylation sites tested were 
completely responsible for the inducability of tr. 11 120-191.  It is though a 
possibility that a combination of mutations would be required to inhibit the 
induction and therefore no effect seen when mutated one by one.  Other post 
transcriptional mechanism that phosphorylation might also be responsible for the 
induction.  The previously identified acetylation responsive lysines at position 
120 and 125 could play a role or even some unidentified DNA damage responsive 
lysines within this domain.  Therefore, in order to search for the mechanism 
responsible for this induction, further studies are required to fully understand 
the mechanism involved it the induction of the DNA binding domain of E2F1. 
3.2.3 Chapter summary 
It was demonstrated in the previous chapter that E2F1 is induced following 
treatment with adriamycin, a DNA damaging agent that is commonly used in 
treatment of various human cancers.  Adriamycin was therefore used to  
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Figure 3-22 Response of truncation 11 with potential phosphorylation sited 
mutated to adriamycin treatment  
E2F1-/- MEFs expressing truncation 11 (tr. 11 120-191) with potential phosphorylation 
sited mutated alanine, phenylalanine or aspartic acid were treated with 2.0 µg/ml 
adriamycin and lysed in SDS lyses buffer 6 and 12 hours following treatment. Extracts 
were then resolved by SDS-PAGE and E2F1 levels measured by Western blotting 
using GFP specific antibody.  Blots were re-probed with a p38 antibody to ensure 
equal loading.  The truncations are as follows A) tr. 11 120-191 S121A and S121D.  
B) tr. 11 120-191 S126A and S126D. C) tr. 11 120-191 Y128F and Y128D. D) tr. 11 
120-191 T130A and T130D. E) tr. 11 120-191 T135/136F and T135/136D.  F) tr. 11 
120-191 Y168F and Y168D 
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investigate the contribution of some of the previously characterized mechanisms 
leading to E2F1 activation and stabilization.  This revealed that singularly or in 
combination they were not fully responsible for the E2F1 induction.  It could not 
be concluded that these mechanisms were not activated and contributed to 
some degree to the induction, but it was apparent that they were dispensable, 
and therefore some other mechanism(s) must play a role in E2F1’s response to 
DNA damage under these conditions.   
In order to find a minimal region of E2F1 that is responsive to DNA damage, 
truncated forms of E2F1 were assessed for inducability.  These studies revealed 
that the first 120 amino acids (tr. 6 Δ120) of E2F1 respond to adriamycin 
treatment which could not be explained by serine 31 phosphorylation, and 
therefore indicate that at least one mechanism of E2F1 induction following DNA 
damage is yet to be discovered.  Using a mutagenesis approach, the potential 
phosphorylation sites within this region were excluded as the sole sites essential 
for this induction.  But whether other phosphorylation events or other 
modifications are responsible for the induction remains to be discovered.   
In addition, the DNA binding domain (tr. 11 120-191) of E2F1 responded to DNA 
damage.  This is a separate region from truncation 6 and indicates that another 
mechanism of E2F1 accumulation is yet to be discovered.  Mutation of potential 
phosphorylation sites within this region did not completely inhibit the induction 
and indicates that either a combination of phosphorylation events or different 
modifications are responsible for this induction.   
Together with previously identified pathways leading to E2F1 stabilization, these 
data indicate that E2F1’s response to DNA damage is complex and perhaps 
overlapping and may involve numerous pathways and different modifications.  
Whether these mechanisms are inhibited in tumour development will need 
thorough investigation since, restoration of the apoptotic pathway of E2F1, for 
example by activating E2F1’s sensitivity to continuously occurrence of mutations 
in tumours, could prove to be useful strategy to kill tumour cells.  Further 
studies on E2F1 induction are therefore crucial in the coming years.   
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3.3 E2F1’s response to oncogene activation 
Oncogenes have been shown to deregulate E2F1 through inhibition of pRb and 
oncogenic stress can induce E2F1’s apoptotic activity (Chellappan et al., 1992; 
Harbour and Dean, 2000; Whyte et al., 1988). The adenoviral early region 1A 
(E1A) oncogene can deregulate E2F1 by interacting with pRb and other cellular 
components involved in cell cycle regulation.  Therefore, E1A has been used as a 
tool to identify cellular regulatory pathways that modulate cell proliferation 
and, when altered, contribute to cancer formation.  The gene encoding E1A has 
evolved to influence cellular decisions leading to cell division and 
differentiation, however, E1A also sensitises cells to the induction of apoptosis 
by diverse stimuli, including many anticancer agents (Lowe et al., 1993). 
These E1A activities are mediated through binding the RB family proteins (pRb, 
p107 and p130) and via the E1A N-terminal domain that interacts with different 
cellular protein complexes including the histone acetyltransferases p300 and 
p400 (Frisch and Mymryk, 2002).  E1A has been shown to lead to significant 
activation of the TAp73 promoter, with mutants lacking the p300-and/or pRb-
binding sites showing reduced ability to activate the TAp73 promoter 
(Flinterman et al., 2005). The importance of p400 has also been evaluated.  In 
2001 Fuchs et al. concluded that the p400 complex is an essential E1A 
transformation target and p400 has also been shown to be required for E1A to 
promote apoptosis (Fuchs et al., 2001; Samuelson et al., 2005).   
A more complete understanding of the role and activity of these complexes will 
provide further insight into the underlying platform and pathways involved in 
oncogene activation.  It was therefore decided to further investigate the effect 
of E1A expression on E2F1 activity and the contribution of the E1A bound cellular 
complexes to the increased sensitivity of cells with deregulated E2F1 caused by 
pRb inhibition.  
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3.3.1 E2F1 is induced following E1A expression 
Expression of adenovirus 5 early region 1 (Ad5 E1, which directs expression of 
both E1A and E1B proteins) has been shown to cause increase in E2F1 protein 
levels (Hateboer et al., 1996b).  However, the effect of E1A expression alone on 
E2F1 protein levels has not been thoroughly investigated.  To examine the effect 
of oncogene activation on E2F1 levels, wild type E1A was retrovirally infected 
into RPE cells and endogenous E2F1 protein levels examined by Western blotting.  
This revealed a noticeable induction of E2F1 protein levels following E1A 
expression when compared with empty vector (pLPC) infection (Fig. 3-23a).  The 
E2F1 protein levels were similar to the protein levels seen when E2F1 was 
overexpressed in the same system.  Blots were re-probed with an actin antibody 
to ensure equal loading.    
In order to examine if the increase in E2F1 protein levels following E1A 
expression was a result of enhanced transcription of the E2F1 gene itself or if 
the changes were post transcriptional, real time PCR was carried out.  RNA was 
isolated from the same RPE cell lines and the E2F1 mRNA levels measured using 
E2F1 specific primers.  No changes were observed in the mRNA levels following 
E1A expression compared with vector control (Fig. 3-23b).  RPE cells over-
expressing E2F1 were used as positive control and resulted in around 30 fold 
mRNA increase compared to vector alone.   
These data indicate that the changes in E2F1 protein levels are not due to 
increased transcription, but are a post-transcriptional effect.  
In order to confirm these results it was decided to use a system where E1A 
activity can be induced by tamoxifen in RPE cells.  In this system E1A is fused 
with a mutant version of the hormone-binding domain of the oestrogen receptor 
(ER).  This version has affinity to the synthetic ligand tamoxifen.  E1A-ER fusion 
is inactive in the absence of tamoxifen because it is complexed with 
intracellular polypeptides such as Hsp90.  Tamoxifen binding releases the 
receptor from the inhibitory complexes leading to nuclear import and activation 
of E1A-ER fusion protein (Fig. 3-24).     
Cells were treated with tamoxifen and lysed 24 hours following treatment.  
Endogenous E2F1 protein levels were measured by Western blotting which  
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Figure 3-23 Endogenous E2F1 protein levels are induced in cells 
overexpressing wild type E1A  
A + B) RPE cells were retrovirally infected with wild type E1A, empty 
vector (pLPC) and E2F1.  A) Cells were harvested in SDS buffer and 
protein levels estimated by Western blot analysis.  Extracts were 
probed with anti E2F1 antibody (C-20) to determine E2F1 expression 
and anti E1A mouse antibody (M58 + M73) to determine E1A 
expression.  Blots were re-probed with an actin antibody to ensure 
equal loading.  B) RNA was extracted and cDNA prepared. Relative 
expression of E2F1 was determined by real-time qPCR. 
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Figure 3-24 The E1A ER system  
E1A is fused with a mutant version of the hormone-binding domain of the 
oestrogen receptor (ER) which has affinity for the synthetic ligand 
tamoxifen.  Inhibitory proteins such as Hsp90 bind to ER and inhibit normal 
function of the E1A-ER fusion protein. Following tamoxifen treatment, 
Hsp90 binding is released from the ER leading to nuclear import and 
activation of the E1A-ER fusion protein  
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revealed noticeable induction in treated cells (Fig. 3-25).  E1A levels were also 
induced following tamoxifen treatment.  No induction was seen in actin levels 
which were used to ensure equal loading of proteins.   
3.3.2 E1A-induced E2F1 is not further induced following DNA 
damage 
E2F1 can by induced by DNA damage and oncogene activation.  In order to 
examine if E2F1 induced by E1A expression can by further induced by DNA 
damage, RPE cells that express the E1A-ER fusion protein were treated with 
adriamycin for 6 and 12 hours in the absence or presence of tamoxifen.  24 hours 
prior to adriamycin treatment cells were treated with tamoxifen to activate 
E1A.  E2F1 levels were then measured by Western blotting.  Consistent with 
previous experiments, E2F1 was induced following adriamycin treatment and 
following E1A activation (Fig. 3-26, lane 1 and 4).  However, when E2F1 levels 
were already induced by E1A activation, no further induction was seen following 
DNA damage (Fig. 3-26, lines 4, 5 and 6).   
The tumour suppressor p53 was significantly induced following DNA damage and 
showed detectable induction following E1A activation.  In contrast with E2F1, 
p53 levels further accumulated following DNA damage in the presence of E1A 
activation.  These results indicate that, different to p53 the mechanism leading 
to E2F1 induction following E1A expression are the same or overlap the 
mechanisms involved in E2F1’s DNA damage response.  However, the possibility 
that E2F1 levels reach saturation point following E1A activation, and can 
therefore not be further induced following DNA damage, can not be excluded. 
3.3.3 E1A expression sensitises cells to drug induced apoptosis 
E1A can sensitise cells to the induction of apoptosis by diverse stimuli, including 
many anticancer agents (Lowe et al., 1993).  In order to confirm this was the 
case in our system, E1A expressing cells were treated with 0.5 µg/ml adriamycin 
for 48 hours.  Apoptosis was measured by flow cytometry (PI staining and sub-G1 
content used as an indicator of apoptotic cells).  Consistent with previous 
reports, E1A expressing cells become very sensitive to drug induced apoptosis  
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Figure 3-25 Endogenous E2F1 protein levels are 
induced following E1A activation in an E1A-ER 
system following treatment with tamoxifen  
RPE cells expressing E1A-ER fusion protein were treated 
with tamoxifen.  24 hours following treatment, cells were 
harvested in SDS buffer and protein levels estimated by 
Western blot analysis.  Extracts were probed with anti 
E2F1 antibody (C-20) to determine E2F1 and E1A 
specific antibody to determine E1A expression.  Blots 
were re-probed with an actin antibody to ensure equal 
loading.  
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Figure 3-26 Endogenous E1A-induced E2F1 protein levels are not further 
induced following DNA damage  
RPE cells expressing E1A-ER fusion protein (RPE E1A-ER) were treated with 2.0 
µg/ml adriamycin (Adr) for 6 and 12 hours (h).  24 hours prior to adriamycin 
treatment cells were treated with tamoxifen or control. Cells were then harvested 
in SDS buffer and protein levels estimated by Western blot analysis.  Extracts 
were probed with anti E2F1 antibody (C-20) to determine E2F1 levels and anti 
p53 antibody (DO1) to determine p53 levels.  Blots were re-probed with an actin 
antibody to ensure equal loading. 
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and showed about 30% accumulation in sub-G1 content compared to 1% in 
parental RPE cells (Fig. 3-27a).   
Similar results were obtained using RPE cells expressing E1A-ER (RPE E1A-ER).  
Following E1A activation by tamoxifen cells were treated with adriamycin.  48 
hours following treatment cells were harvested and apoptosis measured by FACS 
analysis.  This resulted in 30% drug-induced cell death when E1A was active, 
compared with 3% cell death when no tamoxifen was added (Fig. 3-27b).  
Tamoxifen treatment alone had no effect on cell death.   
3.3.4 Deregulated E2F1 is involved in drug induced apoptosis 
E1A binds all the RB family proteins (pRb, p107 and p130) which regulate both 
the activating and repressive E2Fs (E2F1-3 and E2F4-5 respectively).  However, 
E1A induced drug sensitivity is dependent on E1A binding to pRb, which binds the 
activating E2Fs (E2F1-3) (Samuelson and Lowe, 1997; Samuelson et al., 2005).  
E2F1 is the only family member that is induced following DNA damage and many 
studies show that E2F1 is the only member that can induce apoptosis (DeGregori 
et al., 1997; Kowalik et al., 1998; Leone et al., 2001; Lissy et al., 2000).  It is 
therefore most likely that E2F1 induction following E1A expression plays a 
crucial role in the increased drug sensitivity. 
The importance of high levels of deregulated E2F1 in drug induced apoptosis was 
tested.  An RNAi approach was used to silence E2F1 levels in RPE E1A-ER cells.  
Cell line stably expressing a scrambled hairpin was created as a control (RPE 
E1A-ER pRS-Scr).  Significant knockdown of E2F1 protein was obtained compared 
with a cell line stably expressing a scrambled hairpin with no effect seen on 
actin (Fig. 3-28a, compare lane 1 and lane 3).  Both cell lanes showed E2F1 
induction following tamoxifen treatment, however the levels of E2F1 were 
significantly lower in the pSR-E2F1 line compared to the cells expressing the 
scrambled control.  E2F1 knockdown did not have an effect on basal levels of 
p53, which also showed marginal induction following E1A activation in both cell 
lines. 
The effect of E2F1 knockdown on drug-induced apoptosis in E1A expressing cells 
was tested.  The two cell lines were treated with tamoxifen and adriamycin for 
48 hours and apoptosis measured by flow cytometry.  There was a detectable 
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Figure 3-27 E1A expression sensitizes cells to drug induced apoptosis  
A) RPE cells expressing wt E1A (RPE E1A) were treated with 0.5 µg/ml 
adriamycin (Adr) for 48 hours.  Following treatment DNA content of cells was 
assessed by flow cytometry.  The percentage of cells with a sub-G1 DNA was 
taken as a measure of apoptotic rate. B) RPE cells expressing E1A-ER fusion 
protein (RPE E1A-ER) were treated with tamoxifen (Tam), 0.5 µg/ml 
adriamycin (Adr) or tamoxifen plus adriamycin for 48 hours.  Following 
treatment DNA content of cells was assessed by flow cytometry.  The 
percentage of cells with a sub-G1 DNA was taken as a measure of apoptotic 
rate. 
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decrease in apoptosis in the cell line with E2F1 knockdown, compared with cells 
expressing the scrambled hairpin (Fig. 3-28b).   
These results demonstrate that induced E2F1 protein levels contribute to 
increased drug sensitivity in circumstances when E2F1 is deregulated by pRb 
inhibition.   
3.3.5 Description of E1A truncations 
E1A activities are mediated through binding to different cellular protein 
complexes via the E1A N-terminal domain.  It is possible that E1A binding to 
these cellular complexes is crucial for the E2F1 induction observed with wild 
type E1A.  That can be examined by using previously characterized functional 
mutants of E1A (Seger et al., 2002).  These mutants retain their ability to bind 
to pRb but have a single mutation or lack domains within E1A that are necessary 
for binding to other complexes.  These mutants can therefore be used to identify 
complexes that may be involved in E2F1 induction.   
The first truncation, R2G, has the 2nd arginine mutated to glycine.  This mutation 
abolishes the binding of E1A to the co-activator p300/CBP (Fig. 3-29).  Deletion 
mutant Δ2-11 lacks amino acids 2 to 11 and is also unable to bind to the 
p300/CBP co-activator complex.  Both R2G and Δ2-11 remain their ability to bind 
to the p400/TRRAP chromatin remodelling protein complex.  Deletion mutant 
Δ2-24 lacks amino acids 2 to 24.  Deleting residues 2-24 abolishes binding to both 
p300/CBP and the p400/TRRAP protein complex.  Deletion mutant Δ2-36 lacks 
residues 2 to 36 and is also unable to bind to the p300/CBP and p400/TRRAP 
protein complex.  Deletion mutant Δ26-35 lacks residues 26 to 35.  Δ26-35 binds 
p300/CBP but has lost binding capability (or only binds weakly when 
overexpressed) to p400/TRRAP (Samuelson et al., 2005).  Deletion mutant Δ48-
60 lacks residues 48 to 60 and has lost binding capacity to the p300/CBP complex 
but retains it ability to interact with the p400/TRRAP complex.  The last E1A 
truncation, 143 has the C-terminal end removed and only consists of the first 143 
amino acids.  Truncation 143 has lost its binding ability to the transcriptional co-
repressor CtBP but can bind both p300/CBP and p400/TRRAP complexes (Fig. 3-
29). 
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Figure 3-28 Knockdown of E2F1 reduces drug-induced apoptosis in E1A 
expressing  
A) RPE cells expressing E1A-ER fusion protein and scrambled or E2F1 specific 
shE2F1 (RPE E1A-ER pRS Scr or pRS E2F1) were treated with tamoxifen 
(Tam) for 24 hours.  The cells were then lysed in SDS lysis buffer, extracts 
resolved by SDS-PAGE and endogenous E2F1 and p53 levels measured by 
Western blotting using E2F1 (C-20) and p53 (DO1) specific antibodies. Blots 
were re-probed with an actin antibody to ensure equal loading. B) RPE E1A-ER 
pRS Scr and pRS E2F1 cells were treated with tamoxifen (Tam) and 0.5 µg/ml 
adriamycin (Adr) for 48 hours.  Following treatment DNA content of cells were 
assessed by flow cytometry. The percentage of cells with a sub-G1 DNA 
content were taken as the apoptotic population. 
 
136 
E1A
 binding
YesYesNo
NoYesYes
YesYesNo
YesNo Yes
YesNo No
YesNo No
YesYesNo
p300/
CBP
p400/
TRRAP CtBP
R2G
∆2-24
∆26-35
∆2-11
∆48-60
143
∆2-36
CR1 CR2
CR1 CR2*
CR1 CR2∆2-11
CR1 CR2∆2-24
CR1 CR2∆26-35
CR1 CR2∆2-36
CR2∆48-60
R2G
∆2-24
∆26-35
∆2-11
∆48-60
143
∆2-36
p300/CBP
P400/
CtBP
30-761-25
4-47
171-243
CR1 CR2E1A
1 40 80 120 140 243
TRRAP
A)
B)
Figure 3-29 Description of E1A truncations  
A) Previously described functional mutants of E1A lack domains within E1A that are 
necessary for binding to known protein complexes.  R2G has the 2nd arginine 
mutated to glycine.  143 only consists of the first 143 amino acids.  Other truncations 
lack residues indicated in white boxes.  B) All truncations except 143 bind to the 
transcription co-repressor CtBP. R2G, Δ2-11 and Δ48-60 have all lost their ability to 
bind to the co-activator p300/CBP but remain their ability to bind to the p400/TRRAP 
chromatin remodelling protein complex. Deletion mutants Δ2-24 and Δ2-36 are unable 
to bind to both p300/CBP and the p400/TRRAP protein complex. Δ26-35 binds 
p300/CBP but has lost binding capability. 
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3.3.6 E1A binding to the p400/TRRAP is essential for E1A-induced 
E2F1 accumulation 
All the E1A truncations were infected into RPE cells and their expression 
confirmed by Western blotting using an E1A specific antibody (Fig. 3-30).  All 
truncations showed similar expression level compared to wild type E1A with the 
exception of truncation 143.  The detection by Western blotting of truncation 
143 was much lower than the other truncations, however whether this was due 
to truncated protein having lower affinity to the antibody has not been 
determined.  Blots were re-probed with an actin antibody to ensure equal 
loading.   
In order to investigate the effect of the expression of these truncations on E2F1 
protein levels the blot was re-probed with E2F1 specific antibody (Fig. 3-30).  
Robust induction of E2F1 protein level was seen with R2G and Δ2-11 indicating 
that E1A binding to the p300/CBP complex was dispensable for this affect.  The 
induction seen following expression of mutant Δ48-60 also indicated that E1A 
binding to the p300/CBP complex is not necessary to induce E2F1 levels.  E2F1 
induction was seen in cells expressing truncation 143 indicating that the C-
terminal end of E1A and therefore E1A binding to the CtBP co-repressor was also 
dispensable for this affect.   
Interestingly, truncations Δ2-24, Δ2-36 and Δ26-35 all failed to induce E2F1 
levels.  All of these truncations are deficient in binding to the p400/TRRAP 
protein complex (Samuelson et al., 2005).  This therefore indicates that E1A 
binding to the p400/TRRAP protein complex is potentially important for E1A to 
induce E2F1 accumulation.  
3.3.7 E1A binding to the p400/TRRAP complex is essential for 
increased drug sensitivity 
Next, it was assessed what impact expressing the E1A truncations had on drug-
induced apoptosis.  Cells expressing the E1A mutants were treated with 
adriamycin for 48 hours and apoptosis measured by flow cytometry.   
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Figure 3-30 E1A truncations deficient in binding p400/TRRAP fail to induce 
E2F1 levels  
RPE cells expressing wild type E1A, E1A truncations or empty vector (pLPC) 
were harvested in SDS buffer and protein levels estimated by Western blot 
analysis. Extracts were probed with anti-E1A (M58 +M73) and anti-E2F1 (C-20) 
antibodies to determine E1A and E2F1 expression.  Blots were re-probed with 
an actin antibody to ensure equal loading.  The red square indicates E1A 
truncations which fail to induce E2F1 levels. 
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This revealed that R2G, Δ2-11 and Δ48-60 mutants, which all are unable to bind 
to the p300/CBP complex, are as sensitive to drug induced apoptosis as wild type 
E1A (Fig. 3-31).  This indicates that E1A interacting with the p300/CBP complex 
is largely dispensable for these effects.  Truncation 143 which lacks the C-
terminal end of E1A is also capable of increasing chemosensitivity, even though 
it showed much lover expression levels by Western blotting.  Truncation 143 is 
unable to bind to the CtBP co-repressor, indicating that CtBP interaction is 
dispensable for E1A promoting drug induced apoptosis. 
Conversely, truncations Δ2-24, Δ2-36 and Δ26-35 which are all deficient in 
binding to the p400/TRRAP cpmplex, were all more resistant to adriamycin.    
This suggests that E1A binding to the p400/TRRAP protein complex is important 
in mediating increased drug sensitivity.   
The mutants that failed to increase drug sensitivity are the same as failed to 
induce E2F1 levels following their expression.  This indicates that E1A’s 
capability in promoting drug sensitivity is not only through E2F1 deregulation by 
pRb inhibition, but also by increasing E2F1 levels by binding to the p400/TRRAP 
protein complex.  However, the E1A mutants used in this study are perhaps not 
refined enough to exclude other E1A targets as potential reason for the effect 
observed.  Therefore, a more extensive analysis is necessary to confirm the 
involvement in p400/TRRAP in E2F1 induction and increased drug sensitivity.   
3.3.8 p400 knockdown induces E2F1 levels 
E1A has been shown to bind and inhibit pRb but whether E1A interaction 
activates or inhibits the p400/TRRAP complex is not clear.  The possibility of E1A 
inhibiting the p400/TRRAP protein complex to induce E2F1 levels was assessed. 
In order to examine the effect of p400 inhibition on E2F1 levels three siRNAs 
designed to target p400 were used.  RPE cells expressing E1A truncations Δ2-36 
and Δ26-35 were transfected with siRNA oligos targeting p400 or non-targeting 
siRNA as control.  Transfection of all three p400 specific oligos resulted in over 
50 % reduction of p400 mRNA levels measured by real time qPCR (Fig. 3-32a).  
The effect of p400 knockdown on E2F1 proteins were next measured by Western 
blotting.  p400 knockdown resulted in E2F1 induction with all three p400 oligos  
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Figure 3-31 E1A mutants which fail to bind p400/TRRAP do not increase 
drug sensitivity  
DNA content of RPE cells expressing wt E1A, E1A truncations and empty 
vector (pLPC)l were assessed 48 hours following treatment with 0.5 µg/ml 
adriamycin.  The percentage of cells with a sub-G1 DNA was taken as a 
measure of apoptotic rate. The red square indicates E1A truncations which fail 
to induce apoptosis. 
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when compared with scrambled control (Fig. 3-32b). The effect was observed 
both in cell expressing Δ2-36 and Δ26-35 E1A truncatons. 
Consistent with previous studies, knockdown of p400 had the opposite effect on 
p53 protein levels (Samuelson et al., 2005).   Detectable reduction in p53 levels 
were seen following siRNA transfection with all three oligos and in both cell 
lines.  Actin was used to ensure equal loading. 
3.3.9 p400 knockdown sensitizes cells to drug-induced apoptosis 
In order to investigate the effect of p400 inhibition on drug sensitivity, RPE cells 
expressing E1A truncations Δ2-36 and Δ26-35 were treated with adriamycin 
following p400 knockdown.  Apoptosis was measured as before using flow 
cytometry with sub-G1 content as indicator of apoptotic cells.  In line with 
figure 3-32 where E2F1 levels were increased following p400 knockdown, an 
induction of apoptosis was observed following treatment with adriamycin (Fig. 3-
33). 
Slight variation in apoptosis was seen between individual p400 oligos with oligo 2 
showing the strongest induction of death in both cell lines.  However, given that 
p400 knockdown decreased p53 levels, the effect of increase in E2F1 levels 
could have greater significance than this assay indicated.  Therefore, these data 
strongly signify that E2F1 induction by p400 knockdown is important in 
sensitizing cells to drug-induced apoptosis.  They also further support the 
hypothesis that E1A inhibits the p400/TRRAP protein complex and that inhibition 
is responsible for E2F1 induction and increased drug sensitivity. 
3.3.10 E2F1 overexpression sensitizes Δ2-36 expressing cells to 
drug-induced apoptosis 
Overexpression of E2F1 allowed us to analyse the effect of E2F1 induction on 
chemosensitivity without decreasing p53 levels.  Therefore the importance of 
E2F1 protein levels on chemosensitivity in cells with already deregulated E2F1 
pathway was examined using adenoviral E2F1.  RPE cells expressing E1A Δ2-36 or 
vector as a control, were infected with adenoviral E2F1 24 hours prior to  
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Figure 3-32 E2F1 is induced following p400 knockdown  
A) RPE cells expressing E1A ∆2-36 or ∆26-35 truncations were transfected with 
three siRNA oligos designed to target p400.  Scrambled siRNA was used as 
control.  24 hours following transfection, RNA was extracted from samples and 
cDNA prepared and used for real-time qPCR analysis.  p400 knockdown was 
measured by using p400 specific primers.  18S rRNA primers were used to 
normalise for total RNA control. B) 48 hours following siRNA transfections cells 
were lysed in SDS lyses buffer.  Extracts were resolved by SDS-PAGE and 
endogenous E2F1 and p53 levels measured by Western blotting using E2F1 (C-
20) and p53 (DO1) specific antibodies. Blots were re-probed with an actin 
antibody to ensure equal loading.  
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Figure 3-33 p400 silencing enhances drug-induced apoptosis  
RPE cells expressing E1A  ∆2-36 or E1A ∆26-35 were transfected with three 
siRNA oligos targeting p400 (1-3).  A scrambled siRNA oligo was used as a 
control (Scr).  24 hours following transfection, cells were treated with 0.5 µg/ml 
adriamycin.  48 hours following treatment DNA content were assessed by flow 
cytometry.  The percentage of cells with a sub-G1 DNA was taken as a measure 
of apoptotic rate. 
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adriamycin treatment.  Adenovirus expressing empty vector were used as an 
expression control.   
Following adenoviral and adriamycin treatment, apoptosis was measured using 
flow cytometry.  Overexpression of E2F1, without adriamycin treatment, had no 
effect on apoptosis in Δ2-36 expressing cells or control cell line (Fig. 3-34a).  
Consistent with previous data, adriamycin treatment had little effect on 
apoptosis in RPE control cells and showed slight increase in apoptosis in the Δ2-
36 expressing cell line.  However, a robust increase in apoptosis was observed 
when E2F1 was overexpressed prior to adriamycin treatment in the Δ2-36 
expressing cells, whereas E2F1 overexpression had little effect on 
chemosensitivity on control cell line.  
Equal expression of adenoviral E2F1 was verified by Western blotting using E2F1 
specific antibody (Fig. 3-34b).  p53 levels were also analysed by Western blotting 
and revealed robust induction in response to adriamycin treatment but no 
changes were observed between the different cell lines.  E1A Δ2-36 expression 
was confirmed using E1A specific antibody and actin was used to ensure equal 
loading of proteins. 
These results demonstrate that high levels of E2F1 sensitize cells to drug-
induced apoptosis in cells where pocket proteins are inhibited by the E1A 
oncoprotein.  These effects are independent of p53 status since similar 
accumulation of p53 was observed in both cell lines following DNA damage. 
3.3.11 E1A is dependent on binding to pRb to induce E2F1 levels 
E1A, in addition to many viral oncoproteins such as the HPV protein E7, binds to 
the pRb pocket domain via a Leu-x-Cys-x-Glu (LxCxE) binding motif (Singh et al., 
2005).  E1A contains two conserved regions, CR1 and CR2 and E1A binds to 
hypophosphorylated form of pRb, primarily through the motif that is located in 
CR2.  The interaction of E1A with pRb deregulates E2F1 and results in a 
stimulation of E2F1-dependant transcription (Frisch and Mymryk, 2002).  
In order to investigate if E2F1 induction by wild type E1A was dependent on E1A 
binding to pRb, a pRb binding deficient mutant form of E1A, which lacks the CR2 
domain (E1A ΔCR2) was used.  Following infection of virus expressing E1A ΔCR2  
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Figure 3-34 E2F1 overexpression sensitizes E1A ∆ 2-36 expressing cells to 
drug-induced apoptosis  
A-B) RPE cells expressing E1A ∆2-36 truncation or empty vector (contr) were 
infected with adenoviral E2F1 or empty virus (E.v.) (MOI 3.8 IFU/cell).  A) 24 hours 
following infection cells were treated with 0.5 µg/ml adriamycin Adr). 48 hours 
following adriamycin treatment, the DNA content of cells were assessed.  The 
percentage of cells with a sub-G1 DNA content was taken as a measure of 
apoptotic rate. B) 24 hours following adenoviral infection cells were treated with 0.5 
µg/ml adriamycin. 24 hours following adriamycin treatment cells were lysed in SDS 
lyses buffer.  Extracts were resolved by SDS PAGE and endogenous E2F1, E1A 
and p53 levels measured by Western blotting using E2F1 (C-20), E1A and p53 
(DO1) specific antibodies. Blots were re-probed with an actin antibody to ensure 
equal loading. 
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into RPE cells, E2F1 levels were measured by Western blotting.  This revealed 
that E1A ΔCR2 failed to induce E2F1 levels to the same degree as wild type E1A 
despite being expressed at similar levels.  This indicates that E1A is dependent 
on binding to pRb to induce E2F1 levels (Fig. 3-35a). 
3.3.12 E2F1 deregulation by pRb inhibition is essential in 
increasing drug sensitivity 
In order to examine the importance of pRb inhibition and E2F1 induction by E1A 
on drug sensitivity, RPE cells expressing E1A ΔCR2 were treated with adriamycin.  
48 hours following treatment, apoptosis was measured and compared with cells 
expressing empty vector or wild type E1A.  Cells expressing E1A ΔCR2 were more 
resistant to adriamycin induced apoptosis (12% sub-G1) than cells expressing wild 
type E1A (46% sub-G1) (Fig. 3-35b).  This data confirms the importance of E2F1 
deregulation by pRb inhibition in drug sensitivity and also advocates the 
importance of E2F1 induction in the response.  However, E1A ΔCR2 expressing 
cells showed a minor increase in apoptosis compared to empty vector control.  
This suggest that either E1A ΔCR2 can weakly bind to pRb via CR1 and deregulate 
some E2F1 proteins, or E1A binding to other proteins can alter cells drug 
sensitivity.   
3.3.13 E1A is dependent on pRb binding to complex with E2F1 
As discussed previously, E1A binds and inhibits pRb function, which results in 
activation of E2F1.  The results presented in this chapter suggest that the ability 
of E1A to induce E2F1 levels depends on E1A binding to the p400/TRRAP protein 
complex and to pRb.  It was therefore hypothesized that pRb acts as a scaffold 
between E1A and E2F1, and allows E1A to complex with E2F1 which leads to the 
E2F1 accumulation.  To test this hypothesis, it was investigated if E2F1 can be 
found in a complex with E1A and pRb.  In addition it was tested if E1A binding to 
pRb is essential for E2F1 to complex with E1A.  In order to do so, E1A and E1A 
ΔCR2 were immunoprecipitated with anti-E1A antibody from RPE cells expressing 
these proteins.  An anti-HA antibody was used as an immunoprecipitation 
control.  Immunoprecipitated proteins were then probed with anti-pRb and E2F1 
antibodies proteins to assess it they co-immunoprecipitate with E1A.  As 
expected, pRb co-immunoprecipitated with wild type E1A but not with E1A ΔCR2  
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Figure 3-35 Deregulation of E2F1 by pRB inhibition is 
necessary for increased drug sensitivity  
A) RPE cells expressinb wild type E1A, pRB binding deficient 
mutant of E1A (∆CR2) and empty vector (pLPC) were 
harvested in SDS lysis buffer and protein levels estimated by 
Western blot analysis.  Extracts were probed with an anti-E2F1 
antibody (C-20) to determine E2F1 expression and anti-E1A 
antibody (M58 + M73) to determine E1A expression.  Blots 
were re-probed with an actin antibody to ensure equal loading. 
B) DNA content of RPE cells expressing wt E1A, ∆CR2 or 
empty vector were assessed by flow cytometry 48 hours 
following treatment with 0.5 µg/ml adriamycin.  The percentage 
of cells with a sub-G1 DNA was taken as a measure of 
apoptotic rate. 
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truncation (Fig. 13-36).  Re-probing blots with E2F1 antibody revealed that E2F1 
also co-immunoprecipitated with wild type E1A, but not E1A ΔCR2, suggesting 
that E1A is dependent on binding to pRb to complex with E2F1. 
However, it can not be excluded that E1A can directly bind E2F1 via the CR2 
domain in a pRb independent manner.  Therefore, the ΔCR2 mutant would fail to 
co-immunoprecipitate E2F1, but independently of pRb binding.  In addition, it is 
a possibility that increased E2F1 expression in wild type E1A expressing cells 
results in increase in co-immunoprecipitated E2F1.  
3.3.14 E2F1 is induced following E1A activation in pRb-/- cells 
In order to assess if E1A is dependent on pRb binding to induce E2F1 levels, E1A-
ER fusion protein was virally infected into wild type and pRb knockout (pRb-/-) 
MEFs (te Riele et al., 1992).  Cells were treated with tamoxifen and lysed 24 
hours following treatment.  Endogenous E2F1 protein levels were measured by 
Western blotting which revealed noticeable induction in treated cells of both 
cell lines (Fig. 3-37).  No induction was seen in actin levels which were used to 
ensure equal loading of proteins. 
These data indicate that E1A is able to induce E2F1 accumulation without 
binding to E2F1 via pRb.  However, it is possible that the other pRB family 
proteins, p107 or p130, substitute for pRb and bind to E2F1 in pRb-/- cells.  
Therefore p107 or p130 could provide the platform for E1A-E2F1 interaction, 
resulting in E2F1 accumulation following E1A expression.  In support of this 
possibility results from Gao et al have shown that in Saos2 cells, which are pRb-/-
, p130 formed complexes with E2F1 (Gao et al., 2002).   
3.3.15 E2F1 is not induced following E1A expression in pRB 
family knockout cells 
In order to assess it E1A is dependent on binding to any of the members of the 
pRB family to induce E2F1 levels, E1A-ER fusion protein was virally infected into 
triple knockout (pRb-/-, p107-/- and p130-/-) MEFs (TKO) (Dannenberg et al., 
2000).  Cells were treated with tamoxifen and lysed 24 hours following 
treatment.  Endogenous E2F1 protein levels were measured by Western blotting  
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Figure 3-36 E1A is dependent on pRb binding in 
order to form a complex with E2F1  
RPE cells expressing wild type E1A or the E1A ∆CR2 
truncation were immunoprecipitated with an E1A specific 
antibody or anty-HA andibody as negative control.  
Extracts were then resolved by SDS PAGE as detailed in 
the materials and methods.  Co-immunoprecipitated 
E2F1 and pRb protein levels were measured by Western 
blotting using E2F1 (C-20) and pRb (C-15) specific 
antibodies. Blots were re-probed with E1A antibody to 
measure precipitated protein levels. 
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Figure 3-37 Endogenous E2F1 protein levels are 
induced following E1A activation in an E1A-ER 
system following treatment with tamoxifen in wild 
type and pRb-/- MEFs  
Wild type and pRb-null MEFs expressing E1A-ER were 
treated with tamoxifen.  24 hours following treatment, 
cells were harvested in SDS buffer and protein levels 
estimated by Western blot analysis.  Extracts were 
probed with anti E2F1 antibody (C-20) to determine E2F1 
protein levels.  Blots were re-probed with an actin 
antibody to ensure equal loading.   
 
151 
which revealed no induction in treated TKO cells whereas pRb-/- cells showed 
noticeable E2F1 induction (Fig. 3-38).  No induction was seen in actin levels 
which were used to ensure equal loading of proteins. 
This data indicate that E1A is dependent on binding to any of the pRB family 
members to induce E2F1 levels.   
3.3.16 E2F1 induction following E1A activation does not require 
the transactivation domain of E2F1 
Recent observations have defined an alternative E2F1 binding site within pRb.  
Previously it has been shown that the large pocket domain (amino acids 379-928) 
is sufficient for stable interaction with E2F (Qin et al., 1992).  The second E2F 
interaction site is located entirely within the C-terminal domain (amino acids 
792-928) and is specific for E2F1 (Dick and Dyson, 2003).  E2F1/pRb complexes 
formed through this site have low affinity for DNA, but the interaction is 
sufficient for pRb to regulate E2F1-induced apoptosis, and interestingly, E2F1 
loses the ability to interact with this site following DNA damage.  This indicates 
that interaction through this E2F1-specific site is regulated separately from 
other pRb-E2F interactions.  
The previously reported pRb binding site in E2F1 is located in the C-terminal 
transactivation domain (amino acids 409-426).  However, with the identification 
of the new E2F1 binding domain in pRb, it was shown that the C-terminus of pRb 
is able to interact with E2F1 truncation that lacks the transactivation domain 
(E2F1 1-374) (Dick and Dyson, 2003). It was further suggested that C-terminus of 
pRb likely requires the marked box region of E2F1 for binding and makes contact 
with multiple places in the N terminus as well.  The low DNA binding affinity of 
the E2F1/pRb complexes formed through this site may explain why the 
interaction was overlooked in previous studies. 
In order to assess if E1A expression is able to induce levels of E2F1 that lack the 
“classic” pRb binding domain, viruses expressing either full length E2F1 or a 
truncated version which lacks the transactivation domain of  E2F1 (E2F1 Δ374) 
were infected into E2F1-/- MEFs expressing E1A ER.  Both cell lines showed 
similar basal expression levels (Fig. 3-39).  Cells were then treated with  
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Figure 3-38 Endogenous E2F1 protein levels are not 
induced following E1A activation in an E1A-ER system 
following treatment with tamoxifen in triple knockout 
(pRb-/-, p017-/- and p130-/-) MEFs  
pRb-null and triple knockout (TKO) MEFs expressing E1A ER 
were treated with tamoxifen.  24 hours following treatment, 
cells were harvested in SDS buffer and protein levels 
estimated by Western blot analysis.  Extracts were probed 
with anti E2F1 antibody (C-20) to determine E2F1 protein 
levels.  Blots were re-probed with an actin antibody to ensure 
equal loading. 
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Figure 3-39 E2F1 Δ374 protein levels are induced following E1A 
activation in an E1A-ER system following treatment with 
tamoxifen  
E2F1-/- MEFs expressing E1A-ER fusion protein and full length or 
E2F1 lacking the transactivation domain (E2F1Δ374) were treated 
with tamoxifen.  24 hours following treatment cell were harvested in 
SDS buffer and protein levels estimated by Western blot analysis.  
Extracts were probed with anti E2F1 antibody (C-20) to determine full 
length E2F1 protein levels and E2F1 antibody (KH95/20) to detect 
E2F1Δ374 protein levels.  Blots were re-probed with an actin antibody 
to ensure equal loading. 
 
Tamoxifen - + - +
E2F1 Δ374
Actin
E2F1
Actin
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tamoxifen and lysed 24 hours following treatment.  E2F1 protein levels were 
measured by Western blotting.  That revealed noticeable induction following 
treatment in both cell lines.  Actin levels were used to ensure equal loading of 
proteins. 
This shows that E1A can induce E2F1 levels independent of E2F1 binding pRb via 
the originally identified pRb binding domain.  It therefore remains a possibility 
that E1A binds pRb, which then uses the recently identified binding domains to 
interact with E2F1.  That interaction could allow E1A to complex with and 
induce levels of E2F1. 
It was next investigated if E2F1 binding to DNA was necessary for E1A-induced 
accumulation.  Virus expressing DNA binding deficient E2F1 132E was infected 
into E2F1-/- MEFs expressing E1A ER.  Cells were then treated with tamoxifen and 
lysed 24 hours following treatment.  E2F1 protein levels were measured by 
Western blotting.  In line with an interaction with the new E2F1 binding domain, 
this revealed noticeable induction following treatment, indicating that E1A-
induced accumulation of E2F1 is independent of E2F1 binding DNA (Fig. 3-40).  
Actin levels were used to ensure equal loading of proteins. 
3.3.17 Acetylation mutant is induced following E1A activation 
As previously discussed, E2F1 has also been shown to be acetylated on lysine 
117, 120 and 125 leading to increased stability of the protein following DNA 
damage (Martinez-Balbas et al., 2000; Pediconi et al., 2003).  One possibility is 
that acetylation on these lysines are involved in the E2F1 induction seen 
following E1A activation.  In order to test that, the mutant with all three lysine 
residues substituted to arginine (K117R/K120R/K125R) was used.  Virus 
expressing the acetylation mutant was infected into E2F1-/- MEFs expressing E1A 
ER.  Cells were then treated with tamoxifen and lysed 24 hours following 
treatment.  E2F1 protein levels were measured by Western blotting.  This 
revealed noticeable induction following treatment, indicating that E1A-induced 
accumulation of E2F1 is independent of acetylation on lysines 117, 120 and 125 
(Fig. 3-41).  Actin levels were used to ensure equal loading of proteins. 
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Figure 3-40 DNA binding deficient mutant of E2F1 is 
induced following E1A activation in an E1A-ER system 
following treatment with tamoxifen  
E2F1-/- MEFs expressing E1A-ER fusion and DNA binding 
deficient mutant of E2F1 (E2F1 132E) were treated with 
tamoxifen.  24 hours following treatment harvested in SDS 
buffer and protein levels estimated by Western blot analysis.  
Extracts were probed with anti E2F1 antibody (C-20) to 
determine E2F1 protein levels.  Blots were re-probed with an 
actin antibody to ensure equal loading. 
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E2F1 132E
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Figure 3-41 Acetylation mutant of E2F1 is induced 
following E1A activation in an E1A-ER system following 
treatment with tamoxifen.  
E2F1-/- MEFs expressing E1A-ER fusion protein were infected 
with virus expressing mutant of E2F1 with three lysine 
residues substituted to arginine (E2F1 
K117R/K120R/K125R). Cells were treated with tamoxifen and 
24 hours following treatment harvested in SDS buffer and 
protein levels estimated by Western blot analysis.  Extracts 
were probed with anti E2F1 antibody (C-20) to determine 
E2F1 protein levels.  Blots were re-probed with an actin 
antibody to ensure equal loading. 
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3.3.18 Chapter summary 
It was demonstrated in the previous chapters that E2F1 is induced following DNA 
damage and is involved in drug-induced apoptosis.  The results in this chapter 
illustrate that E2F1 is also induced following oncogene activation.  E1A 
expression induces E2F1 levels in a post-transcriptional manner.  This induction 
also contributes to increased chemosensitivity. 
E1A is dependent on binding both to the pRB family of proteins and the 
p400/TRRAP chromatin remodelling complex to induce E2F1 accumulation.  E1A 
binding to these proteins is also crucial to sensitize cells to drug-induced 
apoptosis.  Truncated forms of E1A that are deficient in binding to either the 
pRB family of proteins or the p400/TRRAP complex fail to induce E2F1 levels.  
They are also impaired in their ability to increase drug sensitivity. 
E1A induced E2F1 levels in wild type MEFs and pRb-/- MEFs, indicating that E1A is 
not dependent of pRb binding to mediate the effect.  However, E2F1 is not 
induced in triple knockout MEFs (pRb-/-, p107-/- and p130-/-), indicating that E1A 
is dependent on expression of at least one of the pRB family members to induce 
E2F1 accumulation.   
Using p400 specific siRNAs to silence p400 resulted in an increase in E2F1 levels.  
This indicates that E1A also inhibits the p400/TRRAP complex to mediated E2F1 
induction.  p400 knockdown also sensitized cells to drug-induced apoptosis. 
Overexpression of E2F1 in cells with deregulated E2F1 sensitizes cells to drug-
induced apoptosis.  RPE cells expressing E1A Δ2-36, which deregulates E2F1 
through pRb binding but does not bind the p400/TRRAP complex and therefore 
not induce E2F1 levels, were infected with adenovirus expressing E2F1.  
Overexpression of E2F1 sensitized these cells to death following adriamycin 
treatment.  The increased chemosensitivity is independent of p53 changes, since 
p53 accumulation is similar in both E1A Δ2-36 expressing cells and control cells. 
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4 Chapter 4: Discussion 
4.1 Regulation of E2F1 stability is important for DNA 
damage-induced apoptosis 
E2F1 is tightly controlled during the normal cell cycle.  The abundance of E2F1 is 
highest in G1/S phase but kept relatively low during the remainder of the cell 
cycle.  The mechanisms than control the accumulation of E2F1 activity during 
the cell cycle are complex involving multiple mechanisms including the 
ubiquitin-mediated degradation pathway.  Furthermore, studies have shown that 
E2F1 is upregulated in response to DNA damage caused by ionising radiation or 
UV exposure (Blattner et al., 1999; Hofferer et al., 1999; Huang et al., 1997).  
Chemotherapeutic drugs that lead to DNA damage have also been shown to 
induce E2F1 levels in cells (Meng et al., 1999).  It is unclear if the same 
mechanisms that regulate E2F1 stability during the cell cycle also regulate E2F1 
stability following DNA damage.  Given E2F1’s important role in inducing 
apoptosis, it is important to understand the mechanism(s) responsible for E2F1 
stabilization. 
The present studies show that E2F1 is induced by three different 
chemotherapeutic drugs; adriamycin, actinomycin D and etoposide in Mouse 
Embryonic Fibroblasts (MEFs).  These drugs all cause DNA damage by interfering 
with DNA replication or transcription and have been used in treatment of many 
tumour types.  E2F1 in primary human Retinal Pigment Epithelial (RPE) cells 
showed similar induction in response to adriamycin.  The induction is rapid and 
easily detectable after 6 hours following treatment in both cell lines.  No 
changes were observed in RNA levels following adriamycin treatment in RPE 
cells, indicating that the induction is post-transcriptional.  This result is 
consistent with previous studies which showed that E2F1 upregulation is due to 
an increase in the half life of the protein (Blattner et al., 1999; Lin et al., 2001; 
Stevens et al., 2003).  Studies have also indicated that the accumulation of E2F1 
in response to DNA damage is not a result of cell cycle arrest, since the other 
activating E2Fs, which also accumulate in G1/S phase, show no induction 
following DNA damage (Lin et al., 2001). 
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The studies here show that regulation of E2F1 stability is important for apoptosis 
caused by DNA damage.  MEFs in which E2F1 has been deleted (E2F1-/-) show 
increased drug resistance compared to wild type MEFs.  Re-introducing full 
length human E2F1 into E2F1-/- MEFs rescued the drug sensitivity observed in 
wild type MEFs.  Furthermore, E2F1 induction following DNA damage is also 
important for apoptosis induction in RPE cells, since adriamycin-induced 
apoptosis is inhibited by siRNA of E2F1.  Previously it has been shown that, in 
line with the selective induction of E2F1 protein in response to DNA damage, 
drug-induced apoptosis is inhibited by an siRNA targeting E2F1 but not by siRNAs 
specially targeting E2F2 or E2F3 (Wang et al., 2004).  This finding underlines the 
specific role of E2F1 in this response.  In line with these findings, the results 
presented here demonstrating reduction in death when either E2F1 is deleted or 
silenced further support the critical role of E2F1 in DNA damage-induced 
apoptosis. 
It is well documented that p53 is induced following DNA damage and p53 levels 
have been shown to rise during E2F1 mediated apoptosis, which corresponds 
with an increase in ARF expression (Bates et al., 1998).  However, it is 
demonstrated here that the ability of induced E2F1 to sensitize RPE cells to 
drug-induced apoptosis is independent of p53.  The p53 protein is induced 
following adriamycin treatment.  This induction is however not affected by E2F1 
knockdown and is therefore unlikely to be contributing to the decrease in 
apoptosis observed in E2F1 knockdown cells.  This raises the possibility that 
downstream E2F1 apoptotic targets are activated following adriamycin and this 
activation is crucial for the response.  That possibility could be tested by 
knocking down potential candidates with siRNA.  Many genes, such as p73 or 
Apaf1 may mediate this response, since many of them have been shown to 
contribute to p53-independent E2F1-induced apoptosis (Furukawa et al., 2002; 
Stiewe and Putzer, 2000).  In addition, in order to search for the E2F1 target 
genes that mediate the response following adriamycin treatment a microarray 
study could be carried out using the two different cell lines.  That should give 
indications which genes are affected by the E2F1 knockdown and respond 
differently to the DNA damage, leading to the decrease in apoptosis observed. 
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4.2 E2F1’s response beyond known mechanisms 
Recent studies have shown that E2F1 accumulation following DNA damage is 
mediated by the stress-responsive kinases ATM/ATR and Chk2.  ATM 
phosphorylates E2F1 at serine 31, while Chk2 is responsible for serine 364 
phosphorylation (Lin et al., 2001; Stevens et al., 2003).  Both these 
phosphorylation events have been shown to lead to E2F1 stabilization.  Using 
E2F-/- MEFs the contribution of these events to E2F1 stabilization were tested.  
These mechanisms were analysed in MEFs because, perhaps in contrast with 
many tumour cell lines, they might have all possible mechanisms leading to E2F1 
stabilization intact.  The results revealed that neither of these phosphorylation 
events are required for E2F1 induction since an E2F1 double mutant harbouring 
the mutations S31A/S364 was shown to accumulate following adriamycin 
treatment.   
The results show human E2F1 to be induced following DNA damage in wild type 
MEFs.  However, it is not clear if human E2F1 can by phosphorylated at serine 
364 in MEFs.  While serine 31 is conserved between human and mouse E2F1, 
serine 364 is not present in mouse E2F1.  If mouse Chk2 has the ability to 
recognise Chk2 consensus phosphorylation site in the human protein is not known 
(Fig. 4-1a).  
The three lysine residues that have previously been shown to be acetylated in 
human cells (K117, K120 and K125) are conserved in mice (Fig 4-1b).  
Nonetheless, a mutant carrying arginine substitution for these lysine residues did 
not completely inhibit E2F1 induction following treatment with adriamycin.  This 
indicates that acetylation at these sites is not required for E2F1 induction 
following DNA damage.  However, other acetylation events can not be excluded 
to be involved.  Both wild type and the triple acetylation mutant of E2F1 are 
induced following HDAC inhibition with TSA indicating that other acetylation 
events might play a role.  Due to the low affinity of the anti-acetylated lysine 
antibody for acetylated E2F1 (data not shown) it has not been possible to verify 
if the acetylation mutant is acetylated following DNA damage. 
The C-terminal activation domain of E2F1 contains two separate domains that 
are necessary for pRb and Mdm2 binding.  Both of these proteins bind E2F1  
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Figure 4-1 Comparison of human and mouse E2F1 sequences 
A) Comparison of human and mouse E2F1 sequences indicate that serine 31 
is conserved between human and mouse E2F1.  On the other hand, serine 
364 is not present in mouse E2F1. B) Comparison of human and mouse 
E2F1 sequences indicate that the three lysine residues that have previously 
shown to be acetylated in human cells (K117, K120 and K125) are conserved 
in mouse E2F1. 
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directly and have been shown to block ubiquitination and stabilise E2F1 by 
protecting it from degradation (Campanero and Flemington, 1997; Hateboer et 
al., 1996b; Hofmann et al., 1996; Zhang et al., 2005).  However MDM2’s effect 
on E2F1 stability may be context specific.  In addition to mediating E2F1’s 
stabilization, Mdm2 has also been shown to promote E2F1 degradation (Blattner 
et al., 1999; Loughran et al,, 2000).  The results presented here indicate that 
DNA damage-induced accumulation of E2F1 occurs also via inhibition of 
proteasomal degradation.  However, both pRb and Mdm2 can by excluded from 
playing an essential role in the DNA damage response.  A  MDM2 binding deficient 
mutant of E2F1 is induced to comparable levels as wild type following DNA 
damage.  This is also further supported by the response of truncation 1 (tr. 1 
Δ374), which lacks the entire transactivation domain and the regions that bind 
pRb and MDM2, but is stabilized following DNA damage.  In addition, E2F1 has 
been shown to be induced following DNA damage in pRb-/- MEFs (O'Connor and 
Lu, 2000). 
What is the mechanism leading to E2F1 induction following DNA damage, if it 
does not involve the known phosphorylation sites, the known acetylation sites or 
interaction with proteins within the transactivation domain?  One possibility is 
modification changes that inhibit Skp2 mediated E2F1 degradation.  Skp2 binds 
to the N-terminal end of E2F1 and promotes its ubiquitination (Marti et al., 
1999).  Serine 31 is positioned close to the Skp2 binding site and has been 
suggested to alter E2F1 degradation by inhibiting Skp2 binding (Mundle and 
Saberwal, 2003).   Direct Mdm2-E2F1 binding has also been suggested to displace 
Skp2 from E2F1 and inhibit its ubiquitination (Zhang et al., 2005).  The responses 
of the S31A mutant and tr. 1 Δ374 rule these possibilities out.  However, it is still 
possible that other modifications regulated Skp2 binding to E2F1 and effect E2F1 
stability following DNA damage.  The contribution of Skp2 to E2F1 accumulation 
following DNA damage could me tested in cells where Skp2 is knocked down by 
siRNA or in Skp2-/- MEFs. 
ARF has also been shown to interact with E2F1 and target it for protein 
degradation (Martelli et al., 2001).  It appears that multiple, independent 
domains within E2F1 serve as targets for ARF-mediated degradation.  That makes 
the identification of the mechanism hard to define.  It is also not clear if the 
interaction of ARF and E2F1 is direct or not.  ARF-mediated E2F1 degradation is 
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inhibited by the proteasome inhibitor LLnL and may therefore be connected with 
ubiquitination of E2F1.  However, to date, no known ubiquitin sites within E2F1 
have been defined.  Further analysis is therefore needed to define the 
biochemical mechanism by which ARF targets E2F1 for degradation.  Also, 
whether ARF plays an essential role in E2F1 induction following DNA damage is 
not known but could be tested in cells with siRNA mediated ARF knockdown or in 
ARF-/- MEFs. 
The DNA damage-induced accumulation of truncation 3 (tr. 3 Δ284), which lacks 
both the transactivation domain and the Chk2 phosphorylation site at S364, 
indicates that the last 53 N-terminal residues are not required for the DNA 
damage response.  This also excludes the requirement of the known cell cycle 
dependent phosphorylation events on E2F1.  E2F1 is phosphorylated at serines 
332 and 337 residues by Cdk4-cyclin D which prevents its interaction with pRb, 
and at serine 375 by cdk2-cyclin A, which inhibits the DNA-binding activity of 
E2F1  (Dynlacht et al., 1994; Fagan et al., 1994; Krek et al., 1995; Xu et al., 
1994).  Therefore, it is unlikely that cell cycle dependent phosphorylation 
events, which can affect E2F1 stability, are involved in DNA damage-induced 
E2F1 stabilization.   
The recently identified E2F1 binding domain in pRb requires the marked box of 
E2F1 as well as making contact with multiple places in the N terminal region of 
E2F1 (Dick and Dyson, 2003).  The two distinct E2F binding sites offer pRb the 
ability to distinguish between E2F proteins and provide it with the opportunity to 
differentially regulate E2F functions.  In addition, DNA damage causes a change 
that prevents E2F1 from binding to this unique interaction site on pRb.  
Therefore, it can be suggested that pathways leading to DNA damage-induced 
E2F1 modification could control the interaction of E2F1 and pRb, which could 
affect E2F1 stability.  However, as discussed previously, E2F1 is induced in pRb-/- 
MEFs, which indicates that E2F1 induction following DNA damage does not 
require pRb (O'Connor and Lu, 2000). 
Most previous studies, which have identified mechanism leading to E2F1 
stabilization following DNA damage, have been carried out in cancer cells.  It is 
probable that cancer cells have already have lost some of the mechanisms 
leading to E2F1 accumulation DNA damage, and therefore make it easier to 
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inhibit the induction of the remaining mechanism.  This cell specificity can 
explain why E2F1 still responds to DNA damage even if it carries mutations in the 
known DNA damage responsive phosphorylation and acetylation sites. 
4.3 Two short E2F1 truncation respond to DNA damage 
The present studies have led to the identification of two E2F1 truncations that 
respond to DNA damage in a manner not involving previously described 
mechanisms.   One truncation only contains the first 120 amino acids of E2F1 (tr. 
6 Δ120).  Given that tr. 6 Δ120 with serine 31 and lysines 117 and 120 mutated (tr.6 
Δ120 S31A/K117A/K120A) is still induced following DNA damage, indicates that 
this region of E2F1 contains residues that are important for the DNA damage 
response.  Whether the response involves protein-protein interaction, 
phosphorylation, acetylation or other forms of post-transcriptional modifications 
is unknown.  It is possible that Skp2 binding to the N-terminus also regulates the 
degradation of this truncation.  It is also possible that this region of E2F1 binds 
to the previously identified C-terminal region in pRb and that interaction is 
abolished following DNA damage, which could lead to increased stability.  The 
potential interaction between tr. 6 Δ120 and these proteins could be tested by co-
immuneprecipitation experiments, using specific antibodies to these proteins.   
It is also possible that ARF mediated ubiquitination is inhibited in tr. 6 Δ120 
following DNA damage and that inhibition is responsible for the accumulation.  
The regions within E2F1 that are able to interact with ARF are not known, and if 
tr. 6 Δ120 is able to interact with ARF was not tested. 
The second minimal truncation identified tr. 11 120-191, consists only of the DNA 
binding domain, and does not include the known ATM and Chk2 phosphorylation 
sites.  This domain comprises two of the known DNA damage responsive 
acetylation sites (K120 and K125) that could be responsible for the induction.  
However, that was not considered to be a likely explanation since substitution of 
all three lysines on full length E2F1 did not alter the induction and neither did 
substitution of two of them on tr. 6 Δ120.  The data therefore indicate that the 
DNA binding domain of E2F1 can respond to DNA damage by a mechanism not 
previously described.  This domain is unable to bind DNA but retains the ability 
to induce apoptosis when overexpressed (Bell et al., 2006).  If this domain can 
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interact with the C-terminus of pRb was not established.  It is also not known if 
tr.11 120-191 is able to bind ARF, which as previously discussed could be involved 
in the DNA damage response.  
The possibility that DNA damage leads to changes in ubiquitination on 6 Δ120 or tr. 
11 120-191 could be tested in ubiquitination assays.  The truncations could be co-
expressed in cells with ubiquitin and then immunoprecipitated following DNA 
damage and ubiquitination measured by Western blotting.  That could reveal if 
any changes occur with regard to ubiquitination of the truncation following DNA 
damage. 
DNA damage responses often involve phosphorylation events.  An example is the 
many DNA damage-induced phosphorylation sites which have been identified in 
p53, and contribute to its stability (Lavin and Kozlov, 2007).  It was therefore 
decided to search for potential phosphorylation sites in tr. 6 Δ120 and if tr.11 120-
191.  Using NetPhos 2.0 (http://www.cbs.dtu.dk/services/NetPhos/), a network-
based method for predicting potential phosphorylation sites at serine, threonine 
or tyrosine residues in protein sequences, several potential phosphorylation sites 
were identified in tr. 6 Δ120 and tr.11 120-191.  However, when these potential 
phosphorylation sites were mutated to residues that can not be phosphorylated, 
both truncations showed induction following DNA damage.  That does not rule 
out the possibility that a combination of mutations would be required to inhibit 
the induction.  Further studies are therefore required to fully understand the 
mechanism involved it the induction of tr. 6 Δ120 and tr.11 120-191.  To investigate 
if DNA damage leads to changes in phosphorylation of the truncations mass-
spectrometry could be used.  Phospho-peptide mapping is a technique that 
allows identification of phosphorylated residues on immunoprecipitated 
proteins.  Therefore, changes in phosphorylation on the truncation following DNA 
damage could be revealed using phospho-peptide mapping on full length E2F1 
protein or on the truncations.        
In summary, the data presented here indicate that there are many pathways 
leading to E2F1 stability following DNA damage, some of which remain to be 
discovered.  E2F1’s response to DNA damage is complex and may be overlapping 
and involve many different modifications.  It will be interesting to observe if any 
of the mechanisms are lost during tumour development, which could prevent 
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E2F1-induced apoptosis in tumours where mutations and DNA damage are 
continuously occurring. 
4.4 E1A deregulates and induces E2F1 levels 
E1A, the oncogene from type 5 adenovirus, is known to deregulate E2F by 
targeting the pRB family of pocket proteins (Chellappan et al., 1992; Whyte et 
al., 1988).  Present results show that E1A also induced E2F1 levels in a post-
transcriptional manner.  This is perhaps unexpected because E1A is known to 
disrupt E2F-pocket protein complexes, and should therefore generate free, but 
unstable E2F1, since pRb has been shown to prevent E2F1 degradation 
(Campanero and Flemington, 1997; Hateboer et al., 1996b; Hofmann et al., 
1996).  However, it is possible that this stabilization by E1A serves to activate 
the transcriptional machinery and enhance S-phase entry of adenovirus-infected 
cells. 
4.4.1 E1A induces E2F1 level in a pRB dependent way 
In 1996 Hateboer et al. showed that adenovirus early region 1 (E1) proteins 
cause stabilization of E2F1 and DP (Hateboer et al., 1996b).  These effects were 
dependent on simultaneous expression of both E1A and E1B and required the 
transactivation domain of E2F1.  Present data indicate that the E1A-induced 
E2F1 accumulation is mediated by a different mechanism.  The induction does 
not require the transactivation domain of E2F1 since E2F1 Δ374 is induced 
following E1A activation and E1B expression is dispensable.   
However, E1A is dependent on binding to any one of the pRB family proteins to 
cause E2F1 induction.  A pRB binding deletion mutant of E1A (E1A ∆CR2) fails to 
bind to pRB family proteins and fails to induce E2F1 levels.  The results in pRb-/- 
MEFs, where E2F1 is induced following E1A expression, indicate that the other 
pRB family members can substitute for pRb when pRb does not exists.  In pRb-/- 
MEFs it is possible that either p 107 or p130 provide a scaffold for E1A forming a 
ternary complex with E2F1.  That could be tested by immumoprecipitaion 
experiment in the wild type and pRb-/- MEFs.  However, the results from the TKO 
MEFs support the dependence of the pRB family proteins for the effect by E1A 
(figure 4-2).  In order to test if one of the pRB family members is sufficient for  
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Figure 4-2 E1A is dependent on presence of the pRB family proteins to induce 
E2F1 accumulation.  
E1A deregulates E2F activity by binding to the pRB family of pocket proteins.  pRb 
binds preferably to E2F1 and could therefore bring together E1A and E2F1 in wild 
type cells.  However, the other family members can compensate for pRb in pRb-null 
cells and and allow for a ternary complex with E1A and E2F1 in pRb-null cells.  In 
TKO cells (null for all pRB family proteins) E1A fails to induce E2F1 levels, possibly 
by failing to interact with E2F1 as a result of lack of all the pRB proteins. 
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E1A to interact with E2F1, pRb, p107 and p130 could be transfected separately 
into the TKO MEFs and investigated which of them could rescue the E2F1 
accumulation effect by E1A.  In addition, immunoprecipitation experiments 
could reveal if all members could compensate for pRb knockout and interact 
with E2F1 to provide the platform for E1A interaction.   
But how then can E1A induce E2F1 Δ374 levels?  This can be explained by the 
recently identified pRb binding domain within E2F1.  pRb binding to E2F1 via this 
domain is not dependent on the transactivation domain, but  requires the 
marked box region of E2F1 for binding and makes contact with multiple regions 
within the N terminus as well.  Therefore, E1A could interact with pRb which 
then binds E2F1 via the alternative interaction.  This could be tested by 
immunoprecipitation experiments in the MEFs expressing wild type and tr.1 Δ374, 
where the interaction between tr. 1 Δ374, E1A and pRb could be investigated.  In 
addition, a mutant form of pRb which only binds E2F1 via the alternative binding 
site could be tested for its ability to rescue the E2F1 accumulation following E1A 
activation in the TKO MEFs. 
The recently identified E2F1-pRb complex was shown to have low affinity for 
DNA binding (Dick and Dyson, 2003).  Present data show that E2F1 induction 
following E1A activation does not require E2F1 to bind DNA.  E2F1 132E, a DNA 
binding deficient mutant is induced to similar levels as wild type E2F1 following 
E1A expression. 
4.4.2 E1A is dependent on binding to the p400/TRRAP protein 
complex to induce E2F1 levels 
A sequence within the E1A N-terminus (amino acids 4-47) interacts with a 
proteins of 400 kDa, which has previously been identified as p400 and TRRAP 
(transactivation/transformation-domain-associated protein) (Barbeau et al., 
1994; Howe and Bayley, 1992; McMahon et al., 1998).  This p400 binding region 
has been shown to be vital for E1A-mediated transformation in mouse cells 
(Fuchs et al., 2001).  p400 is related to the yeast SW12/SNF2 chromatin 
remodelling complex and modulates both transcriptional activation and 
repression.  ATP-dependent nucleosome remodelling complexes control the 
access of transcription factors to promoter region by modifying chromatin 
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structures and nucleosome positioning (Sudarsanam and Winston, 2000).  p400 
has been found in several large multisubunit complexes, including P/CAF 
complex and Tip60 histone acetyltransferase (HAT) complex which is involved in 
DNA repair and apoptosis (Ikura et al., 2000).  Consistent with the finding that 
Tip60 contains p400, immunoprecipitation (IP) experiments have showed that 
p400 associates with a number of proteins also present in the Tip60 complex, 
including the DNA helicase TAP54 (McMahon et al., 1998).   
TRRAP is a component of various large HAT complexes including Tip60 and 
complexes containing GCN5 or P/CAF acetyltransferases.  Thus, since many 
complexes contain TRRAP it appears that only a fraction of endogenous TRRAP is 
bound to p400.  By contrast, analysis of IPs generated with p400 specific 
antibodies suggest that the majority of endogenous p400 molecules exists in 
complex with TRRAP (McMahon et al., 1998).  Studies have shown that E1A binds 
a TRRAP complex that contains GCN5 acetyltransferase during normal adenoviral 
infection which may facilitate infection by deregulating cellular transcriptional 
programs (Lang and Hearing, 2003).  Studies with Myc indicate that TRRAP acts 
as a bridge to recruit HAT activity catalyzed by the GCN5 protein and stimulate 
transcription (McMahon et al., 2000).   
In contrast to repression, the mechanisms of transactivation by E2F have not 
been established in molecular details.  It has been suggested that E2F proteins 
must reverse the pRb-imposed chromatin structure to stimulate transcription.  In 
favour of direct role of E2Fs in histone acetylation, they interact with HATs, 
including P/CAF and GCN5, which enhances E2F-dependent transcription, 
possibly through acetylation of E2F itself (Lang et al., 2001; Martinez-Balbas et 
al., 2000; Marzio et al., 2000; Pediconi et al., 2003) (Fig 4-3).  E2F1 has also 
been shown to bind TRRAP through the E2F1 transactivation domain (Lang et al., 
2001; McMahon et al., 1998).   
In spite of these observations, there is no direct proof of how E1A binding to 
p400/TRRAP effects or mediates E2F1 dependent transcription.  In addition, it is 
not clear what HAT if any, plays a part in the E1A interacting p400/TRRAP 
complex and whether the p400/TRRAP complex can directly affect E2F1 
stability.   
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Figure 4-3 pRb inhibits E2F1 mediated transcription by recruiting 
histone deacetylases (HDACs)  
It has been suggested that E2F1 reverses the pRb inhibition by 
interacting with histone acetyltransferases (HATs), such as P/CAF and 
GCN5, which enhances transcription, possibly through acetylation of 
E2F1 itself.  
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The data presented here indicate that E1A binding to p400/TRRAP is crucial in 
increasing E2F1 levels (Fig 4-4).  Moreover, the p400 knockdown experiments 
suggest that E1A mediates this effect by inhibiting the complex, since p400 
knockdown also leads to increased E2F1 levels.  However, if these effects are 
dependent on HAT activity was not tested.  Due to the low affinity of the anti-
acetylated lysine antibody for acetylated E2F1 (data not shown) it has not been 
possible to verify if E2F1 is acetylated or de-acetylated following E1A 
expression.  
It remains a possibility that p400 plays a vital role in a complex that promotes 
E2F1 down-regulation and E1A inhibits this leading to increased E2F1 stability.  It 
is also possible that p400 knockdown promotes E2F1 stability by increasing the 
access of other HATs that acetylate E2F1 following p400 removal. 
These questions could be answered in in vitro acetylation assays where 
acetylated E2F1 could be more easily detected.  Knockdown experiments could 
also be carried out in order to assess if E2F1 induction is dependent on the HATs 
known to mediate HAT activity in p400 complexes.  That could reveal if the 
accumulation is dependent on p/CAF, Tip60, GCN5 or other known p400 
interacting HATs.   
4.4.3 E2F1 overexpression sensitizes cells with de-regulated pRb 
pathway to drug-induced apoptosis 
The data presented, using the E1A mutant Δ2-36 indicate that adenoviral 
mediated induction of E2F1 increases chemosensitivity in cells where the E2F1 
pathway is already deregulated (Fig. 3-34).  The increased chemosensitivity is 
independent of p53 changes, since p53 accumulation is similar in both E1A Δ2-36 
expressing cells and control cells. 
That indicates that activation of the E2F1 pathway in tumours could be a way to 
increase chemotherapy-induced cell death either in the presence or absence of 
p53.  Defects in the pRb pathway may be universal in human cancers and include 
deletion or mutation of the pRb gene itself (Harbour and Dean, 2000).  In 
addition, viral oncoproteins such as the E7 protein from high-risk papilloma virus  
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Figure 4-4 E1A binding to the p400/TRRP 
chromatin remodelling complex is essential to 
induce E2F1  
p400 knockdown also induces the levels of E2F1 
indicating that E1A mediates the effect by inhibiting 
p400 activity.  Whereas p400 promotes acetylation 
on chromatin when bound to E1A is not clear and if 
p400 affect acetylation directly on E2F1 is not 
known.  
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(HVP) also target the pRb protein leading to de-regulated E2F1 activity 
(Chellappan et al., 1992) 
Therefore these tumours should have high E2F1 activity.  However, it is not 
known if other viral oncoproteins known to target the pRB family proteins also 
bind the p400/TRRAP complex.  Furthermore it is not clear if E2F1 levels are 
high specifically in tumours expressing viral oncogenes.  Could p400 inhibition 
lead to increased E2F1 levels and increased chemosensitivity in these tumours?  
Thorough investigation is needed to define p400/TRRAP expression and activity 
in tumour and how it correlates with E2F1 protein levels and activity. 
4.4.4 Conclusion  
The results presented here demonstrate that DNA damaging agents that are 
regularly used to treat cancer induce E2F1 levels by a post-transcriptional 
mechanism.  This induction is important for drug-induced apoptosis and is in line 
with the notion that E2F1 plays a role in drug induced apoptosis in a p53-
independent manner.  This connection between DNA damage and E2F1-
depentent apoptosis following drug treatment is of particular significance. 
Using adriamycin as a DNA damaging agent, studies revealed that the previously 
identified mechanisms leading to E2F1 induction could not singularly or in 
combination be fully responsible for the E2F1 induction following DNA damage.  
Therefore, other mechanism(s) must play a role in E2F1’s response to DNA 
damage under these conditions. 
The results describe two minimal domains of E2F1 that respond to adriamycin 
treatment which could not be explained by previously identified mechanisms.  
That indicates that the E2F1’s response to DNA damage is complex and perhaps 
overlapping and may involve numerous pathways and different modifications.  
Whether these mechanisms are inhibited in tumour development will need 
thorough investigation. 
In addition, E2F1 protein levels are induced following oncogene activation.  E1A 
expression induces E2F1 levels in a post-transcriptional manner which 
contributes to increased chemosensitivity.  E1A is not only dependent on 
deregulating E2F1 by binding the pRB family of proteins to induce E2F1 levels 
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and increase chemosensitivity.   E1A is also dependent on binding to the 
p400/TRRAP chromatin remodelling complex to induce E2F1 accumulation and 
sensitize cells to drug-induced apoptosis. 
Overexpression of E2F1 in cells with deregulated E2F1 sensitizes cells to drug-
induced apoptosis in a way that is independent of p53 activity.  That provides 
the potential that activation of the E2F1 pathway in tumors with wild type or 
mutated p53 can be considered as a therapeutic option. 
These results contribute to the understanding of how activation of the E2F1 
pathway can be targeted therapeutically leading to enhanced chemotherapy-
induced tumour cell death.  
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